US20220401478A1 - Ebv-specific immune cells - Google Patents
Ebv-specific immune cells Download PDFInfo
- Publication number
- US20220401478A1 US20220401478A1 US17/753,875 US202017753875A US2022401478A1 US 20220401478 A1 US20220401478 A1 US 20220401478A1 US 202017753875 A US202017753875 A US 202017753875A US 2022401478 A1 US2022401478 A1 US 2022401478A1
- Authority
- US
- United States
- Prior art keywords
- ebv
- antigen
- immune cells
- cells
- lytic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002865 immune cell Anatomy 0.000 title claims abstract description 198
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims abstract description 449
- 239000000427 antigen Substances 0.000 claims abstract description 398
- 102000036639 antigens Human genes 0.000 claims abstract description 398
- 108091007433 antigens Proteins 0.000 claims abstract description 398
- 230000002101 lytic effect Effects 0.000 claims abstract description 198
- 238000000034 method Methods 0.000 claims abstract description 174
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 136
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims abstract description 131
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 79
- 210000000612 antigen-presenting cell Anatomy 0.000 claims abstract description 78
- 230000004936 stimulating effect Effects 0.000 claims abstract description 54
- 210000004027 cell Anatomy 0.000 claims description 240
- 206010028980 Neoplasm Diseases 0.000 claims description 139
- 201000011510 cancer Diseases 0.000 claims description 96
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 73
- 201000010099 disease Diseases 0.000 claims description 56
- 101150062763 BMRF1 gene Proteins 0.000 claims description 54
- 101150026402 DBP gene Proteins 0.000 claims description 48
- 101150059079 EBNA1 gene Proteins 0.000 claims description 48
- 101150078891 BRLF1 gene Proteins 0.000 claims description 43
- 101150009389 BZLF1 gene Proteins 0.000 claims description 43
- -1 BMLF1 Proteins 0.000 claims description 39
- 101150000167 BMRF2 gene Proteins 0.000 claims description 39
- 101150113776 LMP1 gene Proteins 0.000 claims description 36
- 239000008194 pharmaceutical composition Substances 0.000 claims description 27
- 101150075502 BALF1 gene Proteins 0.000 claims description 25
- 101150003725 TK gene Proteins 0.000 claims description 25
- 101150036640 BLLF2 gene Proteins 0.000 claims description 24
- 101100493802 Epstein-Barr virus (strain B95-8) BDLF3 gene Proteins 0.000 claims description 21
- 101150010153 BARF1 gene Proteins 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 19
- 206010025323 Lymphomas Diseases 0.000 claims description 17
- 208000035475 disorder Diseases 0.000 claims description 17
- 101150093926 BALF5 gene Proteins 0.000 claims description 14
- 101150013616 BHRF1 gene Proteins 0.000 claims description 14
- 101100122503 Human herpesvirus 6A (strain Uganda-1102) gN gene Proteins 0.000 claims description 14
- 101150074866 BGLF5 gene Proteins 0.000 claims description 13
- 101150074429 BKRF4 gene Proteins 0.000 claims description 13
- 101150065426 BVRF2 gene Proteins 0.000 claims description 13
- 101100437512 Epstein-Barr virus (strain B95-8) BHLF1 gene Proteins 0.000 claims description 13
- 101100381650 Epstein-Barr virus (strain B95-8) BILF1 gene Proteins 0.000 claims description 13
- 101100381651 Epstein-Barr virus (strain B95-8) BILF2 gene Proteins 0.000 claims description 13
- 101100261341 Epstein-Barr virus (strain B95-8) TRM1 gene Proteins 0.000 claims description 13
- 101100504448 Human herpesvirus 6A (strain Uganda-1102) gH gene Proteins 0.000 claims description 13
- 101150029683 gB gene Proteins 0.000 claims description 13
- 101150113929 EBNA2 gene Proteins 0.000 claims description 12
- 101710147543 Epstein-Barr nuclear antigen leader protein Proteins 0.000 claims description 12
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 206010015108 Epstein-Barr virus infection Diseases 0.000 claims description 11
- 206010017758 gastric cancer Diseases 0.000 claims description 11
- 208000010749 gastric carcinoma Diseases 0.000 claims description 11
- 201000000498 stomach carcinoma Diseases 0.000 claims description 11
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 8
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 230000002147 killing effect Effects 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 230000000638 stimulation Effects 0.000 description 89
- 210000001744 T-lymphocyte Anatomy 0.000 description 80
- 150000001413 amino acids Chemical group 0.000 description 48
- 230000014509 gene expression Effects 0.000 description 34
- 239000006143 cell culture medium Substances 0.000 description 32
- 108090000623 proteins and genes Proteins 0.000 description 32
- 210000003719 b-lymphocyte Anatomy 0.000 description 27
- 102000003812 Interleukin-15 Human genes 0.000 description 25
- 108090000172 Interleukin-15 Proteins 0.000 description 25
- 102100021592 Interleukin-7 Human genes 0.000 description 24
- 108010002586 Interleukin-7 Proteins 0.000 description 24
- 238000001727 in vivo Methods 0.000 description 22
- 102000004127 Cytokines Human genes 0.000 description 21
- 108090000695 Cytokines Proteins 0.000 description 21
- 239000002609 medium Substances 0.000 description 18
- 230000004044 response Effects 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 16
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 description 14
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 description 14
- 210000004443 dendritic cell Anatomy 0.000 description 13
- 238000000338 in vitro Methods 0.000 description 13
- 239000012980 RPMI-1640 medium Substances 0.000 description 12
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 238000003501 co-culture Methods 0.000 description 11
- 238000011161 development Methods 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 11
- 108090001005 Interleukin-6 Proteins 0.000 description 10
- 102000004889 Interleukin-6 Human genes 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- 102000013462 Interleukin-12 Human genes 0.000 description 9
- 108010065805 Interleukin-12 Proteins 0.000 description 9
- 230000001093 anti-cancer Effects 0.000 description 9
- 238000012258 culturing Methods 0.000 description 9
- 210000002919 epithelial cell Anatomy 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 238000012546 transfer Methods 0.000 description 9
- 230000003612 virological effect Effects 0.000 description 9
- 206010027476 Metastases Diseases 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000009401 metastasis Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 210000000822 natural killer cell Anatomy 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 7
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 230000000139 costimulatory effect Effects 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 239000012091 fetal bovine serum Substances 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 230000010076 replication Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 108090000331 Firefly luciferases Proteins 0.000 description 6
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 6
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 6
- 230000000770 proinflammatory effect Effects 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 5
- 102000000588 Interleukin-2 Human genes 0.000 description 5
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 108090000978 Interleukin-4 Proteins 0.000 description 5
- 102000004388 Interleukin-4 Human genes 0.000 description 5
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 5
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 5
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 230000036210 malignancy Effects 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 4
- 108091054437 MHC class I family Proteins 0.000 description 4
- 108091054438 MHC class II family Proteins 0.000 description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 4
- 206010057249 Phagocytosis Diseases 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 4
- 108010067390 Viral Proteins Proteins 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 230000032823 cell division Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000001461 cytolytic effect Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000002688 persistence Effects 0.000 description 4
- 230000008782 phagocytosis Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000029812 viral genome replication Effects 0.000 description 4
- 238000012447 xenograft mouse model Methods 0.000 description 4
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 3
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 3
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 3
- 102100035793 CD83 antigen Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 102000006354 HLA-DR Antigens Human genes 0.000 description 3
- 108010058597 HLA-DR Antigens Proteins 0.000 description 3
- 208000017604 Hodgkin disease Diseases 0.000 description 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 3
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 230000006044 T cell activation Effects 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000004940 costimulation Effects 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000000779 depleting effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 206010061311 nervous system neoplasm Diseases 0.000 description 3
- 210000004789 organ system Anatomy 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 210000003289 regulatory T cell Anatomy 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 description 2
- 229940123205 CD28 agonist Drugs 0.000 description 2
- 208000015943 Coeliac disease Diseases 0.000 description 2
- 102000016559 DNA Primase Human genes 0.000 description 2
- 108010092681 DNA Primase Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108091034120 Epstein–Barr virus-encoded small RNA Proteins 0.000 description 2
- 101710170470 Glycoprotein 42 Proteins 0.000 description 2
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 2
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 206010027406 Mesothelioma Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000029918 bioluminescence Effects 0.000 description 2
- 238000005415 bioluminescence Methods 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 208000035269 cancer or benign tumor Diseases 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 108091008034 costimulatory receptors Proteins 0.000 description 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000004964 innate lymphoid cell Anatomy 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 230000000366 juvenile effect Effects 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000001806 memory b lymphocyte Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 201000005962 mycosis fungoides Diseases 0.000 description 2
- 230000017066 negative regulation of growth Effects 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 230000008884 pinocytosis Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 208000017805 post-transplant lymphoproliferative disease Diseases 0.000 description 2
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000007420 reactivation Effects 0.000 description 2
- 238000007430 reference method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 102000002627 4-1BB Ligand Human genes 0.000 description 1
- 108010082808 4-1BB Ligand Proteins 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 1
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 101150008118 BRRF1 gene Proteins 0.000 description 1
- 101150017888 Bcl2 gene Proteins 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 229940122738 CD3 agonist Drugs 0.000 description 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 244000205754 Colocasia esculenta Species 0.000 description 1
- 235000006481 Colocasia esculenta Nutrition 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102100030886 Complement receptor type 1 Human genes 0.000 description 1
- 102100032768 Complement receptor type 2 Human genes 0.000 description 1
- 206010010504 Congenital HIV infection Diseases 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 101710134178 DNA polymerase processivity factor BMRF1 Proteins 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 102100023933 Deoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrial Human genes 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 101100487860 Epstein-Barr virus (strain B95-8) BBLF2 gene Proteins 0.000 description 1
- 101100191368 Epstein-Barr virus (strain B95-8) BSLF1 gene Proteins 0.000 description 1
- 101100070290 Epstein-Barr virus (strain B95-8) HELI gene Proteins 0.000 description 1
- 101900224158 Epstein-Barr virus DNA polymerase catalytic subunit Proteins 0.000 description 1
- 101000830028 Escherichia phage Mu Uncharacterized protein gp25 Proteins 0.000 description 1
- 102000015212 Fas Ligand Protein Human genes 0.000 description 1
- 108010039471 Fas Ligand Protein Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102100021186 Granulysin Human genes 0.000 description 1
- 101710168479 Granulysin Proteins 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 208000005794 Hairy Leukoplakia Diseases 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000727061 Homo sapiens Complement receptor type 1 Proteins 0.000 description 1
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 1
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 description 1
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000584743 Homo sapiens Recombining binding protein suppressor of hairless Proteins 0.000 description 1
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 1
- 102100034980 ICOS ligand Human genes 0.000 description 1
- 206010021450 Immunodeficiency congenital Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 201000004404 Neurofibroma Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 102000004473 OX40 Ligand Human genes 0.000 description 1
- 108010042215 OX40 Ligand Proteins 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 102000004503 Perforin Human genes 0.000 description 1
- 108010056995 Perforin Proteins 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 101150093191 RIR1 gene Proteins 0.000 description 1
- 102100030000 Recombining binding protein suppressor of hairless Human genes 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 102000004389 Ribonucleoproteins Human genes 0.000 description 1
- 108010081734 Ribonucleoproteins Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 101800001271 Surface protein Proteins 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 1
- 241000270666 Testudines Species 0.000 description 1
- 201000009365 Thymic carcinoma Diseases 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 206010073328 Undifferentiated nasopharyngeal carcinoma Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 241000021375 Xenogenes Species 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 210000001943 adrenal medulla Anatomy 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000000981 bystander Effects 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 108010011219 dUTP pyrophosphatase Proteins 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 210000002050 maxilla Anatomy 0.000 description 1
- 210000001370 mediastinum Anatomy 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 201000011682 nervous system cancer Diseases 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 208000029974 neurofibrosarcoma Diseases 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 210000002747 omentum Anatomy 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 206010030979 oral hairy leukoplakia Diseases 0.000 description 1
- 208000020668 oropharyngeal carcinoma Diseases 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000002888 pairwise sequence alignment Methods 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 210000003681 parotid gland Anatomy 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 210000001599 sigmoid colon Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 208000023747 urothelial carcinoma Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000006490 viral transcription Effects 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/03—Herpetoviridae, e.g. pseudorabies virus
- C07K14/05—Epstein-Barr virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1114—T cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Definitions
- the present disclosure relates at least to the fields of molecular and cell biology, immunology, and also relates to methods of medical treatment and prophylaxis.
- NPC undifferentiated nasopharyngeal carcinomas
- EBV Epstein-Barr virus
- EBV+malignancies occurring outside the setting of immunosuppression express only 1 to 4 of about 90 EBV proteins and whilst these antigens are poorly immunogenic, they provide target antigens for EBVSTs.
- EBV-specific T cells to treat EBV-positive malignancies employ EBV-transformed B cells in the expansion of EBV-specific T cells (NCT02578641), or involve stimulating PBMCs with peptides corresponding to EBV type II latency antigens (NCT01555892).
- the present disclosure is based on the unexpected finding that peptides corresponding to EBV lytic antigens can be used to generate/expand populations of EBV-specific immune cells which are useful for the treatment of EBV-associated diseases.
- populations of immune cells generated/expanded by stimulating immune cells using peptides of EBV lytic antigens display cytolytic activity against EBV-infected cells.
- populations of immune cells generated/expanded by stimulating immune cells using peptides of EBV lytic antigens are demonstrated to display similar or improved ability to treat EBV-positive cancer in vivo as compared to populations of immune cells generated/expanded by stimulating immune cells using peptides of EBV latent antigens.
- the inventors further demonstrate that populations of immune cells comprising immune cells specific for EBV lytic antigens and immune cells specific for EBV latent antigens are more effective for treating EBV-associated disease than populations of immune cells comprising immune cells specific for EBV latent antigens only.
- the present disclosure provides a method for generating or expanding a population of immune cells comprising immune cells specific for an Epstein Barr Virus (EBV) lytic antigen, comprising stimulating immune cells specific for an EBV lytic antigen by contacting peripheral blood mononuclear cells (PBMCs) with: (i) one or more peptides corresponding to all or part of one or more EBV lytic antigens; or (ii) antigen presenting cells (APCs) presenting one or more peptides corresponding to all or part of one or more EBV lytic antigens.
- EBV Epstein Barr Virus
- the method further comprises re-stimulating the immune cells specific for an EBV lytic antigen by contacting them with APCs presenting one or more peptides corresponding to all or part of one or more EBV lytic antigens.
- Also provided is a method for generating or expanding a population of immune cells comprising immune cells specific for an Epstein Barr Virus (EBV) lytic antigen and immune cells specific for an EBV latent antigen, comprising stimulating immune cells specific for an EBV lytic antigen and immune cells specific for an EBV latent antigen by contacting peripheral blood mononuclear cells (PBMCs) with: (i) one or more peptides corresponding to all or part of one or more EBV lytic antigens, and one or more peptides corresponding to all or part of one or more EBV latent antigens; or (ii) antigen presenting cells (APCs) presenting one or more peptides corresponding to all or part of one or more EBV lytic antigens, and one or more peptides corresponding to all or part of an EBV latent antigen.
- PBMCs peripheral blood mononuclear cells
- APCs antigen presenting cells
- the method further comprises re-stimulating the immune cells specific for an EBV lytic antigen and the immune cells specific for an EBV latent antigen by contacting them with APCs presenting one or more peptides corresponding to all or part of one or more EBV lytic antigens, and one or more peptides corresponding to all or part of an EBV latent antigen.
- the one or more EBV lytic antigens are selected from BZLF1, BRLF1, BMLF1, BMRF1, BXLF1, BALF1, BALF2, BGLF5, BHRF1, BNLF2A, BNLF2B, BHLF1, BLLF2, BKRF4, BMRF2, BALF4, BILF1, BILF2, BNFR1, BVRF2, BALF3, BALF5 and BDLF3.
- the one or more EBV lytic antigens are selected from the group consisting of BZLF1, BRLF1, BMLF1, BMRF1, BXLF1, BALF1, BALF2, BGLF5, BHRF1, BNLF2A, BNLF2B, BHLF1, BLLF2, BKRF4, BMRF2, BALF4, BILF1, BILF2, BNFR1, BVRF2, BALF3, BALF5, BDLF3, and a combination thereof.
- the one or more EBV lytic antigens are selected from BZLF1, BRLF1, BMLF1, BMRF1, BALF2, BNLF2A, BNLF2B, BMRF2 and BDLF3. In some embodiments the one or more EBV lytic antigens are selected from the group consisting of BZLF1, BRLF1, BMLF1, BMRF1, BALF2, BNLF2A, BNLF2B, BMRF2, BDLF3, and a combination thereof.
- the one or more EBV latent antigens are selected from EBNA1, EBNA-LP, EBNA2, EBNA3A, EBNA3B, EBNA3C, BARF1, LMP1, LMP2A and LMP2B. In some embodiments the one or more EBV latent antigens are selected from the group consisting of EBNA1, EBNA-LP, EBNA2, EBNA3A, EBNA3B, EBNA3C, BARF1, LMP1, LMP2A, LMP2B, and a combination thereof.
- the one or more EBV latent antigens are selected from EBNA1, LMP1, LMP2A and LMP2B. In some embodiments the one or more EBV latent antigens are selected from the group consisting of EBNA1, LMP1, LMP2A, LMP2B, and a combination thereof.
- the PBMCs are PBMCs depleted of CD45RA-positive cells.
- EBV Epstein Barr Virus
- Also provided is an isolated population of immune cells comprising immune cells specific for an Epstein Barr Virus (EBV) lytic antigen and immune cells specific for an EBV latent antigen.
- EBV Epstein Barr Virus
- composition comprising an isolated population of immune cells according to the present disclosure.
- the disease or disorder associated with EBV infection is an EBV-associated cancer.
- the cancer is an EBV-associated cancer.
- the EBV-associated cancer is selected from EBV-positive lymphoma, EBV-positive nasopharyngeal carcinoma, and EBV-positive gastric carcinoma.
- Also provided is a method for killing a cell infected with EBV comprising contacting a cell infected with EBV with an isolated population of immune cells or a pharmaceutical composition according to the present disclosure.
- the method may be an in vitro or an in vivo method.
- Also provided is a method for killing a cancer cell comprising contacting a cancer cell with an isolated population of immune cells or a pharmaceutical composition according to the present disclosure.
- the method may be an in vitro or an in vivo method.
- the cancer cell is infected with EBV.
- the present disclosure is based on the unexpected finding that immune cells specific for EBV lytic antigens are capable of killing EBV-infected cells, and that populations of cells comprising immune cells specific for EBV latent antigens and EBV lytic antigens display improved ability to control EBV-positive malignancies as compared to populations of cells only comprising immune cells specific for EBV latent antigens.
- Epstein-Barr Virus (EBV) virology is described e.g. in Stanfield and Heiliq, F1000Res. (2017) 6:386 and Odumade et al., Clin Microbiol Rev (2011) 24(1):193-209, both of which are hereby incorporated by reference in entirety.
- EBV infects epithelial cells via binding of viral protein BMRF2 to ⁇ 1 integrins, and binding of viral protein gH/gL with integrins av ⁇ 6 and av ⁇ 8.
- EBV infects B cells through interaction of viral glycoprotein gp350 with CD21 and/or CD35, followed by interaction of viral gp42 with MHC class II. These interactions trigger fusion of the viral envelope with the cell membrane, allowing the virus to enter the cell. Once inside, the viral capsid dissolves and the viral genome is transported to the nucleus.
- EBV has two modes of replication; latent and lytic.
- the latent cycle does not result in production of virions, and can take place in place B cells and epithelial cells.
- the EBV genome circular DNA resides in the cell nucleus as an episome and is copied by the host cell's DNA polymerase.
- latency only a fraction of EBV's genes are expressed, in one of three different patterns known as latency programs, which produce distinct sets of viral proteins and RNAs.
- the latent cycle is described e.g. in Amon and Farrell, Reviews in Medical Virology (2004) 15(3): 149-56, which is hereby incorporated by reference in entirety.
- Latency programs II and III further involve expression of EBNALP, LMP1, LMP2A and LMP2B proteins, and latency program III further involves expression of EBNA2, EBNA3A, EBNA3B and EBNA3C.
- EBNA1 is multifunctional, and has roles in gene regulation, extrachromosomal replication, and maintenance of the EBV episomal genome through positive and negative regulation of viral promoters (Duellman et al., J Gen Virol. (2009); 90(Pt 9): 2251-2259).
- EBNA2 is involved in the regulation of latent viral transcription and contributes to the immortalization of cells infected with EBV (Kempkes and Ling, Curr Top Microbiol Immunol. (2015) 391:35-59).
- EBNA-LP is required for transformation of native B cells, and recruits transcription factors for viral replication (Szymula et al., PLoS Pathog. (2016); 14(2):e1006890).
- EBNA3A, 3B and 3C interact with RBPJ to influence gene expression, contributing to survival and growth of infected cells (Wang et al., J Virol. (2016) 90(6):2906-2919).
- LMP1 regulates expression of genes involved in B cell activation (Chang et al., J. Biomed. Sci. (2003) 10(5): 490-504).
- LMP2A and LMP2B inhibit normal B-cell signal transduction by mimicking the activated B-cell receptor (Portis and Longnecker, Oncogene (2004) 23(53): 8619-8628).
- EBERs form ribonucleoprotein complexes with host cell proteins, and are proposed to have roles in cell transformation.
- the latent cycle can progress according to any of latency programs I to III in B cells, and usually progresses from III to II to I.
- EBV Upon infection of a resting na ⁇ ve B cell, EBV enters latency program III. Expression of latency III genes activates the B cell, which becomes a proliferating blast. EBV then typically progresses to latency II by restricting expression to a subset of genes, which cause differentiation of the blast to a memory B cell. Further restriction of gene expression causes EBV to enter latency I.
- EBNA1 expression allows EBV to replicate when the memory B cell divides. In epithelial cells, only latency II occurs.
- EBV In primary infection, EBV replicates in oropharyngeal epithelial cells and establishes Latency III, II, and I infections in B-lymphocytes. EBV latent infection of B-lymphocytes is necessary for virus persistence, subsequent replication in epithelial cells, and release of infectious virus into saliva. EBV Latency III and II infections of B-lymphocytes, Latency II infection of oral epithelial cells, and Latency II infection of NK- or T-cell can result in malignancies, marked by uniform EBV genome presence and gene expression.[26]
- Latent EBV in B cells can be reactivated to switch to lytic replication.
- the lytic cycle results in the production of infectious virions and can take place in place B cells and epithelial cells, and is reviewed e.g. by Kenney in Chapter 25 of Arvin et al., Human Herpesviruses: Biology, Therapy and Immunoprophylaxis; Cambridge University Press (2007), which is hereby incorporated by reference in entirety.
- Lytic replication requires the EBV genome to be linear.
- the latent EBV genome is episomal, and so it must be linearised for lytic reactivation.
- lytic replication normally only takes place after reactivation from latency.
- Immediate-early lytic gene products such as BZLF1 and BRLF1 act as transactivators, enhancing their own expression, and the expression of later lytic cycle genes.
- Early lytic gene products have roles in viral replication (e.g. EBV DNA polymerase catalytic component BALF5; DNA polymerase processivity factor BMRF1, DNA binding protein BALF2, helicase BBLF4, primase BSLF1, and primase-associated protein BBLF2/3) and deoxynucleotide metabolism (e.g. thymidine kinase BXLF1, dUTPase BORF2).
- Other early lytic gene products act transcription factors (e.g. BMRF1, BRRF1), have roles in RNA stability and processing (e.g. BMLF1), or are involved in immune evasion (e.g. BHRF1, which inhibits apoptosis).
- Late lytic gene products are traditionally classed as those expressed after the onset of viral replication. They generally encode structural components of the virion such as nucleocapsid proteins, as well as glycoproteins which mediate EBV binding and fusion (e.g. gp350/220, gp85, gp42, gp25). Other late lytic gene products have roles in immune evasion; BCLF1 encodes a viral homologue of IL-10, and BALF1 encodes a protein with homology to the anti-apoptotic protein Bcl2.
- EBV antigens expressed in EBV-positive cancers are described e.g. in Craddock and Heslop Update Cancer Ther. (2008) March; 3(1): 33-41, Gottschalk and Rooney Curr Top Microbiol Immunol. (2015) 391: 427-454, and Shinozaki-Ushiku et al., Int J Oncol. (2015) 46(4):1421-34.
- EBV-associated lymphoma arising in immunocompromised subjects e.g. following HSCT or solid organ transplant, subjects having congenital immunodeficiency or HIV infection display type III latency, and express EBNA1, EBNA2, EBNA-LP, EBNA3A, EBNA3B, EBNA3C, BARF1, LMP1 and LMP2.
- EBV-positive Burkitt's lymphoma displays type I latency, expressing EBNA1 and BARF1.
- EBV-positive gastric carcinoma displays type I or type II latency.
- EBV latent antigens and not lytic cycle antigens
- lytic cycle gene products have recently been detected in EBV-positive malignancies including gastric carcinoma, nasopharyngeal carcinoma and B cell lymphoma.
- aspects of the present disclosure employ peptides corresponding to EBV antigens.
- an EBV lytic antigen is selected from BZLF1, BRLF1, BMLF1, BMRF1, BXLF1, BALF1, BALF2, BARF1, BGLF5, BHRF1, BNLF2A, BNLF2B, BHLF1, BLLF2, BKRF4, BMRF2, FU, EBNA1-FUK, BALF4, BILF1, BILF2, BNFR1, BVRF2, BALF3, BALF5, BDLF3 and gp350.
- the EBV lytic antigen may be selected from the group consisting of BZLF1, BRLF1, BMLF1, BMRF1, BXLF1, BALF1, BALF2, BARF1, BGLF5, BHRF1, BNLF2A, BNLF2B, BHLF1, BLLF2, BKRF4, BMRF2, FU, EBNA1-FUK, BALF4, BILF1, BILF2, BNFR1, BVRF2, BALF3, BALF5, BDLF3, gp350, and a combination thereof.
- an EBV lytic antigen is selected from BZLF1, BRLF1, BMLF1, BMRF1, BXLF1, BALF1, BALF2, BGLF5, BHRF1, BNLF2A, BNLF2B, BHLF1, BLLF2, BKRF4, BMRF2, BALF4, BILF1, BILF2, BNFR1, BVRF2, BALF3, BALF5 and BDLF3.
- the EBV lytic antigen may be selected from the group consisting of BZLF1, BRLF1, BMLF1, BMRF1, BXLF1, BALF1, BALF2, BGLF5, BHRF1, BNLF2A, BNLF2B, BHLF1, BLLF2, BKRF4, BMRF2, BALF4, BILF1, BILF2, BNFR1, BVRF2, BALF3, BALF5, BDLF3 and a combination thereof.
- an EBV lytic antigen is selected from BZLF1, BRLF1, BMLF1, BMRF1, BALF2, BNLF2A, BNLF2B, BMRF2 and BDLF3.
- the EBV lytic antigen may be selected from the group consisting of BZLF1, BRLF1, BMLF1, BMRF1, BALF2, BNLF2A, BNLF2B, BMRF2, BDLF3 and a combination thereof.
- an EBV lytic antigen is selected from BZLF1, BRLF1, BMRF1, BMLF1, BXLF1, BALF1, BLLF2, BALF2, BNLF2A, BNLF2B and BMRF2.
- the EBV lytic antigen may be selected from the group consisting of BZLF1, BRLF1, BMRF1, BMLF1, BXLF1, BALF1, BLLF2, BALF2, BNLF2A, BNLF2B, BMRF2, and a combination thereof.
- an EBV lytic antigen is selected from BZLF1, BRLF1, BMRF1, BMLF1, BXLF1, BALF1, BLLF2, BALF2 and BNLF2A.
- the EBV lytic antigen may be selected from the group consisting of BZLF1, BRLF1, BMRF1, BMLF1, BXLF1, BALF1, BLLF2, BALF2, BNLF2A, and a combination thereof.
- an EBV lytic antigen is selected from BZLF1, BRLF1, BMRF1, BMLF1, BALF2, BNLF2A, BNLF2B and BMRF2.
- the EBV lytic antigen may be selected from the group consisting of BZLF1, BRLF1, BMRF1, BMLF1, BALF2, BNLF2A, BNLF2B, BMRF2, and a combination thereof.
- an EBV lytic antigen is selected from an immediate-early lytic antigen, an early lytic antigen or a late lytic antigen.
- an immediate-early lytic antigen is selected from BZLF1, BRLF1 and BMRF1.
- the immediate-early lytic antigen may be selected from the group consisting of BZLF1, BRLF1, BMRF1, and a combination thereof.
- an early lytic antigen is selected from BMLF1, BMRF1, BXLF1, BALF1, BALF2, BARF1, BGLF5, BHRF1, BNLF2A, BNLF2B, BHLF1, BLLF2, BKRF4, BMRF2, FU and EBNA1-FUK.
- the early lytic antigen may be selected from the group consisting of BMLF1, BMRF1, BXLF1, BALF1, BALF2, BARF1, BGLF5, BHRF1, BNLF2A, BNLF2B, BHLF1, BLLF2, BKRF4, BMRF2, FU, EBNA1-FUK, and a combination thereof.
- an early lytic antigen is selected from BMLF1, BMRF1, BXLF1, BALF1, BALF2, BGLF5, BHRF1, BNLF2A, BNLF2B, BHLF1, BLLF2, BKRF4 and BMRF2.
- the early lytic antigen may be selected from the group consisting of BMLF1, BMRF1, BXLF1, BALF1, BALF2, BGLF5, BHRF1, BNLF2A, BNLF2B, BHLF1, BLLF2, BKRF4, BMRF2, and a combination thereof.
- an early lytic antigen is selected from BMLF1, BMRF1, BALF2, BNLF2A, BNLF2B and BMRF2.
- the early lytic antigen may be selected from the group consisting of BMLF1, BMRF1, BALF2, BNLF2A, BNLF2B, BMRF2, and a combination thereof.
- a late lytic antigen is selected from BALF4, BILF1, BILF2, BNFR1, BVRF2, BALF3, BALF5, BDLF3 and gp350.
- a late lytic antigen may be selected from the group consisting of BALF4, BILF1, BILF2, BNFR1, BVRF2, BALF3, BALF5, BDLF3, gp350, and a combination thereof.
- a late lytic antigen is selected from BALF4, BILF1, BILF2, BNFR1, BVRF2, BALF3, BALF5 and BDLF3.
- a late lytic antigen may be selected from the group consisting of BALF4, BILF1, BILF2, BNFR1, BVRF2, BALF3, BALF5, BDLF3, and a combination thereof.
- a late lytic antigen is BDLF3.
- an EBV latent antigen is selected from EBNA1, EBNA-LP, EBNA2, EBNA3A, EBNA3B, EBNA3C, BARF1, LMP1, LMP2A and LMP2B.
- An EBV latent antigen may be selected from the group consisting of EBNA1, EBNA-LP, EBNA2, EBNA3A, EBNA3B, EBNA3C, BARF1, LMP1, LMP2A, LMP2B, and a combination thereof.
- an EBV latent antigen is selected from EBNA1, LMP1, LMP2A and LMP2B.
- An EBV latent antigen may be selected from the group consisting of EBNA1, LMP1, LMP2A, LMP2B, and a combination thereof. In some embodiments, an EBV latent antigen is selected from EBNA1, LMP1 and LMP2A. The EBV latent antigen may be selected from the group consisting of EBNA1, LMP1, LMP2A, and a combination thereof.
- an EBV latent antigen is selected from type III latency antigen, a type II latency antigen or a type I latency antigen.
- a type III latency antigen is selected from EBNA1, EBNA-LP, LMP1, LMP2A, LMP2B, BARF1, EBNA2, EBNA3A, EBNA3B and EBNA3C.
- the type III latency antigen may be selected from the group consisting of EBNA1, EBNA-LP, LMP1, LMP2A, LMP2B, BARF1, EBNA2, EBNA3A, EBNA3B, EBNA3C, and a combination thereof.
- a type II latency antigen is selected from EBNA1, EBNA-LP, LMP1, LMP2A, LMP2B and BARF1.
- a type II latency antigen may be selected from the group consisting of EBNA1, EBNA-LP, LMP1, LMP2A, LMP2B, BARF1, and a combination thereof.
- a type I latency antigen is selected from EBNA1 and BARF1.
- a type I latency antigen may be selected from the group consisting of EBNA1, BARF1, and a combination thereof.
- EBV antigen e.g. an EBV antigen referred to herein
- the present disclosure also contemplates isoforms, fragments, variants (including mutants) of the given EBV antigen.
- the amino acid sequence for a given EBV antigen e.g. an EBV antigen referred to herein, can be retrieved e.g. from The UniProt Knowledgebase (UniProtKB)—see The UniProt Consortium, Nucleic Acids Research (2019), 47(D1): D506-D515.
- an “isoform”, “fragment” or “variant” of a reference EBV antigen may optionally be characterised as having at least 60%, preferably one of 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of the reference EBV antigen (e.g. a reference isoform of the antigen).
- a “fragment” generally refers to a fraction of the reference protein, and may be of any length (by number of amino acids), although may optionally be at least 20% of the length of the reference protein (that is, the protein from which the fragment is derived) and may have a maximum length of one of 50%, 75%, 80%, 85%, 90%, 95% or 99% of the length of the reference protein.
- a “variant” generally refers to a protein having an amino acid sequence comprising one or more amino acid substitutions, insertions, deletions or other modifications relative to the amino acid sequence of the reference protein, but retaining a considerable degree of sequence identity (e.g. at least 60%) to the amino acid sequence of the reference protein.
- An “isoform” generally refers to a variant of the reference protein expressed by EBV.
- references to “one or more” antigens from a given list means anywhere between one and all of the antigens recited in the list. Depending on the number of antigens listed, reference to “one or more” can mean e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, etc. of the recited antigens.
- aspects of the present disclosure employ peptides corresponding to EBV antigens in methods to generate/expand populations of immune cells specific for EBV antigens.
- a “peptide” refers to a chain of two or more amino acid monomers linked by peptide bonds.
- a peptide typically has a length in the region of about 2 to 50 amino acids.
- a “polypeptide” is a polymer chain of two or more peptides. Polypeptides typically have a length greater than about 50 amino acids.
- a peptide which “corresponds to” a reference antigen comprises or consists of an amino acid sequence of the reference antigen.
- a peptide “corresponding to” EBNA1 comprises or consists of a sequence of amino acids which is found within the amino acid sequence of EBNA1 (i.e. is a subsequence of the amino acid sequence of EBNA1).
- Peptides employed herein typically have a length of 5-30 amino acids, e.g. one of 5-25 amino acids, 10-20 amino acids, or 12-18 amino acids. In some embodiments, peptides have a length of one of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acids. In some embodiments, peptides have a length of about 15 amino acids.
- Proteins as used herein may refer to populations comprising non-identical peptides.
- the methods employ peptides corresponding to more than one antigen.
- the peptides comprise at least one peptide corresponding to EBNA1, and at least one peptide corresponding to LMP1.
- the methods employ peptides corresponding to all or part of a reference antigen.
- Peptides corresponding to all of a given antigen cover the full length of the amino acid sequence of the antigen. That is to say that together, the peptides contain all of the amino acids of the amino acid sequence of the given antigen.
- Peptides corresponding to part of a given antigen cover part of the amino acid sequence of the antigen.
- the peptides together may cover e.g. greater than 10%, e.g. greater than one of 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95% of the amino acid sequence of the antigen.
- the methods employ overlapping peptides.
- “Overlapping” have amino acids, and more typically sequences of amino acids, in common.
- a first peptide consists of an amino acid sequence corresponding to positions 1 to 15 of the amino acid sequence of EBNA1
- a second peptide consists of an amino acid sequence corresponding to positions 5 to 20 of the amino acid sequence of EBNA1.
- the first and second peptides are overlapping peptides corresponding to EBNA1, overlapping by 11 amino acids.
- overlapping peptides overlap by one of 1-20, 5-20, 8-15 or 10-12 amino acids. In some embodiments overlapping peptides overlap by one of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acids. In some embodiments overlapping peptides overlap by 11 amino acids.
- the methods employ peptides having a length of 5-30 amino acids, overlapping by 1-20 amino acids, corresponding to all or part of a given reference antigen.
- the methods employ peptides having a length of 15 amino acids, overlapping by 11 amino acids, corresponding to all a given reference antigen. Mixtures of such peptides may be referred to herein as “pepmix peptide pools” or “pepmixes” for a given antigen.
- EBNA1 pepmix used in Example 1 herein refers to a pool of 158, 15mer peptides overlapping by 11 amino acids, spanning the full length of the amino acid sequence for EBNA1 as shown in UniProt: P03211-1, v1.
- peptides corresponding to” a given EBV antigen may be pepmix for the antigen.
- aspects of the present disclosure concern generating/expanding populations of immune cells specific for EBV.
- an “immune cell specific for EBV” expresses/comprises a receptor (preferably a T cell receptor) capable of recognising a peptide of an antigen of EBV (e.g. when presented by an MHC molecule).
- EBV-specific immune cells may express/comprise such a receptor as a result of expression of endogenous nucleic acid encoding such antigen receptor, or as a result of having been engineered to express such a receptor.
- the immune cells may be a cell of hematopoietic origin, e.g. a neutrophil, eosinophil, basophil, dendritic cell, lymphocyte, or monocyte.
- a lymphocyte may be e.g. a T cell, B cell, NK cell, NKT cell or innate lymphoid cell (ILC), or a precursor thereof.
- the immune cell may express e.g. CD3 polypeptides (e.g. CD3 ⁇ CD3 ⁇ CD3 ⁇ or CD3 ⁇ ), TCR polypeptides (TCR ⁇ or TCR ⁇ ), CD27, CD28, CD4 or CD8.
- Typical culture conditions i.e. cell culture media, additives, temperature, gaseous atmosphere), cell numbers, culture periods, etc. can be determined by reference e.g. to Ngo et al., J Immunother. (2014) 37(4):193-203, which is hereby incorporated by reference in its entirety.
- cultures of cells according to the present disclosure may be maintained at 37° C. in a humidified atmosphere containing 5% CO 2 .
- the cells of cell cultures according to the present disclosure can be established and/or maintained at any suitable density, as can readily be determined by the skilled person. For example, cultures may be established at an initial density of ⁇ 0.5 ⁇ 10 6 to ⁇ 5 ⁇ 10 6 cells/ml of the culture (e.g. ⁇ 1 ⁇ 10 6 cells/ml).
- Cultures can be performed in any vessel suitable for the volume of the culture, e.g. in wells of a cell culture plate, cell culture flasks, a bioreactor, etc.
- cells are cultured in a bioreactor, e.g. a bioreactor described in Somerville and Dudley, Oncoimmunology (2012) 1(8):1435-1437, which is hereby incorporated by reference in its entirety.
- cells are cultured in a GRex cell culture vessel, e.g. a GRex flask or a GRex 100 bioreactor.
- the methods generally comprise culturing populations of immune cells (e.g. heterogeneous populations of immune cells (e.g. peripheral blood mononuclear cells; PBMCs) comprising cells having antigen-specific receptors in the presence of antigen-presenting cells (APCs) presenting viral antigen peptide:MHC complexes, under conditions providing appropriate costimulation and signal amplification so as to cause activation and expansion.
- PBMCs peripheral blood mononuclear cells
- APCs antigen-presenting cells
- T cell activation is well known to the skilled person and described in detail, for example, in Immunobiology, 5th Edn. Janeway C A Jr, Travers P, Walport M, et al. New York: Garland Science (2001), Chapter 8, which is incorporated by reference in its entirety.
- the methods involve steps in which T cells comprising T cell receptors (TCRs) specific for EBV antigen peptide:MHC complex are stimulated by APCs presenting the EBV antigen peptide:MHC complex for which the TCR is specific.
- TCRs T cell receptors
- the APCs are infected with virus encoding, or comprise/express the EBV antigen/peptide(s), and present the EBV antigen peptide in the context of an MHC molecule. Stimulation causes T cell activation, and promotes cell division (proliferation), resulting in generation and/or expansion of a population of T cells specific for the EBV antigen.
- the population of cells obtained following stimulation is enriched for T cells specific for the EBV antigen as compared to the population prior to stimulation (i.e. the EBV antigen-specific T cells are present at an increased frequency in the population following stimulation).
- a population of T cells specific for the EBV antigen is expanded/generated out of a heterogeneous population of T cells having different specificities.
- a population of T cells specific for an EBV antigen may be generated from a single T cell by stimulation and consequent cell division.
- An existing population of T cells specific for an EBV antigen may be expanded by stimulation and consequent cell division of cells of the population of EBV antigen-specific T cells.
- the immune cells specific for EBV antigens herein are preferably T cells.
- the T cell is a CD3+, CD4+ T cell.
- the T cell is a CD3+, CD8+ T cell.
- the T cell is a T helper cell (TH cell).
- the T cell is a cytotoxic T cell (e.g. a cytotoxic T lymphocyte (CTL)).
- CTL cytotoxic T lymphocyte
- An EBV-specific T cell may display certain functional properties of a T cell in response to the viral antigen for which the T cell is specific, or in response a cell comprising/expressing the virus/antigen.
- the properties are functional properties associated with effector T cells, e.g. cytotoxic T cells.
- an EBV-specific T cell may display one or more of the following properties: cytotoxicity to a cell comprising/expressing EBV or the EBV antigen for which the T cell is specific; proliferation, IFN ⁇ expression, CD107a expression, IL-2 expression, TNF ⁇ expression, perforin expression, granzyme expression, granulysin expression, and/or FAS ligand (FASL) expression in response to a cell comprising/expressing EBV or the EBV antigen for which the T cell is specific.
- cytotoxicity to a cell comprising/expressing EBV or the EBV antigen for which the T cell is specific proliferation, IFN ⁇ expression, CD107a expression, IL-2 expression, TNF ⁇ expression, perforin expression, granzyme expression, granulysin expression, and/or FAS ligand (FASL) expression in response to a cell comprising/expressing EBV or the EBV antigen for which the T cell is specific.
- EBV-specific T cells express/comprise a TCR capable of recognising a peptide of the EBV antigen for which the T cell is specific when presented by the appropriate MHC molecule.
- EBV-specific T cells may be CD4+ T cells and/or CD8+ T cells.
- the methods of the present disclosure comprise stimulating immune cells specific for an EBV antigen by contacting populations of immune cells with peptide(s) corresponding to EBV antigen(s) or APCs presenting peptide(s) corresponding to EBV antigen(s).
- stimulations or stimulation steps”.
- Such method steps typically involve maintenance of the cells in culture in vitro/ex vivo, and may be referred to as “stimulation cultures”.
- the methods comprise one or more additional stimulation steps. That is, in some embodiments the methods comprise one or more further steps of re-stimulating the cells obtained by a stimulation step. Such further stimulation steps may be referred to herein as “re-stimulations” or “re-stimulation steps”. Such method steps typically involve maintenance of the cells in culture in vitro/ex vivo, and may be referred to as “re-stimulation cultures”.
- contacting PBMCs (for stimulations) or populations of cells obtained by stimulation step described herein (for re-stimulations) with peptide(s) corresponding to EBV antigen(s) generally involves culturing the PBMCs/population of cells in vitro/ex vivo in cell culture medium comprising the peptide(s).
- contacting PBMCs/populations of cells with APCs presenting peptide(s) corresponding to EBV antigen(s) generally involves co-culturing the APCs and the PBMCs/population of cells in vitro/ex vivo in cell culture medium.
- the methods comprise contacting PBMCs with peptide(s) corresponding to EBV antigen(s).
- APCs within the population of PBMCs e.g. dendritic cells, macrophages and B cells
- internalise e.g. by phagocytosis, pinocytosis
- the methods comprise contacting the population of cells obtained by a stimulation step described herein with peptide(s) corresponding to EBV antigen(s).
- APCs within the population of cells e.g. dendritic cells, macrophages and B cells
- internalise e.g. by phagocytosis, pinocytosis
- the methods comprise contacting PBMCs with APCs presenting peptide(s) corresponding to EBV antigen(s). In some embodiments, the methods comprise contacting the population of cells obtained by a stimulation step described herein with APCs presenting peptide(s) corresponding to EBV antigen(s).
- Co-culture of T cells and APCs in stimulations and re-stimulations according to the disclosure is performed in cell culture medium.
- the cell culture medium can be any cell culture medium in which T cells and APCs according can be maintained in culture in vitro/ex vivo.
- Culture medium suitable for use in the culture of lymphocytes is well known to the skilled person, and includes, for example, RPMI-1640 medium, AIM-V medium, Iscoves medium, etc.
- cell culture medium may comprise RPMI-1640 medium and/or Click's medium (also known as Eagle's Ham's amino acids (EHAA) medium).
- RPMI-1640 medium also known as Eagle's Ham's amino acids (EHAA) medium.
- EHAA Eagle's Ham's amino acids
- the formulation of RPMI-1640 medium is described in e.g. Moore et al., JAMA (1967) 199:519-524, and the formulation of Click's media is described in Click et al., Cell Immunol (1972) 3:264-276.
- RPMI-1640 medium can be obtained from e.g. ThermoFisher Scientific
- Click's medium can be obtained from e.g. Sigma-Aldrich (Catalog No. C5572).
- the methods of the present disclosure involve culturing PBMCs that have been contacted with peptide(s) corresponding to EBV antigen(s), or in the presence of APCs presenting peptide(s) corresponding to EBV antigen(s), in cell culture medium comprising RPMI-1640 medium and Click's medium.
- the methods of the present disclosure involve culturing the population of cells obtained by a stimulation step described herein that have been contacted with peptide(s) corresponding to EBV antigen(s), or in the presence of APCs presenting peptide(s) corresponding to EBV antigen(s), in cell culture medium comprising RPMI-1640 medium and Click's medium.
- the cell culture medium comprises (by volume) 25-65% RPMI-1640 medium, and 25-65% Click's medium. In some embodiments the cell culture medium comprises 30-60% RPMI-1640 medium, and 30-60% Click's medium. In some embodiments the cell culture medium comprises 35-55% RPMI-1640 medium, and 35-55% Click's medium. In some embodiments the cell culture medium comprises 40-50% RPMI-1640 medium, and 40-50% Click's medium. In some embodiments the cell culture medium comprises 45% RPMI-1640 medium, and 45% Click's medium.
- the cell culture medium may comprise one or more cell culture medium additives.
- Cell culture medium additives are well known to the skilled person, and include antibiotics (e.g. penicillin, streptomycin), serum (e.g. fetal bovine serum (FBS), bovine serum albumin (BSA)), L-glutamine, cytokines/growth factors, etc.
- the cell culture medium comprises (by volume) 5-20% FBS, e.g. 7.5-15% FBS, or 10% FBS. In some embodiments, the cell culture medium comprises 0.5-5% GlutaMax, e.g. 1% GlutaMax. In some embodiments, the cell culture medium comprises 0.5-5% Pen/Strep, e.g. 1% Pen/Strep.
- aspects of the present disclosure employ antigen-presenting cells (APCs) in methods for generating/expanding populations of immune cells specific for EBV.
- APCs antigen-presenting cells
- APCs according to the present disclosure may be professional APCs.
- Professional APCs are specialised for presenting antigen to T cells; they are efficient at processing and presenting MHC-peptide complexes at the cell surface, and express high levels of costimulatory molecules.
- Professional APCs include dendritic cells (DCs), macrophages, and B cells.
- Non-professional APCs are other cells capable of presenting MHC-peptide complexes to T cells, in particular MHC Class I-peptide complexes to CD8+ T cells.
- the APC is an APC capable of cross-presentation on MHC class I of antigen internalised by the APC (e.g. taken-up by endocytosis/phagocytosis).
- APCs capable of cross-presentation include e.g. dendritic cells (DCs), macrophages, B cells and sinusoidal endothelial cells.
- DCs dendritic cells
- macrophages macrophages
- B cells sinusoidal endothelial cells.
- APCs for stimulating immune cells specific for EBV antigen(s) are comprised within the population of cells (e.g. PBMCs) comprising the immune cells specific for EBV antigen(s), which populations of cells specific for EBV antigen(s) are to be expanded in accordance with the methods of the present disclosure.
- APCs may be e.g. dendritic cells, macrophages, B cells or any other cell type within the population of cells which is capable of presenting antigen to immune cells specific for EBV antigen(s)
- the methods employ APCs that have been modified to express/comprise EBV antigen(s)/peptide(s) thereof.
- the APCs may present peptide(s) corresponding to EBV antigen(s) as a result of having been contacted with the peptide(s), and having internalised them.
- APCs may have been “pulsed” with the peptide(s), which generally involves culturing APCs in vitro in the presence of the peptide(s), for a period of time sufficient for the APCs to internalise the peptide(s).
- the APCs may present peptide(s) corresponding to EBV antigen(s) as a result of expression from nucleic acid encoding the antigen within the cell.
- APCs may comprise nucleic acid encoding EBV antigen(s) as a consequence of their having been infected with EBV (e.g. in the case of B cells, e.g. LCLs).
- APCs may comprise nucleic acid encoding EBV antigen(s) as a consequence of nucleic acid encoding the antigen(s) having been introduced into the cell, e.g. via transfection, transduction, electroporation, etc.
- Nucleic acid encoding EBV antigen(s) may be provided in a plasmid/vector.
- APCs employed in the methods of the present disclosure are selected from activated T cells (ATCs), dendritic cells, B cells (including e.g. LCLs), and artificial antigen presenting cells (aAPCs) such as those described in Neal et al., J Immunol Res Ther (2017) 2(1):68-79 and Turtle and Riddell Cancer J. (2010) 16(4):374-381.
- ATCs activated T cells
- dendritic cells include e.g. LCLs
- aAPCs artificial antigen presenting cells
- APCs are autologous with respect to the population of cells with which they are to be co-cultured for the generation/expansion of populations of immune cells comprising immune cells specific for EBV antigen(s). That is, in some embodiments the APCs are from (or are derived from cells obtained from) the same subject as the subject from which the population of cells with which they are to be co-cultured were obtained.
- ATCs polyclonal activated T cells
- methods for preparing ATCs are described e.g. in Ngo et al., J Immunother. (2014) 37(4):193-203, incorporated by reference herienabove.
- ATCs can be generated by non-specifically activating T cells in vitro by stimulating PBMCs with agonist anti-CD3 and agonist anti-CD28 antibodies, in the presence of IL-2.
- Dendritic cells may be generated according to methods well known in the art, e.g. as described in Ngo et al., J Immunother. (2014) 37(4):193-203. Dendritic cells may be prepared from monocytes which may be obtained by CD14 selection from PBMCs. The monocytes may be cultured in cell culture medium causing their differentiation to immature dendritic cells, which may comprise e.g. IL-4 and GM-CSF. Immature dendritic cells may be matured by culture in the presence of IL-6, IL-1 ⁇ , TNF ⁇ , PGE2, GM-CSF and IL-4.
- IL-6 IL-6, IL-1 ⁇ , TNF ⁇ , PGE2, GM-CSF and IL-4.
- LCLs may be generated according to methods well known in the art, e.g. as described in in Hui-Yuen et al., J Vis Exp (2011) 57: 3321, and Hussain and Mulherkar, Int J Mol Cell Med (2012) 1(2): 75-87, both hereby incorporated by reference in their entirety. Briefly, LCLs can be produced by incubation of PBMCs with concentrated cell culture supernatant of cells producing EBV, for example B95-8 cells, in the presence of cyclosporin A.
- aAPCs Artificial antigen presenting cells
- K562cs cells which are engineered to express costimulatory molecules CD80, CD86, CD83 and 4-1 BBL (described e.g. in Suhoski et al., Mol Ther. (2007) 15(5):981-8).
- the APC is not a cell infected with EBV. In some embodiments the APC is not an EBV-infected B cell. In some embodiments the APC is not an EBV-LCL.
- a stimulation step comprises contacting PBMCs peptide(s) corresponding to EBV antigen(s).
- a re-stimulation step comprises contacting immune cells specific for EBV antigen(s) with APCs presenting peptide(s) corresponding to EBV antigen(s).
- a re-stimulation step comprises contacting immune cells specific for EBV antigen(s) with ATCs presenting peptide(s) corresponding to EBV antigen(s).
- the methods further employ agents for enhancing costimulation in stimulations and/or re-stimulations.
- agents include e.g. cells expressing costimulatory molecules (e.g. CD80, CD86, CD83 and/or 4-1 BBL), such as e.g. LCLs or K562cs cells.
- the cells expressing costimulatory molecules are HLA-negative, EBV replication-incompetent LCLs, which are also referred to as “universal LCLs” or “uLCLs”.
- uLCLs are described e.g. in US 2018/0250379 A1.
- agents for enhancing costimulation include e.g. agonist antibodies specific for costimulatory receptors expressed by T cells (e.g. 4-1 BB, CD28, OX40, ICOS, etc.), and costimulatory molecules capable of activating costimulatory receptors expressed by T cells (e.g. CD80, CD86, CD83, 4-1BBL, OX40L, ICOSL, etc.).
- costimulatory molecules capable of activating costimulatory receptors expressed by T cells e.g. CD80, CD86, CD83, 4-1BBL, OX40L, ICOSL, etc.
- Such agents may be provided e.g. immobilised on beads.
- a re-stimulation step comprises contacting immune cells specific for EBV antigen(s) with ATCs presenting peptide(s) corresponding to EBV antigen(s) in the presence of uLCLs.
- Contacting of populations of immune cells with peptide(s) corresponding to EBV antigen(s) or APCs presenting peptide(s) corresponding to EBV antigen(s) may be performed in the presence of one or more cytokines, to facilitate T cell activation and proliferation.
- stimulations are performed in the presence of one or more of IL-7, IL-15, IL-6, IL-12, IL-4, IL-2 and/or IL-21.
- the cytokines are added exogenously to the culture, and additional to cytokines that are produced by the cells in culture.
- the added cytokines are recombinantly-produced cytokines.
- the methods of the present disclosure involve culturing PBMCs that have been contacted with peptide(s) corresponding to EBV antigen(s), or in the presence of APCs presenting peptide(s) corresponding to EBV antigen(s), in the presence of one or more of IL-7, IL-15, IL-6, IL-12, IL-4, IL-2 and/or IL-21.
- culture is in the presence of IL-7, IL-15, IL-6, IL-12, IL-4, IL-2 and/or IL-21. In some embodiments culture is in the presence of IL-7, IL-15, IL-6 and/or IL-12. In some embodiments culture is in the presence of IL-7 and/or IL-15.
- the final concentration of IL-7 in the culture is 1-100 ng/ml, e.g. one of 2-50 ng/ml, 5-20 ng/ml or 7.5-15 ng/ml. In some embodiments the final concentration of IL-7 in the culture is about 10 ng/ml.
- the final concentration of IL-15 in the culture is 1-100 ng/ml, e.g. one of 2-50 ng/ml, 5-20 ng/ml or 7.5-15 ng/ml. In some embodiments the final concentration of IL-15 in the culture is about 10 ng/ml.
- the final concentration of IL-15 in the culture is 10-1000 ng/ml, e.g. one of 20-500 ng/ml, 50-200 ng/ml or 75-150 ng/ml. In some embodiments the final concentration of IL-15 in the culture is about 100 ng/ml.
- the final concentration of IL-6 in the culture is 10-1000 ng/ml, e.g. one of 20-500 ng/ml, 50-200 ng/ml or 75-150 ng/ml. In some embodiments the final concentration of IL-6 in the culture is about 100 ng/ml.
- the final concentration of IL-12 in the culture is 1-100 ng/ml, e.g. one of 2-50 ng/ml, 5-20 ng/ml or 7.5-15 ng/ml. In some embodiments the final concentration of IL-12 in the culture is 10 ng/ml.
- the final concentration of IL-7 is 1-100 ng/ml (e.g. one of 2-50 ng/ml, 5-20 ng/ml or 7.5-15 ng/ml, e.g. 10 ng/ml), and the final concentration of IL-15 is 10-1000 ng/ml (e.g. one of 20-500 ng/ml, 50-200 ng/ml or 75-150 ng/ml, e.g. about 100 ng/ml).
- the final concentration of IL-7 is 1-100 ng/ml (e.g. one of 2-50 ng/ml, 5-20 ng/ml or 7.5-15 ng/ml, e.g. 10 ng/ml), and the final concentration of IL-15 is 10-1000 ng/ml (e.g. one of 20-500 ng/ml, 50-200 ng/ml or 75-150 ng/ml, e.g. about 100 ng/ml).
- the final concentration of IL-7 is 1-100 ng/ml (e.g. one of 2-50 ng/ml, 5-20 ng/ml or 7.5-15 ng/ml, e.g. 10 ng/ml)
- the final concentration of IL-6 is 10-1000 ng/ml (e.g. one of 20-500 ng/ml, 50-200 ng/ml or 75-150 ng/ml, e.g. about 100 ng/ml)
- the final concentration of IL-12 is 1-100 ng/ml (e.g. one of 2-50 ng/ml, 5-20 ng/ml or 7.5-15 ng/ml, e.g.
- IL-15 is 1-100 ng/ml (e.g. one of 2-50 ng/ml, 5-20 ng/ml or 7.5-15 ng/ml, e.g. 10 ng/ml).
- the final concentration of IL-7 in a stimulation culture is 1-100 ng/ml (e.g. one of 2-50 ng/ml, 5-20 ng/ml or 7.5-15 ng/ml, e.g. 10 ng/ml), and the final concentration of IL-15 in a stimulation culture is 10-1000 ng/ml (e.g. one of 20-500 ng/ml, 50-200 ng/ml or 75-150 ng/ml, e.g. about 100 ng/ml).
- the final concentration of IL-7 in a stimulation culture is 1-100 ng/ml (e.g. one of 2-50 ng/ml, 5-20 ng/ml or 7.5-15 ng/ml, e.g. 10 ng/ml)
- the final concentration of IL-6 in a stimulation culture is 10-1000 ng/ml (e.g. one of 20-500 ng/ml, 50-200 ng/ml or 75-150 ng/ml, e.g. about 100 ng/ml)
- the final concentration of IL-12 in a stimulation culture is 1-100 ng/ml (e.g. one of 2-50 ng/ml, 5-20 ng/ml or 7.5-15 ng/ml, e.g.
- the final concentration of IL-15 in a stimulation culture is 1-100 ng/ml (e.g. one of 2-50 ng/ml, 5-20 ng/ml or 7.5-15 ng/ml, e.g. 10 ng/ml).
- the final concentration of IL-7 in a re-stimulation culture is 1-100 ng/ml (e.g. one of 2-50 ng/ml, 5-20 ng/ml or 7.5-15 ng/ml, e.g. 10 ng/ml), and the final concentration of IL-15 in a re-stimulation culture is 10-1000 ng/ml (e.g. one of 20-500 ng/ml, 50-200 ng/ml or 75-150 ng/ml, e.g. about 100 ng/ml).
- Stimulations and re-stimulations according to the present methods typically involve co-culture of T cells and APCs for a period of time sufficient for APCs to stimulate the T cells, and for the T cells to undergo cell division.
- the methods of the present disclosure involve culturing PBMCs that have been contacted with peptide(s) corresponding to EBV antigen(s), or in the presence of APCs presenting peptide(s) corresponding to EBV antigen(s), for a period of one of at least 1 hour, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 4 days, 5 days, 6 days, or at least 7 days.
- culture is for a period of 24 hours to 20 days, e.g. one of 48 hours to 14 days, 3 days to 12 days, 4 to 11 days, or 6 to 10 days or 7 to 9 days.
- the methods of the present disclosure involve culturing the population of cells obtained by a stimulation step described herein that have been contacted with peptide(s) corresponding to EBV antigen(s), or in the presence of APCs presenting peptide(s) corresponding to EBV antigen(s), for a period of one of at least 1 hour, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 4 days, 5 days, 6 days, or at least 7 days.
- culture is for a period of 24 hours to 20 days, e.g. one of 48 hours to 14 days, 3 days to 12 days, 4 to 11 days, or 6 to 10 days or 7 to 9 days.
- Stimulations and re-stimulations may be ended by separating the cells in culture from the media in which they have been cultured, or diluting the culture, e.g. by the addition of cell culture medium.
- the methods comprise a step of collecting the cells at the end of the stimulation or re-stimulation culture.
- a re-stimulation step according to the present disclosure may be established by adding cell culture medium (and any other additives as described herein) in an amount appropriate to achieve the desired percentages/concentrations of cell culture medium, conditioned media (and any additives) for the re-stimulation step.
- the cells may be collected and separated from the cell culture supernatant.
- the cells may be collected by centrifugation, and the cell culture supernatant may be separated from the cell pellet.
- the cell pellet may then be re-suspended in cell culture medium, e.g. for a re-stimulation step.
- the cells may undergo a washing step after collection.
- a washing step may comprise re-suspending the cell pellet in isotonic buffer such as phosphate-buffered saline (PBS), collecting the cells by centrifugation, and discarding the supernatant.
- PBS phosphate-buffered saline
- Methods for generating and/or expanding a populations of immune cells specific for EBV antigen(s) according to the present disclosure typically involve more than a single stimulation step. There is no upper limit to the number of stimulation steps which may be performed in a method according to the present disclosure. In some embodiments the methods comprise more than 2, 3, 4 or 5 stimulation steps. In some embodiments, the methods comprise one of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 stimulation steps. The stimulation steps in a method according to the present disclosure may be different to one another.
- the PBMCs employed in the methods of the disclosure are depleted of CD45RA-positive cells. That is, in some embodiments, the PBMCs are “CD45RA-positive cell-depleted PBMCs”, or are “CD45RA-negative PBMCs”. Depletion of CD45RA-positive cells is intended to reduce the number of NK cells and/or regulatory T cells in the populations of cells generated/expanded according to the methods of the disclosure.
- the methods comprise a step of depleting PBMCs of CD45RA-positive cells, e.g. prior to a stimulation step according to the disclosure. In some embodiments, the methods comprise a step of depleting the cells obtained by a stimulation step according to the present disclosure of CD45RA-positive cells, e.g. prior to a re-stimulation step according to the disclosure. Depletion of CD45RA-positive cells can be achieved by any suitable method, such as by MACS, for example using Miltenyi® Biotec columns and magnetic anti-CD45RA antibody-coated beads.
- the population of cells used to derive APCs employed in the methods of the disclosure is depleted of CD45RA-positive cells. That is, in some embodiments, the population of cells used to derive APCs is a “CD45RA-positive cell-depleted” or “CD45RA-negative” population.
- the ATCs may be derived from a population of CD45RA-positive cell-depleted PBMCs, or from a population of CD45RA-negative PBMCs.
- the methods further comprise modification of the immune cells specific for EBV antigen(s) to increase IL-7-mediated signalling in the cells.
- IL-7-mediated signalling has been shown to increases the survival and anti-tumor activity of tumor-specific T cells—see e.g. in Shum et al., Cancer Discov. (2017) 7(11):1238-1247, and WO 2018/038945 A1.
- B Stimulating immune cells specific for an EBV lytic antigen by contacting PBMCs with BZLF1 pepmix, BRLF1 pepmix, BMRF1 pepmix, BMLF1 pepmix, BXLF1 pepmix, BALF1 pepmix, BLLF2 pepmix, BALF2 pepmix and/or BNLF2A pepmix.
- C Stimulating immune cells specific for an EBV lytic antigen by contacting PBMCs with BZLF1 pepmix, BRLF1 and/or BMRF1 pepmix.
- (T) Stimulating immune cells according to any one of (L) to (S), wherein the APCs are ATCs.
- (W) Stimulating immune cells according to any one of (L) to (V), in the presence of IL-7 and/or IL-15.
- the methods of the present disclosure may optionally be characterised by reference to properties of the methods, and/or properties of the populations of immune cells generated/expanded by the methods.
- a population of immune cells generated/expanded in accordance with the methods of the present disclosure possess one or more of the following properties:
- Immunoblasts may be evaluated for whether they comprise cells which to produce IFN ⁇ in response to stimulation with peptide(s) corresponding to EBV antigens and/or EBV-infected cells (e.g. LCLs) e.g. by ELISPOT analysis, which may be performed e.g. as described in Example 2.
- peptide(s) corresponding to EBV antigens and/or EBV-infected cells e.g. LCLs
- ELISPOT analysis which may be performed e.g. as described in Example 2.
- Suitable models and analysis include the EBV-LCL xenograft model methods employed in Example 4. Metastasis can be evaluated e.g. by monitoring the location of cancerous cells within the animal in such a model, e.g. as performed in Example 4.
- a population of immune cells generated/expanded in accordance with the methods of the present disclosure may possess one or more of the following, as compared to a population of immune cells generated/expanded according to a reference method for generating/expanding EBV-specific immune cells:
- Survival/persistence of a given population of immune cells in vivo can be evaluated e.g. using methods in which cells are labelled with a detectable marker or reporter, and their survival is monitored over time. Such methods include e.g. labelling cells with firefly luciferase, and measuring activity at different time points.
- Production of cytokines by a subject administered with a given population of immune cells can be evaluated e.g. by analysis of a blood-derived sample (e.g. whole blood, plasma, serum) obtained from the subject. Cytokine levels can be determined e.g. by ELISA, e.g. as described in Example 4.
- a blood-derived sample e.g. whole blood, plasma, serum
- Cytokine levels can be determined e.g. by ELISA, e.g. as described in Example 4.
- a reference method for generating/expanding EBV-specific immune cells may be a method as described in Example 1 herein employing latent pepmixes (only) in stimulations.
- the populations of immune cells comprising EBV-specific immune cells generated/expanded as described herein find use in therapeutic and/or prophylactic methods.
- a method for treating/preventing a disease/condition in a subject comprising administering a population of immune cells specific for EBV generated/expanded according to a method of the present disclosure to a subject. Also provided is a population of immune cells specific for EBV generated/expanded according to a method of the present disclosure for use in a method of medical treatment/prophylaxis. Also provided is a population of immune cells generated/expanded according to a method of the present disclosure for use in a method for treating/preventing a disease/condition. Also provided is the use of a population of immune cells specific for EBV generated/expanded according to a method of the present disclosure in the manufacture of a medicament for use in a method for treating/preventing a disease/condition.
- populations of immune cells specific for EBV generated/expanded according to the present disclosure in methods to treat/prevent diseases/conditions by adoptive cell transfer (ACT) is contemplated.
- ACT adoptive cell transfer
- Adoptive cell transfer generally refers to a process by which cells (e.g. immune cells) are obtained from a subject, typically by drawing a blood sample from which the cells are isolated. The cells are then typically modified and/or expanded, and then administered either to the same subject (in the case of adoptive transfer of autologous/autogeneic cells) or to a different subject (in the case of adoptive transfer of allogeneic cells).
- the treatment is typically aimed at providing a population of cells with certain desired characteristics to a subject, or increasing the frequency of such cells with such characteristics in that subject.
- Adoptive transfer may be performed with the aim of introducing a cell or population of cells into a subject, and/or increasing the frequency of a cell or population of cells in a subject.
- the methods comprise:
- the methods comprise:
- the subject from which the immune cells (e.g. PBMCs) are isolated is the same subject to which the generated/expanded population of immune cells specific for EBV is administered (i.e., adoptive transfer may be of autologous/autogeneic cells).
- the subject from which the immune cells (e.g. PBMCs) are isolated is a different subject to the subject to which the generated/expanded population of immune cells specific for EBV is administered (i.e., adoptive transfer may be of allogeneic cells).
- the methods may be effective to reduce the development/progression of a disease/condition, alleviation of the symptoms of a disease/condition or reduction in the pathology of a disease/condition.
- the methods may be effective to prevent progression of the disease/condition, e.g. to prevent worsening of, or to slow the rate of development of, the disease/condition.
- the methods may lead to an improvement in the disease/condition, e.g. a reduction in the symptoms of the disease/condition or reduction in some other correlate of the severity/activity of the disease/condition.
- the methods may prevent development of the disease/condition a later stage (e.g. a chronic stage or metastasis).
- the therapeutic and prophylactic utility of the populations of cells generated/expanded in accordance with the present disclosure extends to the treatment/prevention of any disease/condition that would derive therapeutic or prophylactic benefit from a reduction in EBV load, and/or the number/activity of cells infected with EBV.
- the disease/condition may be a disease/condition in which EBV or cells infected with EBV are pathologically implicated, e.g. a disease/condition in which EBV infection is positively associated with the onset, development or progression of the disease/condition, and/or severity of one or more symptoms of the disease/condition, or for which EBV infection is a risk factor for the onset, development or progression of the disease/condition.
- the treatment may be aimed at one or more of: reducing the EBV load, reducing the number/proportion of EBV-positive cells, reducing the activity of EBV-positive cells, delaying/preventing the onset/progression of symptoms of the disease/condition, reducing the severity of symptoms of the disease/condition, reducing the survival/growth of EBV-positive cells, increasing survival of the subject.
- the disease/condition to be treated/prevented in accordance with the present disclosure is a disease/condition characterised by EBV infection.
- a subject may be selected for treatment described herein based on the detection of EBV/cells infected with EBV, e.g. in the periphery, or in an organ/tissue which is affected by the disease/condition (e.g. an organ/tissue in which the symptoms of the disease/condition manifest), or by the detection of EBV-positive cancer cells (e.g. EBV-positive cells in a tumor).
- the disease/condition may affect any tissue or organ or organ system. In some embodiments the disease/condition may affect several tissues/organs/organ systems.
- a subject may be selected for therapy/prophylaxis in accordance with the present disclosure based on determination that the subject is infected with EBV or comprises cells infected with EBV.
- EBV is implicated in several cancers, as reviewed e.g. in Jha et al., Front Microbiol. (2016) 7:1602, which is hereby incorporated by reference in its entirety.
- the disease to be treated/prevented in accordance with the present disclosure is a cancer.
- Cancer may refer to any unwanted cell proliferation (or any disease manifesting itself by unwanted cell proliferation), neoplasm or tumor.
- the cancer may be benign or malignant and may be primary or secondary (metastatic).
- a neoplasm or tumor may be any abnormal growth or proliferation of cells and may be located in any tissue.
- the cancer may be of tissues/cells derived from e.g. the adrenal gland, adrenal medulla, anus, appendix, bladder, blood, bone, bone marrow, brain, breast, cecum, central nervous system (including or excluding the brain) cerebellum, cervix, colon, duodenum, endometrium, epithelial cells (e.g.
- kidney oesophagus
- glial cells heart, ileum, jejunum, kidney, lacrimal glad, larynx, liver, lung, lymph, lymph node, lymphoblast, maxilla, mediastinum, mesentery, myometrium, nasopharynx, omentum, oral cavity, ovary, pancreas, parotid gland, peripheral nervous system, peritoneum, pleura, prostate, salivary gland, sigmoid colon, skin, small intestine, soft tissues, spleen, stomach, testis, thymus, thyroid gland, tongue, tonsil, trachea, uterus, vulva, and/or white blood cells.
- Tumors may be nervous or non-nervous system tumors.
- Nervous system tumors may originate either in the central or peripheral nervous system, e.g. glioma, medulloblastoma, meningioma, neurofibroma, ependymoma, Schwannoma, neurofibrosarcoma, astrocytoma and oligodendroglioma.
- Non-nervous system cancers/tumors may originate in any other non-nervous tissue, examples include melanoma, mesothelioma, lymphoma, myeloma, leukemia, Non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma, chronic myelogenous leukemia (CML), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), cutaneous T-cell lymphoma (CTCL), chronic lymphocytic leukemia (CLL), hepatoma, epidermoid carcinoma, prostate carcinoma, breast cancer, lung cancer, colon cancer, ovarian cancer, pancreatic cancer, thymic carcinoma, NSCLC, hematologic cancer and sarcoma.
- NHL Non-Hodgkin's lymphoma
- CML chronic myelogenous leukemia
- AML acute myeloid leukemia
- MDS myelodysplastic syndrome
- CTCL
- the cancer is selected from the group consisting of: colon cancer, colon carcinoma, colorectal cancer, nasopharyngeal carcinoma, cervical carcinoma, oropharyngeal carcinoma, gastric carcinoma, hepatocellular carcinoma, head and neck cancer, head and neck squamous cell carcinoma (HNSCC), oral cancer, laryngeal cancer, prostate cancer, lung cancer, small cell lung cancer, non-small cell lung cancer, bladder cancer, urothelial carcinoma, melanoma, advanced melanoma, renal cell carcinoma, ovarian cancer or mesothelioma.
- HNSCC head and neck squamous cell carcinoma
- the cancer to be treated/prevented is an EBV-associated cancer.
- EBV-associated cancers may be a cancers which are caused or exacerbated by infection with EBV, cancers for which infection is a risk factor and/or cancers for which infection is positively associated with onset, development, progression, severity or metastasis.
- EBV-associated cancers which may be treated/prevented in accordance with the present disclosure include B cell-associated cancers such as Burkitt's lymphoma, post-transplant lymphoproliferative disease (PTLD), central nervous system lymphoma (CNS lymphoma), Hodgkin's lymphoma, non-Hodgkin's lymphoma, and EBV-associated lymphomas associated with immunodeficiency (including e.g.
- B cell-associated cancers such as Burkitt's lymphoma, post-transplant lymphoproliferative disease (PTLD), central nervous system lymphoma (CNS lymphoma), Hodgkin's lymphoma, non-Hodgkin's lymphoma, and EBV-associated lymphomas associated with immunodeficiency (including e.g.
- EBV-positive lymphoma associated with X-linked lymphoproliferative disorder EBV-positive lymphoma associated with HIV infection/AIDS, and oral hairy leukoplakia
- epithelial cell related cancers such as nasopharyngeal carcinoma (NPC) and gastric carcinoma (GC).
- the cancer is selected from lymphoma (e.g. EBV-positive lymphoma), head and neck squamous cell carcinoma (HNSCC; e.g. EBV-positive HNSCC), nasopharyngeal carcinoma (NPC; e.g. EBV-positive NPC), and gastric carcinoma (GC; e.g. EBV-positive GC).
- lymphoma e.g. EBV-positive lymphoma
- HNSCC head and neck squamous cell carcinoma
- NPC nasopharyngeal carcinoma
- GC gastric carcinoma
- EBV-infection is also implicated in the development/progression of a variety of autoimmune diseases such as multiple sclerosis and systemic lupus erythematosus (SLE; see e.g. Ascherio and Munger Curr Top Microbiol Immunol. (2015); 390(Pt 1):365-85), and EBV antigen EBNA2 has recently been shown to associate with genetic regions implicated as risk factors for the development of SLE, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, type 1 diabetes, juvenile idiopathioc arthritis and celiac disease (Harley et al., Nat Genet. (2016) 50(5): 699-707).
- SLE systemic lupus erythematosus
- the disease/condition to be treated/prevented in accordance with the present disclosure is selected from SLE, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, type 1 diabetes, juvenile idiopathioc arthritis and celiac disease.
- Populations of cells generated/expanded in accordance with the present disclosure also find use in the treatment/prevention of diseases/conditions independently of EBV infection.
- the populations of cells generated/expanded in accordance with the present disclosure find use in methods for the treatment of cancer.
- the cancer may express a cancer antigen.
- a ‘cancer antigen’ is an antigen which is expressed or over-expressed by cells of a cancer.
- a cancer antigen may be any peptide/polypeptide, glycoprotein, lipoprotein, glycan, glycolipid, lipid, or fragment thereof.
- a cancer antigen's expression may be associated with a cancer.
- a cancer antigen may be abnormally expressed by a cancer cell (e.g. the cancer antigen is expressed with abnormal localisation), or may be expressed with an abnormal structure by a cancer cell.
- a cancer antigen may be capable of eliciting an immune response.
- the antigen is expressed at the cell surface of the cancer cell (i.e. the cancer antigen may be a cancer cell surface antigen).
- the part of the antigen which is bound by the antigen-binding molecule described herein is displayed on the external surface of the cancer cell (i.e. is extracellular).
- the cancer antigen is an antigen whose expression is associated with the development, progression or severity of symptoms of a cancer.
- the cancer-associated antigen may be associated with the cause or pathology of the cancer, or may be expressed abnormally as a consequence of the cancer.
- the cancer antigen is an antigen whose expression is upregulated (e.g. at the RNA and/or protein level) by cells of a cancer, e.g. as compared to the level of expression of by comparable non-cancerous cells (e.g.
- the cancer antigen is preferentially expressed by cancerous cells, and not expressed by comparable non-cancerous cells (e.g. non-cancerous cells derived from the same tissue/cell type).
- the cancer antigen is the product of a mutated oncogene or mutated tumor suppressor gene.
- the cancer antigen is the product of an overexpressed cellular protein, a cancer antigen produced by an oncogenic virus, an oncofetal antigen, a cell surface molecule (e.g. a cell surface protein or glycoprotein).
- the cancer antigen is a cell signalling molecule, e.g. a cytokine, chemokine, interferon, interleukin or lymphokine.
- the cancer antigen is a growth factor or a hormone.
- the cancer is ‘positive’ for the cancer antigen, meaning that the cancer comprises cells expressing the cancer antigen (e.g. cells expressing the cancer antigen at the cell surface).
- a cancer antigen-positive cancer may overexpress the cancer antigen.
- Overexpression of the cancer antigen can be determined by detection of a level of gene or protein expression of the cancer antigen which is greater than the level of expression by equivalent non-cancerous cells/non-tumor tissue.
- Gene/protein expression of the cancer antigen may be a risk factor for, and/or positively associated with, the onset, development, progression or severity of symptoms of the cancer, and/or metastasis.
- the subject in accordance with aspects the disclosure described herein may be any animal or human.
- the subject is preferably mammalian, more preferably human.
- the subject may be a non-human mammal, but is more preferably human.
- the subject may be any gender.
- the subject may be a patient.
- a subject may have been diagnosed with a disease/condition requiring treatment, may be suspected of having such a disease/condition, or may be at risk of developing/contracting such a disease/condition.
- the subject is preferably a human subject.
- the subject to be treated according to a therapeutic or prophylactic method of the disclosure herein is a subject having, or at risk of developing, a disease/condition.
- a subject may be selected for treatment according to the methods based on characterisation for certain markers of such a disease/condition.
- Pairwise and multiple sequence alignment for the purposes of determining percent identity between two or more amino acid or nucleic acid sequences can be achieved in various ways known to a person of skill in the art, for instance, using publicly available computer software such as ClustalOmega (Söding, J. 2005, Bioinformatics 21, 951-960), T-coffee (Notredame et al. 2000, J. Mol. Biol. (2000) 302, 205-217), Kalign (Lassmann and Sonnhammer 2005, BMC Bioinformatics, 6(298)) and MAFFT (Katoh and Standley 2013, Molecular Biology and Evolution, 30(4) 772-780 software.
- the default parameters e.g. for gap penalty and extension penalty, are preferably used.
- a method for generating or expanding a population of immune cells comprising immune cells specific for an Epstein Barr Virus (EBV) lytic antigen, comprising stimulating immune cells specific for an EBV lytic antigen by contacting peripheral blood mononuclear cells (PBMCs) with: (i) one or more peptides corresponding to all or part of one or more EBV lytic antigens; or (ii) antigen presenting cells (APCs) presenting one or more peptides corresponding to all or part of one or more EBV lytic antigens.
- PBMCs peripheral blood mononuclear cells
- APCs antigen presenting cells
- the method further comprises re-stimulating the immune cells specific for an EBV lytic antigen by contacting them with APCs presenting one or more peptides corresponding to all or part of one or more EBV lytic antigens.
- the one or more EBV lytic antigens are selected from BZLF1, BRLF1, BMLF1, BMRF1, BXLF1, BALF1, BALF2, BGLF5, BHRF1, BNLF2A, BNLF2B, BHLF1, BLLF2, BKRF4, BMRF2, BALF4, BILF1, BILF2, BNFR1, BVRF2, BALF3, BALF5 and BDLF3.
- EBV lytic antigens are selected from BZLF1, BRLF1, BMLF1, BMRF1, BALF2, BNLF2A, BNLF2B, BMRF2 and BDLF3.
- PBMCs are PBMCs depleted of CD45RA-positive cells.
- a method for generating or expanding a population of immune cells comprising immune cells specific for an Epstein Barr Virus (EBV) lytic antigen and immune cells specific for an EBV latent antigen, comprising stimulating immune cells specific for an EBV lytic antigen and immune cells specific for an EBV latent antigen by contacting peripheral blood mononuclear cells (PBMCs) with: (i) one or more peptides corresponding to all or part of one or more EBV lytic antigens, and one or more peptides corresponding to all or part of one or more EBV latent antigens; or (ii) antigen presenting cells (APCs) presenting one or more peptides corresponding to all or part of one or more EBV lytic antigens, and one or more peptides corresponding to all or part of one or more EBV latent antigens.
- PBMCs peripheral blood mononuclear cells
- APCs antigen presenting cells
- the method further comprises re-stimulating the immune cells specific for an EBV lytic antigen and the immune cells specific for an EBV latent antigen by contacting them with APCs presenting one or more peptides corresponding to all or part of one or more EBV lytic antigens, and one or more peptides corresponding to all or part of an EBV latent antigen.
- the one or more EBV lytic antigens are selected from BZLF1, BRLF1, BMLF1, BMRF1, BXLF1, BALF1, BALF2, BGLF5, BHRF1, BNLF2A, BNLF2B, BHLF1, BLLF2, BKRF4, BMRF2, BALF4, BILF1, BILF2, BNFR1, BVRF2, BALF3, BALF5 and BDLF3.
- EBV lytic antigens are selected from BZLF1, BRLF1, BMLF1, BMRF1, BALF2, BNLF2A, BNLF2B, BMRF2 and BDLF3.
- EBV latent antigens are selected from EBNA1, EBNA-LP, EBNA2, EBNA3A, EBNA3B, EBNA3C, BARF1, LMP1, LMP2A and LMP2B.
- EBV latent antigens are selected from EBNA1, LMP1, LMP2A and LMP2B.
- PBMCs are PBMCs depleted of CD45RA-positive cells.
- An isolated population of immune cells obtained or obtainable by a method according to claim 1 .
- a method for treating or preventing a disease or disorder comprising administering an isolated population of immune cells according to claim 13 to a subject.
- the disease or disorder is an EBV-associated cancer selected from EBV-positive lymphoma, EBV-positive nasopharyngeal carcinoma, and EBV-positive gastric carcinoma.
- the invention includes the combination of the aspects and preferred features described except where such a combination is clearly impermissible or expressly avoided.
- Methods described herein may be performed in vitro or in vivo. In some embodiments, methods described herein are performed in vitro.
- the term “in vitro” is intended to encompass experiments with cells in culture whereas the term “in vivo” is intended to encompass experiments with intact multi-cellular organisms.
- FIGS. 1 A and 1 B Bar charts showing the number of spot-forming cells (SFCs) per 100,000 cells specific for the indicated EBV antigens, within populations of cells expanded from PBMCs obtained from four different EBV-positive lymphoma patients.
- FIG. 1 A shows the numbers of SFCs per 100,000 cells in response to stimulation with the indicated antigens, amongst EBVSTs generated by stimulations using latent pepmix (T2 EBVSTs), or latent+lytic pepmix (All-EBVSTs).
- FIG. 1 B shows the numbers of SFCs per 100,000 cells in response to stimulation with the indicated antigens, amongst EBVSTs generated by stimulations using lytic pepmix (lytic EBVSTs), or latent+lytic pepmix (All-EBVSTs).
- FIG. 2 Bar chart showing the number of spot-forming cells (SFCs) per 100,000 cells specific for the indicated EBV antigens, within EBVSTs expanded from PBMCs from two EBV-positive lymphoma patients by stimulation using latent pepmix (T2-EBVSTs), lytic pepmix (Lytic-EBVSTs) or latent+lytic pepmix (BR-EBVSTs). The total numbers of cells in bars is indicated.
- SFCs spot-forming cells
- FIG. 3 Bar chart showing the number of spot-forming cells (SFCs) per 100,000 cells specific for the indicated EBV antigens, within EBVSTs expanded from PBMCs from three healthy donor subjects by stimulation using latent pepmix (T2-EBVSTs), immediate-early lytic pepmix (IE-EBVSTs), early lytic pepmix (E-EBVSTs), or latent+lytic pepmix (BR-EBVSTs).
- SFCs spot-forming cells
- FIG. 4 Bar chart showing the percentage of autologous, EBV-LCLs lysed by EBVSTs expanded from PBMCs from three healthy donor subjects by stimulation using latent pepmix (T2-EBVSTs), immediate-early lytic pepmix (IE-EBVSTs), early lytic pepmix (E-EBVSTs), or latent+lytic pepmix (BR-EBVSTs), in an in vitro assay of cytolytic activity.
- T2-EBVSTs latent pepmix
- IE-EBVSTs immediate-early lytic pepmix
- E-EBVSTs early lytic pepmix
- BR-EBVSTs latent+lytic pepmix
- FIG. 5 Bar chart showing the number of spot-forming cells (SFCs) per 100,000 cells specific for the indicated EBV antigens or LCLs, within EBVSTs expanded from PBMCs by stimulation using latent pepmix (T2-EBVSTs), or latent+lytic pepmix (BR-EBVSTs).
- SFCs spot-forming cells
- FIGS. 6 A to 6 C Graphs and images showing the in vivo anti-cancer activity of EBVSTs expanded from PBMCs by stimulation using latent pepmix (T2-EBVSTs) or latent+lytic pepmix (BR-EBVSTs) against autologous EBV-LCLs, in a mouse xenograft model of EBV-positive cancer.
- a control group received PBS instead of EBVSTs.
- FIG. 6 A shows tumor volume (mm 3 ) over time
- FIGS. 6 B and 6 C shows tumor burden over time as measured by luciferase activity of the firefly luciferase-expressing EBV-LCLs.
- FIG. 7 Images showing the burden and location of firefly luciferase-expressing EBV-LCLs in vivo in mice at the indicated day of an experiment investigating the anti-cancer activity of EBVSTs expanded from PBMCs by stimulation using latent pepmix (T2-EBVSTs) or latent+lytic pepmix (BR-EBVSTs) against autologous EBV-LCLs, in a mouse xenograft model of EBV-positive cancer.
- T2-EBVSTs latent pepmix
- BR-EBVSTs latent+lytic pepmix
- FIGS. 8 A to 8 D Images and graphs showing the in vivo anti-cancer activity of EBVSTs expanded from PBMCs by stimulation using latent pepmix (T2-EBVSTs), lytic (2) pepmix (Lytic(2)-EBVSTs) or lytic (2)+latent pepmix (BR(2)-EBVSTs) against autologous EBV-LCLs, in a mouse xenograft model of EBV-positive cancer.
- a control group received PBS instead of EBVSTs.
- FIGS. 8 A to 8 C show tumor burden over time as measured by luciferase activity of the firefly luciferase-expressing EBV-LCLs.
- FIG. 8 A shows the dorsal view
- FIG. 8 B shows the ventral view at the indicated day relative to injection of the EBVSTs.
- FIG. 8 C shows total tumor burden over time.
- FIG. 8 D shows tumor volume (mm 3 ) over time.
- FIGS. 9 A to 9 C Box plots showing the levels of cytokines detected in the serum of mice undergoing treatment with EBVSTs expanded from PBMCs by stimulation using latent pepmix (T2-EBVSTs), lytic (2) pepmix (Lytic(2)-EBVSTs) or lytic (2)+latent pepmix (BR(2)-EBVSTs), in a mouse xenograft model of EBV-positive cancer, at the indicated number of days post-EBVST injection.
- FIG. 9 A shows the level of GM-CSF
- FIG. 9 B shows the level of IFN ⁇
- FIG. 9 C shows the level of IL-10.
- *** P 0.0001.
- FIG. 10 Bar chart showing the number of spot-forming cells (SFCs) per 100,000 cells specific for EBV antigens, within populations of cells expanded by stimulation using latent pepmix from PBMCs obtained from four different healthy donor subjects (D #1 to D #4).
- WW EBVSTs expanded from whole PBMCs, and restimulated using ATCs derived from whole PBMCs;
- WD EBVSTs expanded from whole PBMCs, and restimulated using ATCs derived from PBMCs depleted of CD45RA-positive cells;
- DW EBVSTs expanded from PBMCs depleted of CD45RA-positive cells, and restimulated using ATCs derived from whole PBMCs;
- DD EBVSTs expanded from PBMCs depleted of CD45RA-positive cells, and restimulated using ATCs derived from PBMCs depleted of CD45RA-positive cells
- FIG. 11 Histograms showing expression of CD80 and HLA-DR on ATCs derived from four different healthy donor subjects (D #1 to D #4), from whole PBMCs, or from PBMCs depleted of CD45RA-positive cells, as determined by flow cytometry.
- the inventors describe the generation of populations of cells comprising EBV-specific T cells from PBMC populations, by stimulation with peptides of different EBV antigens.
- the inventors characterise the expanded cell populations for their EBV-reactivity, ability to display effector activity against EBV-infected cells, and their anti-cancer activity against EBV-positive cancer in vivo.
- the inventors also investigate methods for increasing the proportion of EBV-reactive cells in expanded populations, and their anti-cancer activity and persistence in vivo.
- PBMCs Peripheral blood mononuclear cells
- Anti-CD3 (clone OKT3) and anti-CD28 agonist antibodies were coated onto wells of tissue culture plates by addition of 0.5 ml of 1:1000 dilution of 1 mg/ml antibodies, and incubation for 2-4 hr at 37° C., or at 4° C. overnight.
- 1 ⁇ 10 6 PBMCs (in 2 ml of cell culture medium) were stimulated by culture on the anti-CD3/CD28 agonist antibody-coated plates in CTL cell culture medium (containing RPMI-1640 medium, 50% Click's medium, 10% FBS, 1% GlutaMax, 1% Pen/Strep) supplemented with 10 ng/ml IL-7 and 5 ng/ml IL-15. The cells were maintained at 37° C.
- LCLs lacking surface expression of HLA class I and HLA class II i.e. HLA-negative LCLs
- HLA-negative LCLs were obtained by targeted knockout of genes encoding HLA class I and HLA class II molecules in cells of a lymphoblastoid cell line prepared by EBV-transformation of B cells.
- the HLA-negative cells were further modified to knockout genes necessary for EBV replication.
- the resulting cells obtained by the methods are referred to herein as universal LCLs (uLCLs).
- EBV-specific T cells were expanded by stimulating 2 ⁇ 10 6 PBMCs for 9 days with one of the following combinations of pepmixes obtained from JPT Technologies (overlapping 15mer amino acid peptide libraries overlapping by 11 amino acids, spanning the full amino acid sequence of the relevant antigen), in cell culture medium containing 50% Advanced RPMI, 50% Click's medium, 10% FBS, 1% GlutaMax, 1% Pen/Strep, supplemented with IL-7 (10 ng/ml) and IL-15 (100 ng/ml):
- Combinations of pepmixes were used in stimulations at a final amount of 10 ng pepmix mixture per 1 ⁇ 10 6 PBMCs.
- ATCs autologous activated T cells
- the peptide-pulsed ATCs were then mixed with the cells in culture and uLCLs (irradiated at 100Gy), in CTL medium containing IL-7 (10 ng/ml) and IL-15 (100 ng/ml), at a ratio of responder cells:peptide-pulsed ATCs:irradiated uLCLs of 1:1:5.
- IL-7 10 ng/ml
- IL-15 100 ng/ml
- 1 ⁇ 10 5 responder cells, 1 ⁇ 10 5 peptide-pulsed ATCs and 0.5 ⁇ 10 6 irradiated uLCLs were cultured in 2 mL CTL medium in wells of a 24 well tissue culture plate.
- Cells were maintained at 37° C. in a 5% CO 2 atmosphere. After 3-4 days further cell culture medium containing IL-7 (10 ng/ml) and IL-15 (100 ng/ml) was added as necessary. On day 5 or 6 further cell culture medium containing IL-7 (10 ng/ml) and IL-15 (100 ng/ml) was added as necessary, and after 6-7 days the expanded EBVSTs were harvested for analysis or use in experiments.
- IL-7 10 ng/ml
- IL-15 100 ng/ml
- EBVSTs prepared from PBMCs of EBV-positive lymphoma patients using the different pepmixes were analysed by ELISPOT to determine their ability to recognise different EBV antigens.
- EBVSTs were plated at 1 ⁇ 10 5 cells/well in 96-well plates pre-coated with anti-IFN ⁇ capture antibody, and stimulated with pepmixes corresponding to the indicated EBV peptides. After 18-20 hrs incubation, plates were developed for IFN ⁇ + spots, dried overnight at room temperature in the dark, and quantified. The frequency of T cells specific to each antigen was expressed as specific spot-forming cells (SFCs) per input cell number.
- SFCs spot-forming cells
- FIGS. 1 A and 1 B show that T-cells specific for lytic cycle antigens can be generated by stimulation with premixes for lytic cycle antigens alone. Combining the pepmixes for latent and lytic antigens did not compromise the specificity for any single antigen, and the total frequency of antigen-specific T-cells was greater when pepmixes were combined.
- Some patient T-cells show poor specificity when latent antigen pepmixes or lytic antigen pepmixes are used alone, but when latent antigen pepmixes and lytic antigen pepmixes are used in combination, good specificity can be achieved (see donor 2). This is thought to result of the production of cytokines by activated T-cells, which provide help for each other.
- FIG. 2 shows that the number of cells that secrete IFN ⁇ in response to stimulation with pepmixes corresponding to EBV latent and lytic antigens is greater for EBVSTs generated using a combination of latent antigen and lytic antigen pepmixes, than for EBVSTs generated using latent antigen pepmixes alone, or lytic antigen pepmixes alone. There is a super-additive increase in the number of IFN ⁇ -producing cells when a combination of latent antigen and lytic antigen pepmixes.
- EBVSTs prepared from PBMCs of healthy donors using the different pepmixes were analysed by ELISPOT to determine their ability to recognise different EBV antigens, as described above.
- Example 3 Analysis of Cell Killing by EBVSTs Obtained by Stimulation of PBMCs with Pepmixes Corresponding to Different EBV Antigens
- EBVSTs obtained by stimulation of PBMCs using different pepmixes were analysed for their ability to kill autologous EBV-transformed B cell lines.
- EBV antigen-specific T-cells obtained by stimulation of PBMCs using different pepmixes were able to kill autologous EBV-transformed B-cell lines.
- EBVSTs obtained using methods employing lytic antigen pepmixes to kill EBV-LCLs were surprising, because only a small proportion of the LCLs would be expected to be in the lytic cycle (and thus express the target antigen). The results may be explained by phagocytosis and presentation of antigens from dying cells in the lytic phase.
- Example 4 Analysis of In Vivo Anti-Cancer Activity for EBVSTs Obtained by Stimulation of PBMCs with Pepmixes Corresponding to Different EBV Antigens
- the inventors investigated the comparative ability of BR-EBVSTs and T2-EBVSTs to treat EBV-positive cancer in vivo using a murine xenograft model.
- EBV-positive tumors were established by subcutaneous implantation of 3.5 ⁇ 10 6 firefly luciferase-expressing autologous LCLs in matrigel, into the flanks of NSG mice. 8 days later, when tumors were visible, mice were administered with PBS (control group), 5 ⁇ 10 6 BR-EBVSTs, or 5 ⁇ 10 6 T2-EBVSTs by intravenous injection.
- PBS control group
- 5 ⁇ 10 6 BR-EBVSTs 5 ⁇ 10 6 T2-EBVSTs
- Tumors were monitored throughout the experiment by bioluminescence imaging; luciferase activity was monitored by intraperitoneal injection of D-Luciferin (1.5 mg per mouse), and imaging of the mice 10 min later using an IVIS imager (Xenogen). Tumor volume was also monitored by measurement using calipers.
- the BR-EBVSTs and T2-EBVSTs were analysed by ELISPOT for their ability to produce IFN ⁇ in response to stimulation with different EBV antigens or EBV-LCLs.
- the results are shown in FIG. 5 , and demonstrate that populations of immune cells expanded using peptides corresponding to EBV latent and lytic antigens comprise cells reactive to both EBV latent and lytic antigens, and comprise a greater proportion of cells which produce IFN ⁇ in response to stimulation with EBV-LCLs as compared to populations of immune cells expanded using peptides corresponding to EBV latent antigens only.
- FIGS. 6 and 7 show that BR-EBVSTs more rapidly controlled EBV-positive tumors than T2-EBVSTs.
- FIG. 7 also shows that BR-EBVST-treated mice displayed reduced metastasis than mice treated with T2-EBVSTs.
- mice were administered with PBS (control group), 1 ⁇ 10 6 BR(2)-EBVSTs, 1 ⁇ 10 6 Lytic(2)-EBVSTs, or 1 ⁇ 10 6 T2-EBVSTs by intravenous injection.
- Lytic(2)-EVBSTs and BR(2)-EBVSTs used in this experiment were generated as described in Example 1, with the exception that the following combinations of pepmixes were used in stimulations to expand the EBVSTs:
- Pepmixes for BMLF1, BXLF1, BALF1, BLLF2, BALF2 and BNLF2A were prepared by combining individual constituent peptides obtained from Genemed.
- the pepmixes for EBNA1, LMP1, LMP2, BZLF1, BRLF1 and BMRF1 were obtained from JPT technologies as shown in Example 1.
- the EBVSTs generated by methods employing lytic pepmixes are referred to as “Lytic(2)-EBVSTs”, and the EBVSTs generated by methods employing lytic (2)+latent pepmixes (i.e. (vii) above) are referred to as “BR(2)-EBVSTs”.
- Tumors were monitored throughout the experiment by bioluminescence imaging as described above, and tumor volume was also monitored by measurement using calipers.
- Blood plasma samples were also collected from the mice at days 3 and 8 post-EBVST administration, and analysed by ELISA in order to determine the levels of GM-CSF, IFN ⁇ and IL-10.
- EBVSTs expanded by stimulations using peptides of EBV latent+lytic antigens strongly inhibited tumor growth FIGS. 8 A to 8 D .
- mice treated with EBVSTs expanded by stimulations using peptides of EBV latent+lytic antigens also had increased levels of proinflammatory cytokines in their serum relative to mice treated with EBVSTs expanded by stimulations using only EBV latent antigens, whilst mice treated with EBVSTs expanded by stimulations using peptides of EBV lytic antigens only displayed similar or increased levels of proinflammatory cytokines in their serum relative to mice treated with EBVSTs expanded by stimulations using only EBV latent antigens ( FIGS. 9 A and 9 B ).
- mice treated with EBVSTs expanded by stimulations using peptides of EBV latent+lytic antigens had reduced levels of IL-10 in their serum relative to mice treated with EBVSTs expanded by stimulations using only EBV latent antigens, whilst mice treated with EBVSTs expanded by stimulations using peptides of EBV lytic antigens only displayed similar or reduced levels of IL-10 in their serum relative to mice treated with EBVSTs expanded by stimulations using only EBV latent antigens ( FIG. 9 C ).
- BR-EBVSTs were found to kill greater numbers of tumor cells and produce a greater amount of proinflammatory cytokines. Without wishing to be bound by any particular theory, this may result in a change in the tumor microenvironment leading to increased epitope spreading in vivo, and additional tumor cell killing by non-viral tumor antigen-specific T-cells.
- Example 6 Generation of EBV-Specific T Cells from PBMCs Depleted of CD45RA-Positive Cells
- the inventors next investigated the effect of depleting PBMC populations of CD45RA-positive cells on the expanded population of EBV-specific T cells.
- CD45RA is a na ⁇ ve T-cell marker that is also expressed on natural T-regulatory cells and NK cells, so it was reasoned that depletion of CD45RA+ cells would remove the NK cells from the starting PBMC population. Depletion of CD45RA+ cells also removes T regulatory cells that can inhibit the outgrowth of antigen-specific T-cells, especially in cancer patients, and also removes na ⁇ ve cells that can grow as bystander cells and dilute the antigen-specific T-cells.
- PBMCs were depleted of CD45RA-expressing cells using Miltenyi® columns and CD45RA-conjugated beads, and the PBMCs depleted of CD45RA-positive cells were subsequently used to expand EBV-specific T cells by stimulation with latent pepmixes essentially as described in Example 1.
- PBMCs depleted of CD45RA-positive cells were also used as the starting population for producing ATCs used in restimulations, which were produced essentially as described in Example 1.
- EBVSTs prepared according to (i) to (iv) above from PBMCs obtained from four different healthy donors (D #1 to D #4) were analysed by ELISPOT to determine their ability to recognise different EBV antigens.
- ELISPOT analysis was performed essentially as described in Example 2.
- results are shown in FIG. 10 .
- using PBMCs depleted of CD45RA-positive cells as the starting population for expanding EBVSTs yielded an increased proportion of cells in the expanded population that secrete IFN ⁇ in response to stimulation with EBV pepmixes, as compared to methods using whole PBMC populations.
- using PBMCs depleted of CD45RA-positive cells as the starting population for generating ATCs used in restimulations resulted in a greater proportion of cells in the expanded population that secrete IFN ⁇ in response to stimulation with EBV pepmixes.
- the inventors analysed expression of the costimulatory molecule CD80 and HLA-DR (MHC class II) on the ATCs generated from whole PBMCs, or from PBMCs depleted of CD45RA-positive cells, by flow cytometry.
- CD80 and HLA-DR MHC class II
- the results are shown in FIG. 11 .
- the ATCs generated from PBMCs depleted of CD45RA-positive cells had higher expression of CD80 and HLA-DR, and thus improved antigen-presenting and costimulatory properties as compared to ATCs generated from whole PBMCs.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Developmental Biology & Embryology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Methods for generating/expanding populations of immune cells comprising immune cells specific for an Epstein Barr Virus (EBV) lytic antigen are disclosed, the methods comprising stimulating immune cells specific for an EBV lytic antigen by contacting peripheral blood mononuclear cells (PBMCs) with: (i) one or more peptides corresponding to all or part of one or more EBV lytic antigens; or (ii) antigen presenting cells (APCs) presenting one or more peptides corresponding to all or part of one or more EBV lytic antigens. Also disclosed are populations of immune cells comprising immune cells specific for an EBV lytic antigen expanded according to such methods, and uses thereof.
Description
- This invention was made with government support under Grant Number CA126752 awarded by the National Institutes of Health. The government has certain rights in the invention.
- This application claims priority from U.S. Ser. No. 16/388,776 filed Apr. 18 2019, the contents and elements of which are herein incorporated by reference for all purposes and in their entirety.
- The present disclosure relates at least to the fields of molecular and cell biology, immunology, and also relates to methods of medical treatment and prophylaxis.
- Around 40% of lymphomas, all undifferentiated nasopharyngeal carcinomas (NPC) and about 10% of gastric cancers carry the Epstein-Barr virus (EBV) genome and express viral proteins that can be targeted by adoptively transferred EBV-specific T cells (EBVSTs).
- EBV+malignancies occurring outside the setting of immunosuppression express only 1 to 4 of about 90 EBV proteins and whilst these antigens are poorly immunogenic, they provide target antigens for EBVSTs.
- Ongoing clinical trials concerning the use of EBV-specific T cells to treat EBV-positive malignancies employ EBV-transformed B cells in the expansion of EBV-specific T cells (NCT02578641), or involve stimulating PBMCs with peptides corresponding to EBV type II latency antigens (NCT01555892).
- The present disclosure is based on the unexpected finding that peptides corresponding to EBV lytic antigens can be used to generate/expand populations of EBV-specific immune cells which are useful for the treatment of EBV-associated diseases.
- Despite the fact that cells infected with EBV in EBV-associated diseases only display substantial expression of EBV latent antigens, the inventors demonstrate herein that populations of immune cells generated/expanded by stimulating immune cells using peptides of EBV lytic antigens display cytolytic activity against EBV-infected cells. Moreover, populations of immune cells generated/expanded by stimulating immune cells using peptides of EBV lytic antigens are demonstrated to display similar or improved ability to treat EBV-positive cancer in vivo as compared to populations of immune cells generated/expanded by stimulating immune cells using peptides of EBV latent antigens.
- Another unexpected finding was that methods using both EBV lytic antigens and EBV latent antigens in stimulations did not result in a substantial reduction of the frequency of immune cells specific for EBV latent antigens in the expanded population.
- The inventors further demonstrate that populations of immune cells comprising immune cells specific for EBV lytic antigens and immune cells specific for EBV latent antigens are more effective for treating EBV-associated disease than populations of immune cells comprising immune cells specific for EBV latent antigens only.
- In a first aspect the present disclosure provides a method for generating or expanding a population of immune cells comprising immune cells specific for an Epstein Barr Virus (EBV) lytic antigen, comprising stimulating immune cells specific for an EBV lytic antigen by contacting peripheral blood mononuclear cells (PBMCs) with: (i) one or more peptides corresponding to all or part of one or more EBV lytic antigens; or (ii) antigen presenting cells (APCs) presenting one or more peptides corresponding to all or part of one or more EBV lytic antigens.
- In some embodiments the method further comprises re-stimulating the immune cells specific for an EBV lytic antigen by contacting them with APCs presenting one or more peptides corresponding to all or part of one or more EBV lytic antigens.
- Also provided is a method for generating or expanding a population of immune cells comprising immune cells specific for an Epstein Barr Virus (EBV) lytic antigen and immune cells specific for an EBV latent antigen, comprising stimulating immune cells specific for an EBV lytic antigen and immune cells specific for an EBV latent antigen by contacting peripheral blood mononuclear cells (PBMCs) with: (i) one or more peptides corresponding to all or part of one or more EBV lytic antigens, and one or more peptides corresponding to all or part of one or more EBV latent antigens; or (ii) antigen presenting cells (APCs) presenting one or more peptides corresponding to all or part of one or more EBV lytic antigens, and one or more peptides corresponding to all or part of an EBV latent antigen.
- In some embodiments the method further comprises re-stimulating the immune cells specific for an EBV lytic antigen and the immune cells specific for an EBV latent antigen by contacting them with APCs presenting one or more peptides corresponding to all or part of one or more EBV lytic antigens, and one or more peptides corresponding to all or part of an EBV latent antigen.
- In some embodiments in accordance with various aspects of the present disclosure the one or more EBV lytic antigens are selected from BZLF1, BRLF1, BMLF1, BMRF1, BXLF1, BALF1, BALF2, BGLF5, BHRF1, BNLF2A, BNLF2B, BHLF1, BLLF2, BKRF4, BMRF2, BALF4, BILF1, BILF2, BNFR1, BVRF2, BALF3, BALF5 and BDLF3. In some embodiments in accordance with various aspects of the present disclosure the one or more EBV lytic antigens are selected from the group consisting of BZLF1, BRLF1, BMLF1, BMRF1, BXLF1, BALF1, BALF2, BGLF5, BHRF1, BNLF2A, BNLF2B, BHLF1, BLLF2, BKRF4, BMRF2, BALF4, BILF1, BILF2, BNFR1, BVRF2, BALF3, BALF5, BDLF3, and a combination thereof.
- In some embodiments the one or more EBV lytic antigens are selected from BZLF1, BRLF1, BMLF1, BMRF1, BALF2, BNLF2A, BNLF2B, BMRF2 and BDLF3. In some embodiments the one or more EBV lytic antigens are selected from the group consisting of BZLF1, BRLF1, BMLF1, BMRF1, BALF2, BNLF2A, BNLF2B, BMRF2, BDLF3, and a combination thereof.
- In some embodiments the one or more EBV latent antigens are selected from EBNA1, EBNA-LP, EBNA2, EBNA3A, EBNA3B, EBNA3C, BARF1, LMP1, LMP2A and LMP2B. In some embodiments the one or more EBV latent antigens are selected from the group consisting of EBNA1, EBNA-LP, EBNA2, EBNA3A, EBNA3B, EBNA3C, BARF1, LMP1, LMP2A, LMP2B, and a combination thereof.
- In some embodiments the one or more EBV latent antigens are selected from EBNA1, LMP1, LMP2A and LMP2B. In some embodiments the one or more EBV latent antigens are selected from the group consisting of EBNA1, LMP1, LMP2A, LMP2B, and a combination thereof.
- In some embodiments the PBMCs are PBMCs depleted of CD45RA-positive cells.
- Also provided is an isolated population of immune cells obtained or obtainable by a method according to the present disclosure.
- Also provided is an isolated population of immune cells comprising immune cells specific for an Epstein Barr Virus (EBV) lytic antigen.
- Also provided is an isolated population of immune cells comprising immune cells specific for an Epstein Barr Virus (EBV) lytic antigen and immune cells specific for an EBV latent antigen.
- Also provided is a pharmaceutical composition comprising an isolated population of immune cells according to the present disclosure.
- Also provided is an isolated population of immune cells or a pharmaceutical composition according to the present disclosure, for use in a method for treating or preventing a disease or disorder.
- Also provided is the use of an isolated population of immune cells or a pharmaceutical composition according to the present disclosure in the manufacture of a medicament for use in a method of treatment or prevention of a disease or disorder.
- Also provided is a method for treating or preventing a disease or disorder, comprising administering an isolated population of immune cells or a pharmaceutical composition according to the present disclosure to a subject.
- Also provided is an isolated population of immune cells or a pharmaceutical composition according to the present disclosure, for use in a method of treatment or prevention of a disease or disorder associated with EBV infection.
- Also provided is the use of isolated population of immune cells or a pharmaceutical composition according to the present disclosure, in the manufacture of a medicament for use in a method of treatment or prevention of a disease or disorder associated with EBV infection.
- Also provided is a method for treating or preventing a disease or disorder associated with EBV infection, comprising administering an isolated population of immune cells or a pharmaceutical composition according to the present disclosure, to a subject.
- Also provided is an isolated population of immune cells or a pharmaceutical composition according to the present disclosure, for use in a method of treatment or prevention of a cancer.
- Also provided is the use of an isolated population of immune cells or a pharmaceutical composition according to the present disclosure, in the manufacture of a medicament for use in a method of treatment or prevention of a cancer.
- Also provided is a method for treating or preventing a cancer, comprising administering an isolated population of immune cells or a pharmaceutical composition according to the present disclosure, to a subject.
- In some embodiments in accordance with the various aspects of the present disclosure the disease or disorder associated with EBV infection is an EBV-associated cancer.
- In some embodiments in accordance with the various aspects of the present disclosure the cancer is an EBV-associated cancer.
- In some embodiments the EBV-associated cancer is selected from EBV-positive lymphoma, EBV-positive nasopharyngeal carcinoma, and EBV-positive gastric carcinoma.
- Also provided is a method for killing a cell infected with EBV, comprising contacting a cell infected with EBV with an isolated population of immune cells or a pharmaceutical composition according to the present disclosure. The method may be an in vitro or an in vivo method.
- Also provided is the use of an isolated population of immune cells or a pharmaceutical composition according to the present disclosure to kill a cell infected with EBV.
- Also provided is a method for killing a cancer cell, comprising contacting a cancer cell with an isolated population of immune cells or a pharmaceutical composition according to the present disclosure. The method may be an in vitro or an in vivo method.
- Also provided is the use of an isolated population of immune cells or a pharmaceutical composition according to the present disclosure to kill a cancer cell.
- In some embodiments, the cancer cell is infected with EBV.
- The present disclosure is based on the unexpected finding that immune cells specific for EBV lytic antigens are capable of killing EBV-infected cells, and that populations of cells comprising immune cells specific for EBV latent antigens and EBV lytic antigens display improved ability to control EBV-positive malignancies as compared to populations of cells only comprising immune cells specific for EBV latent antigens.
- Epstein-Barr Virus Replication
- Epstein-Barr Virus (EBV) virology is described e.g. in Stanfield and Luftiq, F1000Res. (2017) 6:386 and Odumade et al., Clin Microbiol Rev (2011) 24(1):193-209, both of which are hereby incorporated by reference in entirety.
- EBV infects epithelial cells via binding of viral protein BMRF2 to β1 integrins, and binding of viral protein gH/gL with integrins avβ6 and avβ8. EBV infects B cells through interaction of viral glycoprotein gp350 with CD21 and/or CD35, followed by interaction of viral gp42 with MHC class II. These interactions trigger fusion of the viral envelope with the cell membrane, allowing the virus to enter the cell. Once inside, the viral capsid dissolves and the viral genome is transported to the nucleus.
- EBV has two modes of replication; latent and lytic.
- The latent cycle does not result in production of virions, and can take place in place B cells and epithelial cells. The EBV genome circular DNA resides in the cell nucleus as an episome and is copied by the host cell's DNA polymerase. In latency, only a fraction of EBV's genes are expressed, in one of three different patterns known as latency programs, which produce distinct sets of viral proteins and RNAs. The latent cycle is described e.g. in Amon and Farrell, Reviews in Medical Virology (2004) 15(3): 149-56, which is hereby incorporated by reference in entirety.
- EBNA1 protein and non-coding RNA EBER are expressed in each of latency programs I-Ill. Latency programs II and III further involve expression of EBNALP, LMP1, LMP2A and LMP2B proteins, and latency program III further involves expression of EBNA2, EBNA3A, EBNA3B and EBNA3C.
- EBNA1 is multifunctional, and has roles in gene regulation, extrachromosomal replication, and maintenance of the EBV episomal genome through positive and negative regulation of viral promoters (Duellman et al., J Gen Virol. (2009); 90(Pt 9): 2251-2259). EBNA2 is involved in the regulation of latent viral transcription and contributes to the immortalization of cells infected with EBV (Kempkes and Ling, Curr Top Microbiol Immunol. (2015) 391:35-59). EBNA-LP is required for transformation of native B cells, and recruits transcription factors for viral replication (Szymula et al., PLoS Pathog. (2018); 14(2):e1006890). EBNA3A, 3B and 3C interact with RBPJ to influence gene expression, contributing to survival and growth of infected cells (Wang et al., J Virol. (2016) 90(6):2906-2919). LMP1 regulates expression of genes involved in B cell activation (Chang et al., J. Biomed. Sci. (2003) 10(5): 490-504). LMP2A and LMP2B inhibit normal B-cell signal transduction by mimicking the activated B-cell receptor (Portis and Longnecker, Oncogene (2004) 23(53): 8619-8628). EBERs form ribonucleoprotein complexes with host cell proteins, and are proposed to have roles in cell transformation.
- The latent cycle can progress according to any of latency programs I to III in B cells, and usually progresses from III to II to I. Upon infection of a resting naïve B cell, EBV enters latency program III. Expression of latency III genes activates the B cell, which becomes a proliferating blast. EBV then typically progresses to latency II by restricting expression to a subset of genes, which cause differentiation of the blast to a memory B cell. Further restriction of gene expression causes EBV to enter latency I. EBNA1 expression allows EBV to replicate when the memory B cell divides. In epithelial cells, only latency II occurs.
- In primary infection, EBV replicates in oropharyngeal epithelial cells and establishes Latency III, II, and I infections in B-lymphocytes. EBV latent infection of B-lymphocytes is necessary for virus persistence, subsequent replication in epithelial cells, and release of infectious virus into saliva. EBV Latency III and II infections of B-lymphocytes, Latency II infection of oral epithelial cells, and Latency II infection of NK- or T-cell can result in malignancies, marked by uniform EBV genome presence and gene expression.[26]
- Latent EBV in B cells can be reactivated to switch to lytic replication. The lytic cycle results in the production of infectious virions and can take place in place B cells and epithelial cells, and is reviewed e.g. by Kenney in
Chapter 25 of Arvin et al., Human Herpesviruses: Biology, Therapy and Immunoprophylaxis; Cambridge University Press (2007), which is hereby incorporated by reference in entirety. - Lytic replication requires the EBV genome to be linear. The latent EBV genome is episomal, and so it must be linearised for lytic reactivation. In B cells, lytic replication normally only takes place after reactivation from latency.
- Immediate-early lytic gene products such as BZLF1 and BRLF1 act as transactivators, enhancing their own expression, and the expression of later lytic cycle genes.
- Early lytic gene products have roles in viral replication (e.g. EBV DNA polymerase catalytic component BALF5; DNA polymerase processivity factor BMRF1, DNA binding protein BALF2, helicase BBLF4, primase BSLF1, and primase-associated protein BBLF2/3) and deoxynucleotide metabolism (e.g. thymidine kinase BXLF1, dUTPase BORF2). Other early lytic gene products act transcription factors (e.g. BMRF1, BRRF1), have roles in RNA stability and processing (e.g. BMLF1), or are involved in immune evasion (e.g. BHRF1, which inhibits apoptosis).
- Late lytic gene products are traditionally classed as those expressed after the onset of viral replication. They generally encode structural components of the virion such as nucleocapsid proteins, as well as glycoproteins which mediate EBV binding and fusion (e.g. gp350/220, gp85, gp42, gp25). Other late lytic gene products have roles in immune evasion; BCLF1 encodes a viral homologue of IL-10, and BALF1 encodes a protein with homology to the anti-apoptotic protein Bcl2.
- EBV Antigen Expression in EBV-Associated Cancers
- EBV antigens expressed in EBV-positive cancers are described e.g. in Craddock and Heslop Update Cancer Ther. (2008) March; 3(1): 33-41, Gottschalk and Rooney Curr Top Microbiol Immunol. (2015) 391: 427-454, and Shinozaki-Ushiku et al., Int J Oncol. (2015) 46(4):1421-34.
- EBV-associated lymphoma arising in immunocompromised subjects e.g. following HSCT or solid organ transplant, subjects having congenital immunodeficiency or HIV infection display type III latency, and express EBNA1, EBNA2, EBNA-LP, EBNA3A, EBNA3B, EBNA3C, BARF1, LMP1 and LMP2. EBV-associated EBV-positive Hodgkin's lymphoma, non-Hodgkin's lymphoma, some types and T cell lymphoma, NK cell lymphoma, some cases of B-cell lymphoma and nasopharyngeal carcinoma display type II latency, and express EBNA1, BARF1, LMP1 and LMP2. EBV-positive Burkitt's lymphoma displays type I latency, expressing EBNA1 and BARF1. EBV-positive gastric carcinoma displays type I or type II latency.
- It has previously been thought that only EBV latent antigens (and not lytic cycle antigens) are expressed by cells of EBV-positive cancer cells in immunocompetent subjects. Transcripts encoding lytic cycle gene products have recently been detected in EBV-positive malignancies including gastric carcinoma, nasopharyngeal carcinoma and B cell lymphoma.
- It has not yet been determined whether it is possible to generate populations of immune cells specific for EBV lytic antigens from patients having EBV-positive cancers or healthy donor subjects, whether immune cells specific for EBV lytic antigens would display effector activity against EBV-infected cells, or whether populations of immune cells specific for EBV lytic antigens would be useful to treat EBV-associated cancers.
- EBV Antigens
- Aspects of the present disclosure employ peptides corresponding to EBV antigens.
- In some embodiments in accordance with the various aspects of the present disclosure, an EBV lytic antigen is selected from BZLF1, BRLF1, BMLF1, BMRF1, BXLF1, BALF1, BALF2, BARF1, BGLF5, BHRF1, BNLF2A, BNLF2B, BHLF1, BLLF2, BKRF4, BMRF2, FU, EBNA1-FUK, BALF4, BILF1, BILF2, BNFR1, BVRF2, BALF3, BALF5, BDLF3 and gp350. The EBV lytic antigen may be selected from the group consisting of BZLF1, BRLF1, BMLF1, BMRF1, BXLF1, BALF1, BALF2, BARF1, BGLF5, BHRF1, BNLF2A, BNLF2B, BHLF1, BLLF2, BKRF4, BMRF2, FU, EBNA1-FUK, BALF4, BILF1, BILF2, BNFR1, BVRF2, BALF3, BALF5, BDLF3, gp350, and a combination thereof. In some embodiments, an EBV lytic antigen is selected from BZLF1, BRLF1, BMLF1, BMRF1, BXLF1, BALF1, BALF2, BGLF5, BHRF1, BNLF2A, BNLF2B, BHLF1, BLLF2, BKRF4, BMRF2, BALF4, BILF1, BILF2, BNFR1, BVRF2, BALF3, BALF5 and BDLF3. The EBV lytic antigen may be selected from the group consisting of BZLF1, BRLF1, BMLF1, BMRF1, BXLF1, BALF1, BALF2, BGLF5, BHRF1, BNLF2A, BNLF2B, BHLF1, BLLF2, BKRF4, BMRF2, BALF4, BILF1, BILF2, BNFR1, BVRF2, BALF3, BALF5, BDLF3 and a combination thereof. In some embodiments, an EBV lytic antigen is selected from BZLF1, BRLF1, BMLF1, BMRF1, BALF2, BNLF2A, BNLF2B, BMRF2 and BDLF3. The EBV lytic antigen may be selected from the group consisting of BZLF1, BRLF1, BMLF1, BMRF1, BALF2, BNLF2A, BNLF2B, BMRF2, BDLF3 and a combination thereof.
- In some embodiments, an EBV lytic antigen is selected from BZLF1, BRLF1, BMRF1, BMLF1, BXLF1, BALF1, BLLF2, BALF2, BNLF2A, BNLF2B and BMRF2. The EBV lytic antigen may be selected from the group consisting of BZLF1, BRLF1, BMRF1, BMLF1, BXLF1, BALF1, BLLF2, BALF2, BNLF2A, BNLF2B, BMRF2, and a combination thereof. In some embodiments, an EBV lytic antigen is selected from BZLF1, BRLF1, BMRF1, BMLF1, BXLF1, BALF1, BLLF2, BALF2 and BNLF2A. The EBV lytic antigen may be selected from the group consisting of BZLF1, BRLF1, BMRF1, BMLF1, BXLF1, BALF1, BLLF2, BALF2, BNLF2A, and a combination thereof. In some embodiments, an EBV lytic antigen is selected from BZLF1, BRLF1, BMRF1, BMLF1, BALF2, BNLF2A, BNLF2B and BMRF2. The EBV lytic antigen may be selected from the group consisting of BZLF1, BRLF1, BMRF1, BMLF1, BALF2, BNLF2A, BNLF2B, BMRF2, and a combination thereof.
- In some embodiments, an EBV lytic antigen is selected from an immediate-early lytic antigen, an early lytic antigen or a late lytic antigen.
- In some embodiments an immediate-early lytic antigen is selected from BZLF1, BRLF1 and BMRF1. The immediate-early lytic antigen may be selected from the group consisting of BZLF1, BRLF1, BMRF1, and a combination thereof.
- In some embodiments an early lytic antigen is selected from BMLF1, BMRF1, BXLF1, BALF1, BALF2, BARF1, BGLF5, BHRF1, BNLF2A, BNLF2B, BHLF1, BLLF2, BKRF4, BMRF2, FU and EBNA1-FUK. The early lytic antigen may be selected from the group consisting of BMLF1, BMRF1, BXLF1, BALF1, BALF2, BARF1, BGLF5, BHRF1, BNLF2A, BNLF2B, BHLF1, BLLF2, BKRF4, BMRF2, FU, EBNA1-FUK, and a combination thereof. In some embodiments an early lytic antigen is selected from BMLF1, BMRF1, BXLF1, BALF1, BALF2, BGLF5, BHRF1, BNLF2A, BNLF2B, BHLF1, BLLF2, BKRF4 and BMRF2. The early lytic antigen may be selected from the group consisting of BMLF1, BMRF1, BXLF1, BALF1, BALF2, BGLF5, BHRF1, BNLF2A, BNLF2B, BHLF1, BLLF2, BKRF4, BMRF2, and a combination thereof. In some embodiments an early lytic antigen is selected from BMLF1, BMRF1, BALF2, BNLF2A, BNLF2B and BMRF2. The early lytic antigen may be selected from the group consisting of BMLF1, BMRF1, BALF2, BNLF2A, BNLF2B, BMRF2, and a combination thereof.
- In some embodiments a late lytic antigen is selected from BALF4, BILF1, BILF2, BNFR1, BVRF2, BALF3, BALF5, BDLF3 and gp350. A late lytic antigen may be selected from the group consisting of BALF4, BILF1, BILF2, BNFR1, BVRF2, BALF3, BALF5, BDLF3, gp350, and a combination thereof. In some embodiments a late lytic antigen is selected from BALF4, BILF1, BILF2, BNFR1, BVRF2, BALF3, BALF5 and BDLF3. A late lytic antigen may be selected from the group consisting of BALF4, BILF1, BILF2, BNFR1, BVRF2, BALF3, BALF5, BDLF3, and a combination thereof. In some embodiments a late lytic antigen is BDLF3.
- In some embodiments in accordance with the various aspects of the present disclosure, an EBV latent antigen is selected from EBNA1, EBNA-LP, EBNA2, EBNA3A, EBNA3B, EBNA3C, BARF1, LMP1, LMP2A and LMP2B. An EBV latent antigen may be selected from the group consisting of EBNA1, EBNA-LP, EBNA2, EBNA3A, EBNA3B, EBNA3C, BARF1, LMP1, LMP2A, LMP2B, and a combination thereof. In some embodiments, an EBV latent antigen is selected from EBNA1, LMP1, LMP2A and LMP2B. An EBV latent antigen may be selected from the group consisting of EBNA1, LMP1, LMP2A, LMP2B, and a combination thereof. In some embodiments, an EBV latent antigen is selected from EBNA1, LMP1 and LMP2A. The EBV latent antigen may be selected from the group consisting of EBNA1, LMP1, LMP2A, and a combination thereof.
- In some embodiments, an EBV latent antigen is selected from type III latency antigen, a type II latency antigen or a type I latency antigen.
- In some embodiments a type III latency antigen is selected from EBNA1, EBNA-LP, LMP1, LMP2A, LMP2B, BARF1, EBNA2, EBNA3A, EBNA3B and EBNA3C. The type III latency antigen may be selected from the group consisting of EBNA1, EBNA-LP, LMP1, LMP2A, LMP2B, BARF1, EBNA2, EBNA3A, EBNA3B, EBNA3C, and a combination thereof. In some embodiments a type II latency antigen is selected from EBNA1, EBNA-LP, LMP1, LMP2A, LMP2B and BARF1. A type II latency antigen may be selected from the group consisting of EBNA1, EBNA-LP, LMP1, LMP2A, LMP2B, BARF1, and a combination thereof. In some embodiments a type I latency antigen is selected from EBNA1 and BARF1. A type I latency antigen may be selected from the group consisting of EBNA1, BARF1, and a combination thereof.
- Where an EBV antigen is referred to herein, the present disclosure also contemplates isoforms, fragments, variants (including mutants) of the given EBV antigen. The amino acid sequence for a given EBV antigen, e.g. an EBV antigen referred to herein, can be retrieved e.g. from The UniProt Knowledgebase (UniProtKB)—see The UniProt Consortium, Nucleic Acids Research (2019), 47(D1): D506-D515.
- An “isoform”, “fragment” or “variant” of a reference EBV antigen may optionally be characterised as having at least 60%, preferably one of 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of the reference EBV antigen (e.g. a reference isoform of the antigen).
- A “fragment” generally refers to a fraction of the reference protein, and may be of any length (by number of amino acids), although may optionally be at least 20% of the length of the reference protein (that is, the protein from which the fragment is derived) and may have a maximum length of one of 50%, 75%, 80%, 85%, 90%, 95% or 99% of the length of the reference protein. A “variant” generally refers to a protein having an amino acid sequence comprising one or more amino acid substitutions, insertions, deletions or other modifications relative to the amino acid sequence of the reference protein, but retaining a considerable degree of sequence identity (e.g. at least 60%) to the amino acid sequence of the reference protein. An “isoform” generally refers to a variant of the reference protein expressed by EBV.
- In some embodiments in accordance with the various aspects described herein, reference is made to “one or more” antigens from a given list. Reference to “one or more” antigens means anywhere between one and all of the antigens recited in the list. Depending on the number of antigens listed, reference to “one or more” can mean e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, etc. of the recited antigens.
- Peptides and Pepmixes
- Aspects of the present disclosure employ peptides corresponding to EBV antigens in methods to generate/expand populations of immune cells specific for EBV antigens.
- As used herein, a “peptide” refers to a chain of two or more amino acid monomers linked by peptide bonds. A peptide typically has a length in the region of about 2 to 50 amino acids. A “polypeptide” is a polymer chain of two or more peptides. Polypeptides typically have a length greater than about 50 amino acids.
- As used herein, a peptide which “corresponds to” a reference antigen comprises or consists of an amino acid sequence of the reference antigen. For example, a peptide “corresponding to” EBNA1 comprises or consists of a sequence of amino acids which is found within the amino acid sequence of EBNA1 (i.e. is a subsequence of the amino acid sequence of EBNA1).
- Peptides employed herein typically have a length of 5-30 amino acids, e.g. one of 5-25 amino acids, 10-20 amino acids, or 12-18 amino acids. In some embodiments, peptides have a length of one of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acids. In some embodiments, peptides have a length of about 15 amino acids.
- “Peptides” as used herein may refer to populations comprising non-identical peptides.
- In some embodiments in accordance with various aspects of the present disclosure, the methods employ peptides corresponding to more than one antigen. In such embodiments, there is at least one peptide which corresponds to each of the antigens. For example, where the methods employ peptides corresponding to EBNA1 and LMP1, the peptides comprise at least one peptide corresponding to EBNA1, and at least one peptide corresponding to LMP1.
- In some embodiments the methods employ peptides corresponding to all or part of a reference antigen. Peptides corresponding to all of a given antigen cover the full length of the amino acid sequence of the antigen. That is to say that together, the peptides contain all of the amino acids of the amino acid sequence of the given antigen.
- Peptides corresponding to part of a given antigen cover part of the amino acid sequence of the antigen. In some embodiments where peptides cover part of the amino acid sequence of the antigen, the peptides together may cover e.g. greater than 10%, e.g. greater than one of 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95% of the amino acid sequence of the antigen.
- In some embodiments the methods employ overlapping peptides. “Overlapping” have amino acids, and more typically sequences of amino acids, in common. By way of illustration, a first peptide consists of an amino acid sequence corresponding to
positions 1 to 15 of the amino acid sequence of EBNA1, and a second peptide consists of an amino acid sequence corresponding to positions 5 to 20 of the amino acid sequence of EBNA1. The first and second peptides are overlapping peptides corresponding to EBNA1, overlapping by 11 amino acids. - In some embodiments overlapping peptides overlap by one of 1-20, 5-20, 8-15 or 10-12 amino acids. In some embodiments overlapping peptides overlap by one of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acids. In some embodiments overlapping peptides overlap by 11 amino acids.
- In some embodiments, the methods employ peptides having a length of 5-30 amino acids, overlapping by 1-20 amino acids, corresponding to all or part of a given reference antigen.
- In some embodiments, the methods employ peptides having a length of 15 amino acids, overlapping by 11 amino acids, corresponding to all a given reference antigen. Mixtures of such peptides may be referred to herein as “pepmix peptide pools” or “pepmixes” for a given antigen.
- For example, “EBNA1 pepmix” used in Example 1 herein refers to a pool of 158, 15mer peptides overlapping by 11 amino acids, spanning the full length of the amino acid sequence for EBNA1 as shown in UniProt: P03211-1, v1.
- In some embodiments in accordance with various aspects of the present disclosure, “peptides corresponding to” a given EBV antigen may be pepmix for the antigen.
- Methods for Generating/Expanding Populations of Immune Cells Specific for EBV
- Aspects of the present disclosure concern generating/expanding populations of immune cells specific for EBV.
- An “immune cell specific for EBV” expresses/comprises a receptor (preferably a T cell receptor) capable of recognising a peptide of an antigen of EBV (e.g. when presented by an MHC molecule). EBV-specific immune cells may express/comprise such a receptor as a result of expression of endogenous nucleic acid encoding such antigen receptor, or as a result of having been engineered to express such a receptor.
- The immune cells may be a cell of hematopoietic origin, e.g. a neutrophil, eosinophil, basophil, dendritic cell, lymphocyte, or monocyte. A lymphocyte may be e.g. a T cell, B cell, NK cell, NKT cell or innate lymphoid cell (ILC), or a precursor thereof. The immune cell may express e.g. CD3 polypeptides (e.g. CD3γ CD3ε CD3ζ or CD3δ), TCR polypeptides (TCRα or TCRβ), CD27, CD28, CD4 or CD8.
- Methods for generating/expanding populations of virus-specific immune cells in vitro/ex vivo are well known to the skilled person. Typical culture conditions (i.e. cell culture media, additives, temperature, gaseous atmosphere), cell numbers, culture periods, etc. can be determined by reference e.g. to Ngo et al., J Immunother. (2014) 37(4):193-203, which is hereby incorporated by reference in its entirety.
- Conveniently, cultures of cells according to the present disclosure may be maintained at 37° C. in a humidified atmosphere containing 5% CO2. The cells of cell cultures according to the present disclosure can be established and/or maintained at any suitable density, as can readily be determined by the skilled person. For example, cultures may be established at an initial density of ˜0.5×106 to ˜5×106 cells/ml of the culture (e.g. ˜1×106 cells/ml).
- Cultures can be performed in any vessel suitable for the volume of the culture, e.g. in wells of a cell culture plate, cell culture flasks, a bioreactor, etc. In some embodiments cells are cultured in a bioreactor, e.g. a bioreactor described in Somerville and Dudley, Oncoimmunology (2012) 1(8):1435-1437, which is hereby incorporated by reference in its entirety. In some embodiments cells are cultured in a GRex cell culture vessel, e.g. a GRex flask or a
GRex 100 bioreactor. - The methods generally comprise culturing populations of immune cells (e.g. heterogeneous populations of immune cells (e.g. peripheral blood mononuclear cells; PBMCs) comprising cells having antigen-specific receptors in the presence of antigen-presenting cells (APCs) presenting viral antigen peptide:MHC complexes, under conditions providing appropriate costimulation and signal amplification so as to cause activation and expansion. The process of T cell activation is well known to the skilled person and described in detail, for example, in Immunobiology, 5th Edn. Janeway C A Jr, Travers P, Walport M, et al. New York: Garland Science (2001),
Chapter 8, which is incorporated by reference in its entirety. - Specifically, the methods involve steps in which T cells comprising T cell receptors (TCRs) specific for EBV antigen peptide:MHC complex are stimulated by APCs presenting the EBV antigen peptide:MHC complex for which the TCR is specific. The APCs are infected with virus encoding, or comprise/express the EBV antigen/peptide(s), and present the EBV antigen peptide in the context of an MHC molecule. Stimulation causes T cell activation, and promotes cell division (proliferation), resulting in generation and/or expansion of a population of T cells specific for the EBV antigen.
- The population of cells obtained following stimulation is enriched for T cells specific for the EBV antigen as compared to the population prior to stimulation (i.e. the EBV antigen-specific T cells are present at an increased frequency in the population following stimulation). In this way, a population of T cells specific for the EBV antigen is expanded/generated out of a heterogeneous population of T cells having different specificities. A population of T cells specific for an EBV antigen may be generated from a single T cell by stimulation and consequent cell division. An existing population of T cells specific for an EBV antigen may be expanded by stimulation and consequent cell division of cells of the population of EBV antigen-specific T cells.
- It will be appreciated that in embodiments of the various aspects of the present disclosure, the immune cells specific for EBV antigens herein are preferably T cells. In some embodiments, the T cell is a CD3+, CD4+ T cell. In some embodiments, the T cell is a CD3+, CD8+ T cell. In some embodiments, the T cell is a T helper cell (TH cell). In some embodiments, the T cell is a cytotoxic T cell (e.g. a cytotoxic T lymphocyte (CTL)). The immune cells preferably express/comprise a TCR specific for a peptide of an antigen of EBV.
- An EBV-specific T cell may display certain functional properties of a T cell in response to the viral antigen for which the T cell is specific, or in response a cell comprising/expressing the virus/antigen. In some embodiments, the properties are functional properties associated with effector T cells, e.g. cytotoxic T cells.
- In some embodiments, an EBV-specific T cell may display one or more of the following properties: cytotoxicity to a cell comprising/expressing EBV or the EBV antigen for which the T cell is specific; proliferation, IFNγ expression, CD107a expression, IL-2 expression, TNFα expression, perforin expression, granzyme expression, granulysin expression, and/or FAS ligand (FASL) expression in response to a cell comprising/expressing EBV or the EBV antigen for which the T cell is specific.
- EBV-specific T cells express/comprise a TCR capable of recognising a peptide of the EBV antigen for which the T cell is specific when presented by the appropriate MHC molecule. EBV-specific T cells may be CD4+ T cells and/or CD8+ T cells.
- The methods of the present disclosure comprise stimulating immune cells specific for an EBV antigen by contacting populations of immune cells with peptide(s) corresponding to EBV antigen(s) or APCs presenting peptide(s) corresponding to EBV antigen(s). Such method steps may be referred to herein as “stimulations” or “stimulation steps”. Such method steps typically involve maintenance of the cells in culture in vitro/ex vivo, and may be referred to as “stimulation cultures”.
- In some embodiments, the methods comprise one or more additional stimulation steps. That is, in some embodiments the methods comprise one or more further steps of re-stimulating the cells obtained by a stimulation step. Such further stimulation steps may be referred to herein as “re-stimulations” or “re-stimulation steps”. Such method steps typically involve maintenance of the cells in culture in vitro/ex vivo, and may be referred to as “re-stimulation cultures”.
- It will be appreciated that “contacting” PBMCs (for stimulations) or populations of cells obtained by stimulation step described herein (for re-stimulations) with peptide(s) corresponding to EBV antigen(s) generally involves culturing the PBMCs/population of cells in vitro/ex vivo in cell culture medium comprising the peptide(s). Similarly, it will be appreciated that “contacting” PBMCs/populations of cells with APCs presenting peptide(s) corresponding to EBV antigen(s) generally involves co-culturing the APCs and the PBMCs/population of cells in vitro/ex vivo in cell culture medium.
- In some embodiments, the methods comprise contacting PBMCs with peptide(s) corresponding to EBV antigen(s). In such embodiments, APCs within the population of PBMCs (e.g. dendritic cells, macrophages and B cells) internalise (e.g. by phagocytosis, pinocytosis), process and present the antigens on MHC class I molecules (cross-presentation) and/or MHC class II molecules, for subsequent activation of CD8+ and/or CD4+ T cells within the population of PBMCs.
- In some embodiments, the methods comprise contacting the population of cells obtained by a stimulation step described herein with peptide(s) corresponding to EBV antigen(s). In such embodiments, APCs within the population of cells (e.g. dendritic cells, macrophages and B cells) internalise (e.g. by phagocytosis, pinocytosis), process and present the antigens on MHC class I molecules (cross-presentation) and/or MHC class II molecules, for subsequent re-stimulation of CD8+ and/or CD4+ T cells within the population of cells.
- In some embodiments, the methods comprise contacting PBMCs with APCs presenting peptide(s) corresponding to EBV antigen(s). In some embodiments, the methods comprise contacting the population of cells obtained by a stimulation step described herein with APCs presenting peptide(s) corresponding to EBV antigen(s).
- Co-culture of T cells and APCs in stimulations and re-stimulations according to the disclosure is performed in cell culture medium. The cell culture medium can be any cell culture medium in which T cells and APCs according can be maintained in culture in vitro/ex vivo. Culture medium suitable for use in the culture of lymphocytes is well known to the skilled person, and includes, for example, RPMI-1640 medium, AIM-V medium, Iscoves medium, etc.
- In some embodiments, cell culture medium may comprise RPMI-1640 medium and/or Click's medium (also known as Eagle's Ham's amino acids (EHAA) medium). The compositions of these media are well known to the skilled person. The formulation of RPMI-1640 medium is described in e.g. Moore et al., JAMA (1967) 199:519-524, and the formulation of Click's media is described in Click et al., Cell Immunol (1972) 3:264-276. RPMI-1640 medium can be obtained from e.g. ThermoFisher Scientific, and Click's medium can be obtained from e.g. Sigma-Aldrich (Catalog No. C5572).
- In some embodiments, the methods of the present disclosure involve culturing PBMCs that have been contacted with peptide(s) corresponding to EBV antigen(s), or in the presence of APCs presenting peptide(s) corresponding to EBV antigen(s), in cell culture medium comprising RPMI-1640 medium and Click's medium. In some embodiments, the methods of the present disclosure involve culturing the population of cells obtained by a stimulation step described herein that have been contacted with peptide(s) corresponding to EBV antigen(s), or in the presence of APCs presenting peptide(s) corresponding to EBV antigen(s), in cell culture medium comprising RPMI-1640 medium and Click's medium.
- In some embodiments the cell culture medium comprises (by volume) 25-65% RPMI-1640 medium, and 25-65% Click's medium. In some embodiments the cell culture medium comprises 30-60% RPMI-1640 medium, and 30-60% Click's medium. In some embodiments the cell culture medium comprises 35-55% RPMI-1640 medium, and 35-55% Click's medium. In some embodiments the cell culture medium comprises 40-50% RPMI-1640 medium, and 40-50% Click's medium. In some embodiments the cell culture medium comprises 45% RPMI-1640 medium, and 45% Click's medium.
- In some embodiments the cell culture medium may comprise one or more cell culture medium additives. Cell culture medium additives are well known to the skilled person, and include antibiotics (e.g. penicillin, streptomycin), serum (e.g. fetal bovine serum (FBS), bovine serum albumin (BSA)), L-glutamine, cytokines/growth factors, etc.
- In some embodiments, the cell culture medium comprises (by volume) 5-20% FBS, e.g. 7.5-15% FBS, or 10% FBS. In some embodiments, the cell culture medium comprises 0.5-5% GlutaMax, e.g. 1% GlutaMax. In some embodiments, the cell culture medium comprises 0.5-5% Pen/Strep, e.g. 1% Pen/Strep.
- Aspects of the present disclosure employ antigen-presenting cells (APCs) in methods for generating/expanding populations of immune cells specific for EBV.
- APCs according to the present disclosure may be professional APCs. Professional APCs are specialised for presenting antigen to T cells; they are efficient at processing and presenting MHC-peptide complexes at the cell surface, and express high levels of costimulatory molecules. Professional APCs include dendritic cells (DCs), macrophages, and B cells. Non-professional APCs are other cells capable of presenting MHC-peptide complexes to T cells, in particular MHC Class I-peptide complexes to CD8+ T cells.
- In some embodiments the APC is an APC capable of cross-presentation on MHC class I of antigen internalised by the APC (e.g. taken-up by endocytosis/phagocytosis). Cross-presentation on MHC class I of internalized antigens to CD8+ T cells is described e.g. in Alloatti et al., Immunological Reviews (2016), 272(1): 97-108, which is hereby incorporated by reference in its entirety. APCs capable of cross-presentation include e.g. dendritic cells (DCs), macrophages, B cells and sinusoidal endothelial cells.
- As explained herein, in some embodiments APCs for stimulating immune cells specific for EBV antigen(s) are comprised within the population of cells (e.g. PBMCs) comprising the immune cells specific for EBV antigen(s), which populations of cells specific for EBV antigen(s) are to be expanded in accordance with the methods of the present disclosure. In such embodiments, APCs may be e.g. dendritic cells, macrophages, B cells or any other cell type within the population of cells which is capable of presenting antigen to immune cells specific for EBV antigen(s)
- In some embodiments the methods employ APCs that have been modified to express/comprise EBV antigen(s)/peptide(s) thereof. In some embodiments, the APCs may present peptide(s) corresponding to EBV antigen(s) as a result of having been contacted with the peptide(s), and having internalised them. In some embodiments, APCs may have been “pulsed” with the peptide(s), which generally involves culturing APCs in vitro in the presence of the peptide(s), for a period of time sufficient for the APCs to internalise the peptide(s).
- In some embodiments the APCs may present peptide(s) corresponding to EBV antigen(s) as a result of expression from nucleic acid encoding the antigen within the cell. APCs may comprise nucleic acid encoding EBV antigen(s) as a consequence of their having been infected with EBV (e.g. in the case of B cells, e.g. LCLs). APCs may comprise nucleic acid encoding EBV antigen(s) as a consequence of nucleic acid encoding the antigen(s) having been introduced into the cell, e.g. via transfection, transduction, electroporation, etc. Nucleic acid encoding EBV antigen(s) may be provided in a plasmid/vector.
- In some embodiments, APCs employed in the methods of the present disclosure are selected from activated T cells (ATCs), dendritic cells, B cells (including e.g. LCLs), and artificial antigen presenting cells (aAPCs) such as those described in Neal et al., J Immunol Res Ther (2017) 2(1):68-79 and Turtle and Riddell Cancer J. (2010) 16(4):374-381.
- In some embodiments APCs are autologous with respect to the population of cells with which they are to be co-cultured for the generation/expansion of populations of immune cells comprising immune cells specific for EBV antigen(s). That is, in some embodiments the APCs are from (or are derived from cells obtained from) the same subject as the subject from which the population of cells with which they are to be co-cultured were obtained.
- The use of polyclonal activated T cells (ATCs) as APCs and methods for preparing ATCs are described e.g. in Ngo et al., J Immunother. (2014) 37(4):193-203, incorporated by reference herienabove. Briefly, ATCs can be generated by non-specifically activating T cells in vitro by stimulating PBMCs with agonist anti-CD3 and agonist anti-CD28 antibodies, in the presence of IL-2.
- Dendritic cells may be generated according to methods well known in the art, e.g. as described in Ngo et al., J Immunother. (2014) 37(4):193-203. Dendritic cells may be prepared from monocytes which may be obtained by CD14 selection from PBMCs. The monocytes may be cultured in cell culture medium causing their differentiation to immature dendritic cells, which may comprise e.g. IL-4 and GM-CSF. Immature dendritic cells may be matured by culture in the presence of IL-6, IL-1β, TNFα, PGE2, GM-CSF and IL-4.
- LCLs may be generated according to methods well known in the art, e.g. as described in in Hui-Yuen et al., J Vis Exp (2011) 57: 3321, and Hussain and Mulherkar, Int J Mol Cell Med (2012) 1(2): 75-87, both hereby incorporated by reference in their entirety. Briefly, LCLs can be produced by incubation of PBMCs with concentrated cell culture supernatant of cells producing EBV, for example B95-8 cells, in the presence of cyclosporin A.
- Artificial antigen presenting cells (aAPCs) include e.g. K562cs cells, which are engineered to express costimulatory molecules CD80, CD86, CD83 and 4-1 BBL (described e.g. in Suhoski et al., Mol Ther. (2007) 15(5):981-8).
- In some embodiments the APC is not a cell infected with EBV. In some embodiments the APC is not an EBV-infected B cell. In some embodiments the APC is not an EBV-LCL.
- In some embodiments, a stimulation step comprises contacting PBMCs peptide(s) corresponding to EBV antigen(s). In some embodiments, a re-stimulation step comprises contacting immune cells specific for EBV antigen(s) with APCs presenting peptide(s) corresponding to EBV antigen(s). In some embodiments, a re-stimulation step comprises contacting immune cells specific for EBV antigen(s) with ATCs presenting peptide(s) corresponding to EBV antigen(s).
- In some embodiments the methods further employ agents for enhancing costimulation in stimulations and/or re-stimulations. Such agents include e.g. cells expressing costimulatory molecules (e.g. CD80, CD86, CD83 and/or 4-1 BBL), such as e.g. LCLs or K562cs cells. In some embodiments the cells expressing costimulatory molecules are HLA-negative, EBV replication-incompetent LCLs, which are also referred to as “universal LCLs” or “uLCLs”. uLCLs are described e.g. in US 2018/0250379 A1.
- Other examples of agents for enhancing costimulation include e.g. agonist antibodies specific for costimulatory receptors expressed by T cells (e.g. 4-1 BB, CD28, OX40, ICOS, etc.), and costimulatory molecules capable of activating costimulatory receptors expressed by T cells (e.g. CD80, CD86, CD83, 4-1BBL, OX40L, ICOSL, etc.). Such agents may be provided e.g. immobilised on beads.
- In some embodiments, a re-stimulation step comprises contacting immune cells specific for EBV antigen(s) with ATCs presenting peptide(s) corresponding to EBV antigen(s) in the presence of uLCLs.
- Contacting of populations of immune cells with peptide(s) corresponding to EBV antigen(s) or APCs presenting peptide(s) corresponding to EBV antigen(s) may be performed in the presence of one or more cytokines, to facilitate T cell activation and proliferation. In some embodiments stimulations are performed in the presence of one or more of IL-7, IL-15, IL-6, IL-12, IL-4, IL-2 and/or IL-21. It will be appreciated that the cytokines are added exogenously to the culture, and additional to cytokines that are produced by the cells in culture. In some embodiments the added cytokines are recombinantly-produced cytokines.
- Accordingly, in some embodiments the methods of the present disclosure involve culturing PBMCs that have been contacted with peptide(s) corresponding to EBV antigen(s), or in the presence of APCs presenting peptide(s) corresponding to EBV antigen(s), in the presence of one or more of IL-7, IL-15, IL-6, IL-12, IL-4, IL-2 and/or IL-21.
- In some embodiments culture is in the presence of IL-7, IL-15, IL-6, IL-12, IL-4, IL-2 and/or IL-21. In some embodiments culture is in the presence of IL-7, IL-15, IL-6 and/or IL-12. In some embodiments culture is in the presence of IL-7 and/or IL-15.
- In some embodiments the final concentration of IL-7 in the culture is 1-100 ng/ml, e.g. one of 2-50 ng/ml, 5-20 ng/ml or 7.5-15 ng/ml. In some embodiments the final concentration of IL-7 in the culture is about 10 ng/ml.
- In some embodiments the final concentration of IL-15 in the culture is 1-100 ng/ml, e.g. one of 2-50 ng/ml, 5-20 ng/ml or 7.5-15 ng/ml. In some embodiments the final concentration of IL-15 in the culture is about 10 ng/ml.
- In some embodiments the final concentration of IL-15 in the culture is 10-1000 ng/ml, e.g. one of 20-500 ng/ml, 50-200 ng/ml or 75-150 ng/ml. In some embodiments the final concentration of IL-15 in the culture is about 100 ng/ml.
- In some embodiments the final concentration of IL-6 in the culture is 10-1000 ng/ml, e.g. one of 20-500 ng/ml, 50-200 ng/ml or 75-150 ng/ml. In some embodiments the final concentration of IL-6 in the culture is about 100 ng/ml.
- In some embodiments the final concentration of IL-12 in the culture is 1-100 ng/ml, e.g. one of 2-50 ng/ml, 5-20 ng/ml or 7.5-15 ng/ml. In some embodiments the final concentration of IL-12 in the culture is 10 ng/ml.
- In some embodiments the final concentration of IL-7 is 1-100 ng/ml (e.g. one of 2-50 ng/ml, 5-20 ng/ml or 7.5-15 ng/ml, e.g. 10 ng/ml), and the final concentration of IL-15 is 10-1000 ng/ml (e.g. one of 20-500 ng/ml, 50-200 ng/ml or 75-150 ng/ml, e.g. about 100 ng/ml).
- In some embodiments the final concentration of IL-7 is 1-100 ng/ml (e.g. one of 2-50 ng/ml, 5-20 ng/ml or 7.5-15 ng/ml, e.g. 10 ng/ml), and the final concentration of IL-15 is 10-1000 ng/ml (e.g. one of 20-500 ng/ml, 50-200 ng/ml or 75-150 ng/ml, e.g. about 100 ng/ml).
- In some embodiments the final concentration of IL-7 is 1-100 ng/ml (e.g. one of 2-50 ng/ml, 5-20 ng/ml or 7.5-15 ng/ml, e.g. 10 ng/ml), the final concentration of IL-6 is 10-1000 ng/ml (e.g. one of 20-500 ng/ml, 50-200 ng/ml or 75-150 ng/ml, e.g. about 100 ng/ml), the final concentration of IL-12 is 1-100 ng/ml (e.g. one of 2-50 ng/ml, 5-20 ng/ml or 7.5-15 ng/ml, e.g. 10 ng/ml), and the final concentration of IL-15 is 1-100 ng/ml (e.g. one of 2-50 ng/ml, 5-20 ng/ml or 7.5-15 ng/ml, e.g. 10 ng/ml).
- In some embodiments the final concentration of IL-7 in a stimulation culture is 1-100 ng/ml (e.g. one of 2-50 ng/ml, 5-20 ng/ml or 7.5-15 ng/ml, e.g. 10 ng/ml), and the final concentration of IL-15 in a stimulation culture is 10-1000 ng/ml (e.g. one of 20-500 ng/ml, 50-200 ng/ml or 75-150 ng/ml, e.g. about 100 ng/ml).
- In some embodiments the final concentration of IL-7 in a stimulation culture is 1-100 ng/ml (e.g. one of 2-50 ng/ml, 5-20 ng/ml or 7.5-15 ng/ml, e.g. 10 ng/ml), the final concentration of IL-6 in a stimulation culture is 10-1000 ng/ml (e.g. one of 20-500 ng/ml, 50-200 ng/ml or 75-150 ng/ml, e.g. about 100 ng/ml), the final concentration of IL-12 in a stimulation culture is 1-100 ng/ml (e.g. one of 2-50 ng/ml, 5-20 ng/ml or 7.5-15 ng/ml, e.g. 10 ng/ml), and the final concentration of IL-15 in a stimulation culture is 1-100 ng/ml (e.g. one of 2-50 ng/ml, 5-20 ng/ml or 7.5-15 ng/ml, e.g. 10 ng/ml).
- In some embodiments the final concentration of IL-7 in a re-stimulation culture is 1-100 ng/ml (e.g. one of 2-50 ng/ml, 5-20 ng/ml or 7.5-15 ng/ml, e.g. 10 ng/ml), and the final concentration of IL-15 in a re-stimulation culture is 10-1000 ng/ml (e.g. one of 20-500 ng/ml, 50-200 ng/ml or 75-150 ng/ml, e.g. about 100 ng/ml).
- Stimulations and re-stimulations according to the present methods typically involve co-culture of T cells and APCs for a period of time sufficient for APCs to stimulate the T cells, and for the T cells to undergo cell division.
- In some embodiments, the methods of the present disclosure involve culturing PBMCs that have been contacted with peptide(s) corresponding to EBV antigen(s), or in the presence of APCs presenting peptide(s) corresponding to EBV antigen(s), for a period of one of at least 1 hour, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 4 days, 5 days, 6 days, or at least 7 days. In some embodiments, culture is for a period of 24 hours to 20 days, e.g. one of 48 hours to 14 days, 3 days to 12 days, 4 to 11 days, or 6 to 10 days or 7 to 9 days.
- In some embodiments, the methods of the present disclosure involve culturing the population of cells obtained by a stimulation step described herein that have been contacted with peptide(s) corresponding to EBV antigen(s), or in the presence of APCs presenting peptide(s) corresponding to EBV antigen(s), for a period of one of at least 1 hour, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 4 days, 5 days, 6 days, or at least 7 days. In some embodiments, culture is for a period of 24 hours to 20 days, e.g. one of 48 hours to 14 days, 3 days to 12 days, 4 to 11 days, or 6 to 10 days or 7 to 9 days.
- Stimulations and re-stimulations may be ended by separating the cells in culture from the media in which they have been cultured, or diluting the culture, e.g. by the addition of cell culture medium. In some embodiments, the methods comprise a step of collecting the cells at the end of the stimulation or re-stimulation culture.
- In some embodiments, a re-stimulation step according to the present disclosure may be established by adding cell culture medium (and any other additives as described herein) in an amount appropriate to achieve the desired percentages/concentrations of cell culture medium, conditioned media (and any additives) for the re-stimulation step.
- At the end of the culture period of a given stimulation or re-stimulation step, the cells may be collected and separated from the cell culture supernatant. The cells may be collected by centrifugation, and the cell culture supernatant may be separated from the cell pellet. The cell pellet may then be re-suspended in cell culture medium, e.g. for a re-stimulation step. In some embodiments, the cells may undergo a washing step after collection. A washing step may comprise re-suspending the cell pellet in isotonic buffer such as phosphate-buffered saline (PBS), collecting the cells by centrifugation, and discarding the supernatant.
- Methods for generating and/or expanding a populations of immune cells specific for EBV antigen(s) according to the present disclosure typically involve more than a single stimulation step. There is no upper limit to the number of stimulation steps which may be performed in a method according to the present disclosure. In some embodiments the methods comprise more than 2, 3, 4 or 5 stimulation steps. In some embodiments, the methods comprise one of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 stimulation steps. The stimulation steps in a method according to the present disclosure may be different to one another.
- In some embodiments, the PBMCs employed in the methods of the disclosure are depleted of CD45RA-positive cells. That is, in some embodiments, the PBMCs are “CD45RA-positive cell-depleted PBMCs”, or are “CD45RA-negative PBMCs”. Depletion of CD45RA-positive cells is intended to reduce the number of NK cells and/or regulatory T cells in the populations of cells generated/expanded according to the methods of the disclosure.
- In some embodiments, the methods comprise a step of depleting PBMCs of CD45RA-positive cells, e.g. prior to a stimulation step according to the disclosure. In some embodiments, the methods comprise a step of depleting the cells obtained by a stimulation step according to the present disclosure of CD45RA-positive cells, e.g. prior to a re-stimulation step according to the disclosure. Depletion of CD45RA-positive cells can be achieved by any suitable method, such as by MACS, for example using Miltenyi® Biotec columns and magnetic anti-CD45RA antibody-coated beads.
- In some embodiments, the population of cells used to derive APCs employed in the methods of the disclosure is depleted of CD45RA-positive cells. That is, in some embodiments, the population of cells used to derive APCs is a “CD45RA-positive cell-depleted” or “CD45RA-negative” population. For example, in embodiments wherein ATCs are employed as APCs, the ATCs may be derived from a population of CD45RA-positive cell-depleted PBMCs, or from a population of CD45RA-negative PBMCs.
- In some embodiments the methods further comprise modification of the immune cells specific for EBV antigen(s) to increase IL-7-mediated signalling in the cells. IL-7-mediated signalling has been shown to increases the survival and anti-tumor activity of tumor-specific T cells—see e.g. in Shum et al., Cancer Discov. (2017) 7(11):1238-1247, and WO 2018/038945 A1.
- Particular Exemplary Embodiments of Method Steps
- The following particular exemplary method steps are expressly contemplated in connection with the present disclosure:
- (A) Stimulating immune cells specific for an EBV lytic antigen by contacting PBMCs with BZLF1 pepmix, BRLF1 pepmix, BMRF1 pepmix, BMLF1 pepmix, BALF2 pepmix, BNLF2A pepmix, BNLF2B pepmix and/or BMRF2 pepmix.
- (B) Stimulating immune cells specific for an EBV lytic antigen by contacting PBMCs with BZLF1 pepmix, BRLF1 pepmix, BMRF1 pepmix, BMLF1 pepmix, BXLF1 pepmix, BALF1 pepmix, BLLF2 pepmix, BALF2 pepmix and/or BNLF2A pepmix.
- (C) Stimulating immune cells specific for an EBV lytic antigen by contacting PBMCs with BZLF1 pepmix, BRLF1 and/or BMRF1 pepmix.
- (D) Stimulating immune cells specific for an EBV lytic antigen by contacting PBMCs with BMRF1 pepmix, BMLF1 pepmix, BALF2 pepmix, BNLF2A pepmix, BNLF2B pepmix and/or BMRF2 pepmix.
- (E) Stimulating immune cells specific for an EBV lytic antigen and immune cells specific for an EBV latent antigen by contacting PBMCs with:
-
- BZLF1 pepmix, BRLF1 pepmix, BMRF1 pepmix, BMLF1 pepmix, BALF2 pepmix, BNLF2A pepmix, BNLF2B pepmix and/or BMRF2 pepmix; and
- EBNA1 pepmix, LMP1 pepmix and/or LMP2 pepmix.
- (F) Stimulating immune cells specific for an EBV lytic antigen and immune cells specific for an EBV latent antigen by contacting PBMCs with:
-
- BZLF1 pepmix, BRLF1 pepmix, BMRF1 pepmix, BMLF1 pepmix, BXLF1 pepmix, BALF1 pepmix, BLLF2 pepmix, BALF2 pepmix and/or BNLF2A pepmix; and
- EBNA1 pepmix, LMP1 pepmix and/or LMP2 pepmix.
- (G) Stimulating immune cells specific for an EBV lytic antigen and immune cells specific for an EBV latent antigen by contacting PBMCs with:
-
- BZLF1 pepmix, BRLF1 pepmix and/or BMRF1 pepmix; and
- EBNA1 pepmix, LMP1 pepmix and/or LMP2 pepmix.
- (H) Stimulating immune cells specific for an EBV lytic antigen and immune cells specific for an EBV latent antigen by contacting PBMCs with:
-
- BMRF1 pepmix, BMLF1 pepmix, BALF2 pepmix, BNLF2A pepmix, BNLF2B pepmix and/or BMRF2 pepmix; and
- EBNA1 pepmix, LMP1 pepmix and/or LMP2 pepmix.
- (I) Stimulating immune cells according to any one of (A) to (H), in the presence of IL-7, IL-15, IL-6 and/or IL-12.
- (J) Stimulating immune cells according to any one of (A) to (I), in the presence of IL-7 and/or IL-15.
- (K) Stimulating immune cells according to any one of (A) to (J) wherein the PBMCs are depleted of CD45RA-positive cells.
- (L) Stimulating immune cells specific for an EBV lytic antigen by co-culture with APCs which have been pulsed with BZLF1 pepmix, BRLF1 pepmix, BMRF1 pepmix, BMLF1 pepmix, BALF2 pepmix, BNLF2A pepmix, BNLF2B pepmix and/or BMRF2 pepmix.
- (M) Stimulating immune cells specific for an EBV lytic antigen by co-culture with APCs which have been pulsed with BZLF1 pepmix, BRLF1 pepmix, BMRF1 pepmix, BMLF1 pepmix, BXLF1 pepmix, BALF1 pepmix, BLLF2 pepmix, BALF2 pepmix and/or BNLF2A pepmix.
- (N) Stimulating immune cells specific for an EBV lytic antigen by co-culture with APCs which have been pulsed with BZLF1 pepmix, BRLF1 and/or BMRF1 pepmix.
- (O) Stimulating immune cells specific for an EBV lytic antigen by co-culture with APCs which have been pulsed with BMRF1 pepmix, BMLF1 pepmix, BALF2 pepmix, BNLF2A pepmix, BNLF2B pepmix and/or BMRF2 pepmix.
- (P) Stimulating immune cells specific for an EBV lytic antigen and immune cells specific for an EBV latent antigen by co-culture with APCs which have been pulsed with:
-
- BZLF1 pepmix, BRLF1 pepmix, BMRF1 pepmix, BMLF1 pepmix, BALF2 pepmix, BNLF2A pepmix, BNLF2B pepmix and/or BMRF2 pepmix; and
- EBNA1 pepmix, LMP1 pepmix and/or LMP2 pepmix.
- (Q) Stimulating immune cells specific for an EBV lytic antigen and immune cells specific for an EBV latent antigen by co-culture with APCs which have been pulsed with:
-
- BZLF1 pepmix, BRLF1 pepmix, BMRF1 pepmix, BMLF1 pepmix, BXLF1 pepmix, BALF1 pepmix, BLLF2 pepmix, BALF2 pepmix and/or BNLF2A pepmix; and
- EBNA1 pepmix, LMP1 pepmix and/or LMP2 pepmix.
- (R) Stimulating immune cells specific for an EBV lytic antigen and immune cells specific for an EBV latent antigen by co-culture with APCs which have been pulsed with:
-
- BZLF1 pepmix, BRLF1 pepmix and/or BMRF1; and
- EBNA1 pepmix, LMP1 pepmix and/or LMP2 pepmix.
- (S) Stimulating immune cells specific for an EBV lytic antigen and immune cells specific for an EBV latent antigen by co-culture with APCs which have been pulsed with:
-
- BMRF1 pepmix, BMLF1 pepmix, BALF2 pepmix, BNLF2A pepmix, BNLF2B pepmix and/or BMRF2 pepmix; and
- EBNA1 pepmix, LMP1 pepmix and/or LMP2 pepmix.
- (T) Stimulating immune cells according to any one of (L) to (S), wherein the APCs are ATCs.
- (U) Stimulating immune cells according to (T), wherein the ATCs are derived from PBMCs depleted of CD45RA-positive cells.
- (V) Stimulating immune cells according to any one of (L) to (U), in the presence of uLCLs.
- (W) Stimulating immune cells according to any one of (L) to (V), in the presence of IL-7 and/or IL-15.
- (X) Stimulating immune cells according to any one of (A) to (K), and subsequently stimulating immune cells according to any one of (L) to (W).
- Properties of the Methods/Populations of Immune Cells Generated/Expanded by the Methods
- The methods of the present disclosure may optionally be characterised by reference to properties of the methods, and/or properties of the populations of immune cells generated/expanded by the methods.
- In some embodiments, a population of immune cells generated/expanded in accordance with the methods of the present disclosure possess one or more of the following properties:
-
- a) comprises cells which produce IFNγ in response to stimulation with peptide(s) corresponding to one or more EBV lytic antigens;
- b) comprises cells which produce IFNγ in response to stimulation with peptide(s) corresponding to one or more EBV lytic antigens, and comprises cells which produce IFNγ in response to stimulation with peptide(s) corresponding to one or more EBV latent antigens;
- c) comprises cells which produce IFNγ in response to stimulation with EBV-infected cells;
- d) cytolytic activity against autologous EBV-infected cells;
- e) anticancer activity against EBV-positive cancer in vivo;
- f) inhibition of growth of an EBV-positive tumor in vivo; and
- g) reduction of metastasis of EBV-positive cancer in vivo.
- Populations of immune cells may be evaluated for whether they comprise cells which to produce IFNγ in response to stimulation with peptide(s) corresponding to EBV antigens and/or EBV-infected cells (e.g. LCLs) e.g. by ELISPOT analysis, which may be performed e.g. as described in Example 2.
- Populations of immune cells may be evaluated for cytolytic activity against autologous EBV-infected cells using the methods reviewed in Zaritskaya et al., Expert Rev Vaccines (2011), 9(6):601-616, hereby incorporated by reference in its entirety, such as 51Cr release assay. Analysis may be performed using autologous EBV-LCLs, e.g. as described in Example 3.
- Populations of immune cells may be evaluated in vivo for anticancer activity against EBV-positive cancer and/or inhibition of tumor growth of an EBV-positive tumor by analysis in an appropriate model. Suitable models and analysis include the EBV-LCL xenograft model methods employed in Example 4. Metastasis can be evaluated e.g. by monitoring the location of cancerous cells within the animal in such a model, e.g. as performed in Example 4.
- In some embodiments, a population of immune cells generated/expanded in accordance with the methods of the present disclosure may possess one or more of the following, as compared to a population of immune cells generated/expanded according to a reference method for generating/expanding EBV-specific immune cells:
-
- h) comprises a greater number/proportion of cells which produce IFNγ in response to stimulation with peptide(s) corresponding to one or more EBV antigen(s);
- i) comprises a greater number/proportion of cells which produce IFNγ in response to stimulation with peptide(s) corresponding to one or more EBV lytic antigen(s);
- j) comprises cells specific for a larger number of different EBV antigens (i.e. a wider range of EBV antigens);
- k) comprises a greater number/proportion of cells which produce IFNγ in response to stimulation with EBV-infected cells;
- l) greater anticancer activity against EBV-positive cancer in vivo;
- m) greater inhibition of growth of an EBV-positive tumor in vivo;
- n) greater reduction of metastasis of EBV-positive cancer in vivo;
- o) greater persistence in vivo; and
- p) elicits the production of an increased amount of one or more proinflammatory cytokine(s) (e.g. GM-CSF and/or IFNγ) in a subject administered with the population of immune cells.
- p) elicits the production of a reduced production of one or more anti-inflammatory cytokines (e.g. IL-10) in a subject administered with the population of immune cells.
- Survival/persistence of a given population of immune cells in vivo can be evaluated e.g. using methods in which cells are labelled with a detectable marker or reporter, and their survival is monitored over time. Such methods include e.g. labelling cells with firefly luciferase, and measuring activity at different time points.
- Production of cytokines by a subject administered with a given population of immune cells can be evaluated e.g. by analysis of a blood-derived sample (e.g. whole blood, plasma, serum) obtained from the subject. Cytokine levels can be determined e.g. by ELISA, e.g. as described in Example 4.
- A reference method for generating/expanding EBV-specific immune cells may be a method as described in Example 1 herein employing latent pepmixes (only) in stimulations.
- Methods Using Populations of Immune Cells Generated/Expanded by the Methods
- The populations of immune cells comprising EBV-specific immune cells generated/expanded as described herein find use in therapeutic and/or prophylactic methods.
- A method for treating/preventing a disease/condition in a subject is provided, comprising administering a population of immune cells specific for EBV generated/expanded according to a method of the present disclosure to a subject. Also provided is a population of immune cells specific for EBV generated/expanded according to a method of the present disclosure for use in a method of medical treatment/prophylaxis. Also provided is a population of immune cells generated/expanded according to a method of the present disclosure for use in a method for treating/preventing a disease/condition. Also provided is the use of a population of immune cells specific for EBV generated/expanded according to a method of the present disclosure in the manufacture of a medicament for use in a method for treating/preventing a disease/condition.
- In particular, use of populations of immune cells specific for EBV generated/expanded according to the present disclosure in methods to treat/prevent diseases/conditions by adoptive cell transfer (ACT) is contemplated.
- Adoptive cell transfer generally refers to a process by which cells (e.g. immune cells) are obtained from a subject, typically by drawing a blood sample from which the cells are isolated. The cells are then typically modified and/or expanded, and then administered either to the same subject (in the case of adoptive transfer of autologous/autogeneic cells) or to a different subject (in the case of adoptive transfer of allogeneic cells). The treatment is typically aimed at providing a population of cells with certain desired characteristics to a subject, or increasing the frequency of such cells with such characteristics in that subject. Adoptive transfer may be performed with the aim of introducing a cell or population of cells into a subject, and/or increasing the frequency of a cell or population of cells in a subject.
- Adoptive transfer of immune cells is described, for example, in Kalos and June 2013, Immunity 39(1): 49-60, and Davis et al. 2015, Cancer J. 21(6): 486-491, both of which are hereby incorporated by reference in their entirety. The skilled person is able to determine appropriate reagents and procedures for adoptive transfer of cells according to the present disclosure, for example by reference to Dai et al., 2016 J Nat Cancer Inst 108(7): djv439, which is incorporated by reference in its entirety.
- In some embodiments, the methods comprise:
-
- (a) generating/expanding a population of immune cells specific for EBV in accordance with the methods of the present disclosure, and
- (b) administering the generated/expanded population of immune cells specific for EBV to a subject.
- In some embodiments, the methods comprise:
-
- (a) isolating/obtaining a population of immune cells (e.g. PBMCs) from a subject;
- (b) generating/expanding a population of immune cells specific for EBV in accordance with the methods of the present disclosure, and
- (c) administering the generated/expanded population of immune cells specific for EBV to a subject.
- In some embodiments, the subject from which the immune cells (e.g. PBMCs) are isolated is the same subject to which the generated/expanded population of immune cells specific for EBV is administered (i.e., adoptive transfer may be of autologous/autogeneic cells). In some embodiments, the subject from which the immune cells (e.g. PBMCs) are isolated is a different subject to the subject to which the generated/expanded population of immune cells specific for EBV is administered (i.e., adoptive transfer may be of allogeneic cells).
- In some embodiments the methods may comprise one or more of:
-
- taking a blood sample from a subject;
- isolating immune cells (e.g. PBMCs) from the blood sample;
- generating/expanding a population of immune cells specific for EBV in accordance with the methods of the present disclosure;
- collecting/isolating the population of immune cells specific for EBV;
- mixing the population of immune cells specific for EBV with an adjuvant, diluent, or carrier;
- administering the population of immune cells specific for EBV to a subject.
- The methods may be effective to reduce the development/progression of a disease/condition, alleviation of the symptoms of a disease/condition or reduction in the pathology of a disease/condition. The methods may be effective to prevent progression of the disease/condition, e.g. to prevent worsening of, or to slow the rate of development of, the disease/condition. In some embodiments the methods may lead to an improvement in the disease/condition, e.g. a reduction in the symptoms of the disease/condition or reduction in some other correlate of the severity/activity of the disease/condition. In some embodiments the methods may prevent development of the disease/condition a later stage (e.g. a chronic stage or metastasis).
- It will be appreciated that the therapeutic and prophylactic utility of the populations of cells generated/expanded in accordance with the present disclosure extends to the treatment/prevention of any disease/condition that would derive therapeutic or prophylactic benefit from a reduction in EBV load, and/or the number/activity of cells infected with EBV.
- For example, the disease/condition may be a disease/condition in which EBV or cells infected with EBV are pathologically implicated, e.g. a disease/condition in which EBV infection is positively associated with the onset, development or progression of the disease/condition, and/or severity of one or more symptoms of the disease/condition, or for which EBV infection is a risk factor for the onset, development or progression of the disease/condition.
- The treatment may be aimed at one or more of: reducing the EBV load, reducing the number/proportion of EBV-positive cells, reducing the activity of EBV-positive cells, delaying/preventing the onset/progression of symptoms of the disease/condition, reducing the severity of symptoms of the disease/condition, reducing the survival/growth of EBV-positive cells, increasing survival of the subject.
- In some embodiments, the disease/condition to be treated/prevented in accordance with the present disclosure is a disease/condition characterised by EBV infection.
- In some embodiments, a subject may be selected for treatment described herein based on the detection of EBV/cells infected with EBV, e.g. in the periphery, or in an organ/tissue which is affected by the disease/condition (e.g. an organ/tissue in which the symptoms of the disease/condition manifest), or by the detection of EBV-positive cancer cells (e.g. EBV-positive cells in a tumor). The disease/condition may affect any tissue or organ or organ system. In some embodiments the disease/condition may affect several tissues/organs/organ systems.
- In some embodiments a subject may be selected for therapy/prophylaxis in accordance with the present disclosure based on determination that the subject is infected with EBV or comprises cells infected with EBV.
- EBV is implicated in several cancers, as reviewed e.g. in Jha et al., Front Microbiol. (2016) 7:1602, which is hereby incorporated by reference in its entirety.
- Accordingly, in some embodiments, the disease to be treated/prevented in accordance with the present disclosure is a cancer.
- Cancer may refer to any unwanted cell proliferation (or any disease manifesting itself by unwanted cell proliferation), neoplasm or tumor. The cancer may be benign or malignant and may be primary or secondary (metastatic). A neoplasm or tumor may be any abnormal growth or proliferation of cells and may be located in any tissue. The cancer may be of tissues/cells derived from e.g. the adrenal gland, adrenal medulla, anus, appendix, bladder, blood, bone, bone marrow, brain, breast, cecum, central nervous system (including or excluding the brain) cerebellum, cervix, colon, duodenum, endometrium, epithelial cells (e.g. renal epithelia), gallbladder, oesophagus, glial cells, heart, ileum, jejunum, kidney, lacrimal glad, larynx, liver, lung, lymph, lymph node, lymphoblast, maxilla, mediastinum, mesentery, myometrium, nasopharynx, omentum, oral cavity, ovary, pancreas, parotid gland, peripheral nervous system, peritoneum, pleura, prostate, salivary gland, sigmoid colon, skin, small intestine, soft tissues, spleen, stomach, testis, thymus, thyroid gland, tongue, tonsil, trachea, uterus, vulva, and/or white blood cells.
- Tumors may be nervous or non-nervous system tumors. Nervous system tumors may originate either in the central or peripheral nervous system, e.g. glioma, medulloblastoma, meningioma, neurofibroma, ependymoma, Schwannoma, neurofibrosarcoma, astrocytoma and oligodendroglioma. Non-nervous system cancers/tumors may originate in any other non-nervous tissue, examples include melanoma, mesothelioma, lymphoma, myeloma, leukemia, Non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma, chronic myelogenous leukemia (CML), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), cutaneous T-cell lymphoma (CTCL), chronic lymphocytic leukemia (CLL), hepatoma, epidermoid carcinoma, prostate carcinoma, breast cancer, lung cancer, colon cancer, ovarian cancer, pancreatic cancer, thymic carcinoma, NSCLC, hematologic cancer and sarcoma.
- In some embodiments the cancer is selected from the group consisting of: colon cancer, colon carcinoma, colorectal cancer, nasopharyngeal carcinoma, cervical carcinoma, oropharyngeal carcinoma, gastric carcinoma, hepatocellular carcinoma, head and neck cancer, head and neck squamous cell carcinoma (HNSCC), oral cancer, laryngeal cancer, prostate cancer, lung cancer, small cell lung cancer, non-small cell lung cancer, bladder cancer, urothelial carcinoma, melanoma, advanced melanoma, renal cell carcinoma, ovarian cancer or mesothelioma.
- In some embodiments the cancer to be treated/prevented is an EBV-associated cancer. “EBV-associated” cancers may be a cancers which are caused or exacerbated by infection with EBV, cancers for which infection is a risk factor and/or cancers for which infection is positively associated with onset, development, progression, severity or metastasis.
- EBV-associated cancers which may be treated/prevented in accordance with the present disclosure include B cell-associated cancers such as Burkitt's lymphoma, post-transplant lymphoproliferative disease (PTLD), central nervous system lymphoma (CNS lymphoma), Hodgkin's lymphoma, non-Hodgkin's lymphoma, and EBV-associated lymphomas associated with immunodeficiency (including e.g. EBV-positive lymphoma associated with X-linked lymphoproliferative disorder, EBV-positive lymphoma associated with HIV infection/AIDS, and oral hairy leukoplakia), and epithelial cell related cancers such as nasopharyngeal carcinoma (NPC) and gastric carcinoma (GC).
- In some embodiments the cancer is selected from lymphoma (e.g. EBV-positive lymphoma), head and neck squamous cell carcinoma (HNSCC; e.g. EBV-positive HNSCC), nasopharyngeal carcinoma (NPC; e.g. EBV-positive NPC), and gastric carcinoma (GC; e.g. EBV-positive GC).
- EBV-infection is also implicated in the development/progression of a variety of autoimmune diseases such as multiple sclerosis and systemic lupus erythematosus (SLE; see e.g. Ascherio and Munger Curr Top Microbiol Immunol. (2015); 390(Pt 1):365-85), and EBV antigen EBNA2 has recently been shown to associate with genetic regions implicated as risk factors for the development of SLE, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease,
type 1 diabetes, juvenile idiopathioc arthritis and celiac disease (Harley et al., Nat Genet. (2018) 50(5): 699-707). - Accordingly, in some embodiments the disease/condition to be treated/prevented in accordance with the present disclosure is selected from SLE, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease,
type 1 diabetes, juvenile idiopathioc arthritis and celiac disease. - Populations of cells generated/expanded in accordance with the present disclosure also find use in the treatment/prevention of diseases/conditions independently of EBV infection.
- As described hereinabove, the populations of cells generated/expanded in accordance with the present disclosure find use in methods for the treatment of cancer.
- In some embodiments the cancer may express a cancer antigen. A ‘cancer antigen’ is an antigen which is expressed or over-expressed by cells of a cancer. A cancer antigen may be any peptide/polypeptide, glycoprotein, lipoprotein, glycan, glycolipid, lipid, or fragment thereof. A cancer antigen's expression may be associated with a cancer. A cancer antigen may be abnormally expressed by a cancer cell (e.g. the cancer antigen is expressed with abnormal localisation), or may be expressed with an abnormal structure by a cancer cell. A cancer antigen may be capable of eliciting an immune response. In some embodiments, the antigen is expressed at the cell surface of the cancer cell (i.e. the cancer antigen may be a cancer cell surface antigen). In some embodiments, the part of the antigen which is bound by the antigen-binding molecule described herein is displayed on the external surface of the cancer cell (i.e. is extracellular). In some embodiments the cancer antigen is an antigen whose expression is associated with the development, progression or severity of symptoms of a cancer. The cancer-associated antigen may be associated with the cause or pathology of the cancer, or may be expressed abnormally as a consequence of the cancer. In some embodiments, the cancer antigen is an antigen whose expression is upregulated (e.g. at the RNA and/or protein level) by cells of a cancer, e.g. as compared to the level of expression of by comparable non-cancerous cells (e.g. non-cancerous cells derived from the same tissue/cell type). In some embodiments, the cancer antigen is preferentially expressed by cancerous cells, and not expressed by comparable non-cancerous cells (e.g. non-cancerous cells derived from the same tissue/cell type). In some embodiments, the cancer antigen is the product of a mutated oncogene or mutated tumor suppressor gene. In some embodiments, the cancer antigen is the product of an overexpressed cellular protein, a cancer antigen produced by an oncogenic virus, an oncofetal antigen, a cell surface molecule (e.g. a cell surface protein or glycoprotein). In some embodiments the cancer antigen is a cell signalling molecule, e.g. a cytokine, chemokine, interferon, interleukin or lymphokine. In some embodiments the cancer antigen is a growth factor or a hormone.
- In some embodiments the cancer is ‘positive’ for the cancer antigen, meaning that the cancer comprises cells expressing the cancer antigen (e.g. cells expressing the cancer antigen at the cell surface). A cancer antigen-positive cancer may overexpress the cancer antigen. Overexpression of the cancer antigen can be determined by detection of a level of gene or protein expression of the cancer antigen which is greater than the level of expression by equivalent non-cancerous cells/non-tumor tissue. Gene/protein expression of the cancer antigen may be a risk factor for, and/or positively associated with, the onset, development, progression or severity of symptoms of the cancer, and/or metastasis.
- Subjects
- The subject in accordance with aspects the disclosure described herein may be any animal or human. The subject is preferably mammalian, more preferably human. The subject may be a non-human mammal, but is more preferably human. The subject may be any gender. The subject may be a patient. A subject may have been diagnosed with a disease/condition requiring treatment, may be suspected of having such a disease/condition, or may be at risk of developing/contracting such a disease/condition.
- In embodiments according to the present disclosure the subject is preferably a human subject. In some embodiments, the subject to be treated according to a therapeutic or prophylactic method of the disclosure herein is a subject having, or at risk of developing, a disease/condition. In embodiments according to the present disclosure, a subject may be selected for treatment according to the methods based on characterisation for certain markers of such a disease/condition.
- Sequence Identity
- Pairwise and multiple sequence alignment for the purposes of determining percent identity between two or more amino acid or nucleic acid sequences can be achieved in various ways known to a person of skill in the art, for instance, using publicly available computer software such as ClustalOmega (Söding, J. 2005,
Bioinformatics 21, 951-960), T-coffee (Notredame et al. 2000, J. Mol. Biol. (2000) 302, 205-217), Kalign (Lassmann and Sonnhammer 2005, BMC Bioinformatics, 6(298)) and MAFFT (Katoh and Standley 2013, Molecular Biology and Evolution, 30(4) 772-780 software. When using such software, the default parameters, e.g. for gap penalty and extension penalty, are preferably used. - Numbered Paragraphs
- The following numbered paragraphs (paras) provide further statements of features and combinations of features which are contemplated in connection with the present disclosure:
- 1. A method for generating or expanding a population of immune cells comprising immune cells specific for an Epstein Barr Virus (EBV) lytic antigen, comprising stimulating immune cells specific for an EBV lytic antigen by contacting peripheral blood mononuclear cells (PBMCs) with: (i) one or more peptides corresponding to all or part of one or more EBV lytic antigens; or (ii) antigen presenting cells (APCs) presenting one or more peptides corresponding to all or part of one or more EBV lytic antigens.
- 2. The method according to
claim 1, wherein the method further comprises re-stimulating the immune cells specific for an EBV lytic antigen by contacting them with APCs presenting one or more peptides corresponding to all or part of one or more EBV lytic antigens. - 3. The method according to
claim 1, wherein the one or more EBV lytic antigens are selected from BZLF1, BRLF1, BMLF1, BMRF1, BXLF1, BALF1, BALF2, BGLF5, BHRF1, BNLF2A, BNLF2B, BHLF1, BLLF2, BKRF4, BMRF2, BALF4, BILF1, BILF2, BNFR1, BVRF2, BALF3, BALF5 and BDLF3. - 4. The method according to
claim 1, wherein the one or more EBV lytic antigens are selected from BZLF1, BRLF1, BMLF1, BMRF1, BALF2, BNLF2A, BNLF2B, BMRF2 and BDLF3. - 5. The method according to
claim 1, wherein the PBMCs are PBMCs depleted of CD45RA-positive cells. - 6. A method for generating or expanding a population of immune cells comprising immune cells specific for an Epstein Barr Virus (EBV) lytic antigen and immune cells specific for an EBV latent antigen, comprising stimulating immune cells specific for an EBV lytic antigen and immune cells specific for an EBV latent antigen by contacting peripheral blood mononuclear cells (PBMCs) with: (i) one or more peptides corresponding to all or part of one or more EBV lytic antigens, and one or more peptides corresponding to all or part of one or more EBV latent antigens; or (ii) antigen presenting cells (APCs) presenting one or more peptides corresponding to all or part of one or more EBV lytic antigens, and one or more peptides corresponding to all or part of one or more EBV latent antigens.
- 7. The method according to
claim 6, wherein the method further comprises re-stimulating the immune cells specific for an EBV lytic antigen and the immune cells specific for an EBV latent antigen by contacting them with APCs presenting one or more peptides corresponding to all or part of one or more EBV lytic antigens, and one or more peptides corresponding to all or part of an EBV latent antigen. - 8. The method according to
claim 6, wherein the one or more EBV lytic antigens are selected from BZLF1, BRLF1, BMLF1, BMRF1, BXLF1, BALF1, BALF2, BGLF5, BHRF1, BNLF2A, BNLF2B, BHLF1, BLLF2, BKRF4, BMRF2, BALF4, BILF1, BILF2, BNFR1, BVRF2, BALF3, BALF5 and BDLF3. - 9. The method according to
claim 6, wherein the one or more EBV lytic antigens are selected from BZLF1, BRLF1, BMLF1, BMRF1, BALF2, BNLF2A, BNLF2B, BMRF2 and BDLF3. - 10. The method according to
claim 6, wherein the one or more EBV latent antigens are selected from EBNA1, EBNA-LP, EBNA2, EBNA3A, EBNA3B, EBNA3C, BARF1, LMP1, LMP2A and LMP2B. - 11. The method according to
claim 6, wherein the one or more EBV latent antigens are selected from EBNA1, LMP1, LMP2A and LMP2B. - 12. The method according to
claim 6, wherein the PBMCs are PBMCs depleted of CD45RA-positive cells. - 13. An isolated population of immune cells obtained or obtainable by a method according to
claim 1. - 14. A method for treating or preventing a disease or disorder, comprising administering an isolated population of immune cells according to claim 13 to a subject.
- 15. The method according to claim 14, wherein the disease or disorder is a cancer.
- 16. The method according to claim 14, wherein the disease or disorder is an EBV-associated cancer selected from EBV-positive lymphoma, EBV-positive nasopharyngeal carcinoma, and EBV-positive gastric carcinoma.
- The invention includes the combination of the aspects and preferred features described except where such a combination is clearly impermissible or expressly avoided.
- The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.
- Aspects and embodiments of the present invention will now be illustrated, by way of example, with reference to the accompanying figures. Further aspects and embodiments will be apparent to those skilled in the art. All documents mentioned in this text are incorporated herein by reference.
- Throughout this specification, including the claims which follow, unless the context requires otherwise, the word “comprise,” and variations such as “comprises” and “comprising,” will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.
- It must be noted that, as used in the specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Ranges may be expressed herein as from “about” one particular value, and/or to “about” another particular value. When such a range is expressed, another embodiment includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by the use of the antecedent “about,” it will be understood that the particular value forms another embodiment.
- Where a nucleic acid sequence is disclosed herein, the reverse complement thereof is also expressly contemplated.
- Methods described herein may be performed in vitro or in vivo. In some embodiments, methods described herein are performed in vitro. The term “in vitro” is intended to encompass experiments with cells in culture whereas the term “in vivo” is intended to encompass experiments with intact multi-cellular organisms.
- Embodiments and experiments illustrating the principles of methods and compositions of the disclosure will now be discussed with reference to the accompanying figures.
-
FIGS. 1A and 1B . Bar charts showing the number of spot-forming cells (SFCs) per 100,000 cells specific for the indicated EBV antigens, within populations of cells expanded from PBMCs obtained from four different EBV-positive lymphoma patients.FIG. 1A shows the numbers of SFCs per 100,000 cells in response to stimulation with the indicated antigens, amongst EBVSTs generated by stimulations using latent pepmix (T2 EBVSTs), or latent+lytic pepmix (All-EBVSTs).FIG. 1B shows the numbers of SFCs per 100,000 cells in response to stimulation with the indicated antigens, amongst EBVSTs generated by stimulations using lytic pepmix (lytic EBVSTs), or latent+lytic pepmix (All-EBVSTs). -
FIG. 2 . Bar chart showing the number of spot-forming cells (SFCs) per 100,000 cells specific for the indicated EBV antigens, within EBVSTs expanded from PBMCs from two EBV-positive lymphoma patients by stimulation using latent pepmix (T2-EBVSTs), lytic pepmix (Lytic-EBVSTs) or latent+lytic pepmix (BR-EBVSTs). The total numbers of cells in bars is indicated. -
FIG. 3 . Bar chart showing the number of spot-forming cells (SFCs) per 100,000 cells specific for the indicated EBV antigens, within EBVSTs expanded from PBMCs from three healthy donor subjects by stimulation using latent pepmix (T2-EBVSTs), immediate-early lytic pepmix (IE-EBVSTs), early lytic pepmix (E-EBVSTs), or latent+lytic pepmix (BR-EBVSTs). -
FIG. 4 . Bar chart showing the percentage of autologous, EBV-LCLs lysed by EBVSTs expanded from PBMCs from three healthy donor subjects by stimulation using latent pepmix (T2-EBVSTs), immediate-early lytic pepmix (IE-EBVSTs), early lytic pepmix (E-EBVSTs), or latent+lytic pepmix (BR-EBVSTs), in an in vitro assay of cytolytic activity. -
FIG. 5 . Bar chart showing the number of spot-forming cells (SFCs) per 100,000 cells specific for the indicated EBV antigens or LCLs, within EBVSTs expanded from PBMCs by stimulation using latent pepmix (T2-EBVSTs), or latent+lytic pepmix (BR-EBVSTs). -
FIGS. 6A to 6C . Graphs and images showing the in vivo anti-cancer activity of EBVSTs expanded from PBMCs by stimulation using latent pepmix (T2-EBVSTs) or latent+lytic pepmix (BR-EBVSTs) against autologous EBV-LCLs, in a mouse xenograft model of EBV-positive cancer. A control group received PBS instead of EBVSTs.FIG. 6A shows tumor volume (mm3) over time, andFIGS. 6B and 6C shows tumor burden over time as measured by luciferase activity of the firefly luciferase-expressing EBV-LCLs. -
FIG. 7 . Images showing the burden and location of firefly luciferase-expressing EBV-LCLs in vivo in mice at the indicated day of an experiment investigating the anti-cancer activity of EBVSTs expanded from PBMCs by stimulation using latent pepmix (T2-EBVSTs) or latent+lytic pepmix (BR-EBVSTs) against autologous EBV-LCLs, in a mouse xenograft model of EBV-positive cancer. A control group received PBS instead of EBVSTs. -
FIGS. 8A to 8D . Images and graphs showing the in vivo anti-cancer activity of EBVSTs expanded from PBMCs by stimulation using latent pepmix (T2-EBVSTs), lytic (2) pepmix (Lytic(2)-EBVSTs) or lytic (2)+latent pepmix (BR(2)-EBVSTs) against autologous EBV-LCLs, in a mouse xenograft model of EBV-positive cancer. A control group received PBS instead of EBVSTs.FIGS. 8A to 8C show tumor burden over time as measured by luciferase activity of the firefly luciferase-expressing EBV-LCLs.FIG. 8A shows the dorsal view, andFIG. 8B shows the ventral view at the indicated day relative to injection of the EBVSTs.FIG. 8C shows total tumor burden over time.FIG. 8D shows tumor volume (mm3) over time. -
FIGS. 9A to 9C . Box plots showing the levels of cytokines detected in the serum of mice undergoing treatment with EBVSTs expanded from PBMCs by stimulation using latent pepmix (T2-EBVSTs), lytic (2) pepmix (Lytic(2)-EBVSTs) or lytic (2)+latent pepmix (BR(2)-EBVSTs), in a mouse xenograft model of EBV-positive cancer, at the indicated number of days post-EBVST injection.FIG. 9A shows the level of GM-CSF,FIG. 9B shows the level of IFNγ, andFIG. 9C shows the level of IL-10. *** P=0.0001. -
FIG. 10 . Bar chart showing the number of spot-forming cells (SFCs) per 100,000 cells specific for EBV antigens, within populations of cells expanded by stimulation using latent pepmix from PBMCs obtained from four different healthy donor subjects (D # 1 to D #4). WW=EBVSTs expanded from whole PBMCs, and restimulated using ATCs derived from whole PBMCs; WD=EBVSTs expanded from whole PBMCs, and restimulated using ATCs derived from PBMCs depleted of CD45RA-positive cells; DW=EBVSTs expanded from PBMCs depleted of CD45RA-positive cells, and restimulated using ATCs derived from whole PBMCs; and DD=EBVSTs expanded from PBMCs depleted of CD45RA-positive cells, and restimulated using ATCs derived from PBMCs depleted of CD45RA-positive cells -
FIG. 11 . Histograms showing expression of CD80 and HLA-DR on ATCs derived from four different healthy donor subjects (D # 1 to D #4), from whole PBMCs, or from PBMCs depleted of CD45RA-positive cells, as determined by flow cytometry. - In the following Examples, the inventors describe the generation of populations of cells comprising EBV-specific T cells from PBMC populations, by stimulation with peptides of different EBV antigens. The inventors characterise the expanded cell populations for their EBV-reactivity, ability to display effector activity against EBV-infected cells, and their anti-cancer activity against EBV-positive cancer in vivo. The inventors also investigate methods for increasing the proportion of EBV-reactive cells in expanded populations, and their anti-cancer activity and persistence in vivo.
- Peripheral blood mononuclear cells (PBMCs) were isolated from blood samples obtained from healthy donors or lymphoma patients according to the standard Ficoll-Paque density gradient centrifugation method.
- Generation of ATCs
- Anti-CD3 (clone OKT3) and anti-CD28 agonist antibodies were coated onto wells of tissue culture plates by addition of 0.5 ml of 1:1000 dilution of 1 mg/ml antibodies, and incubation for 2-4 hr at 37° C., or at 4° C. overnight. 1×106 PBMCs (in 2 ml of cell culture medium) were stimulated by culture on the anti-CD3/CD28 agonist antibody-coated plates in CTL cell culture medium (containing RPMI-1640 medium, 50% Click's medium, 10% FBS, 1% GlutaMax, 1% Pen/Strep) supplemented with 10 ng/ml IL-7 and 5 ng/ml IL-15. The cells were maintained at 37° C. in a 5% CO2 atmosphere. The next day, 1 ml of the cell culture medium was replaced with fresh CTL medium containing 20 ng/ml IL-7 and 200 ng/ml IL-15. ATCs were maintained in culture, and subsequently harvested and used in experiments or cryopreserved between days 5-7.
- Universal LCLs
- LCLs lacking surface expression of HLA class I and HLA class II (i.e. HLA-negative LCLs) were obtained by targeted knockout of genes encoding HLA class I and HLA class II molecules in cells of a lymphoblastoid cell line prepared by EBV-transformation of B cells. The HLA-negative cells were further modified to knockout genes necessary for EBV replication. The resulting cells obtained by the methods are referred to herein as universal LCLs (uLCLs).
- Expansion of EBV-specific T cells
- EBV-specific T cells were expanded by stimulating 2×106 PBMCs for 9 days with one of the following combinations of pepmixes obtained from JPT Technologies (overlapping 15mer amino acid peptide libraries overlapping by 11 amino acids, spanning the full amino acid sequence of the relevant antigen), in cell culture medium containing 50% Advanced RPMI, 50% Click's medium, 10% FBS, 1% GlutaMax, 1% Pen/Strep, supplemented with IL-7 (10 ng/ml) and IL-15 (100 ng/ml):
-
- (i) EBNA1 pepmix (JPT Cat. No. PM-EBV-EBNA1)+LMP1 pepmix (JPT Cat. No. PM-EBV-LMP1)+LMP2 pepmix (JPT Cat. No. PM-EBV-LMP2)—“Latent pepmixes”
- (ii) BZLF1 pepmix (JPT Cat. No. PM-EBV-BZLF1)+BRLF1 pepmix (JPT Cat. No. PM-EBV-BRLF1)+BMRF1 pepmix (JPT Cat. No. PM-EBV-BMRF1)+BMLF1 pepmix*+BALF2 pepmix*+BNLF2A pepmix*+BNLF2B pepmix*+BMRF2 pepmix*—“Lytic pepmixes”*Pepmixes for BMLF1, BALF2, BNLF2A, BNLF2B, BMRF2 were prepared by combining individual constituent peptides obtained from Genemed.
- (iii) EBNA1 pepmix+LMP1 pepmix+LMP2 pepmix+BZLF1 pepmix+BRLF1 pepmix+BMRF1 pepmix+BMLF1 pepmix+BALF2 pepmix+BNLF2A pepmix+BNLF2B pepmix+BMRF2 pepmix—“Latent+lytic pepmixes”
- Combinations of pepmixes (i.e. pepmix mixtures) were used in stimulations at a final amount of 10 ng pepmix mixture per 1×106 PBMCs.
-
- (iv) BZLF1 pepmix+BRLF1 pepmix+BMRF1 pepmix—“Immediate-early lytic pepmixes”
- (v) BMRF1 pepmix+BMLF1 pepmix+BALF2 pepmix+BNLF2A pepmix+BNLF2B pepmix+BMRF2 pepmix (JPT Cat. No. PM-EBV-BMRF1)—“Early lytic pepmixes”
- Additional cell culture medium was added as necessary over the course of the 9 days, and cytokines were replenished on
day 5, 6 or 7. - At the end of the 9 day culture period, cells were re-stimulated by co-culture with irradiated, peptide-pulsed autologous activated T cells (ATCs) in the presence of uLCLs. Briefly, 2×106 ATCs were incubated with pepmixes (10 ng pepmix mixture per 1×106 ATCs) at 37° C. for 30 min in CTL medium, and subsequently irradiated at 30Gy and harvested. The peptide-pulsed ATCs were then mixed with the cells in culture and uLCLs (irradiated at 100Gy), in CTL medium containing IL-7 (10 ng/ml) and IL-15 (100 ng/ml), at a ratio of responder cells:peptide-pulsed ATCs:irradiated uLCLs of 1:1:5. Specifically, 1×105 responder cells, 1×105 peptide-pulsed ATCs and 0.5×106 irradiated uLCLs were cultured in 2 mL CTL medium in wells of a 24 well tissue culture plate.
- Cells were maintained at 37° C. in a 5% CO2 atmosphere. After 3-4 days further cell culture medium containing IL-7 (10 ng/ml) and IL-15 (100 ng/ml) was added as necessary. On
day 5 or 6 further cell culture medium containing IL-7 (10 ng/ml) and IL-15 (100 ng/ml) was added as necessary, and after 6-7 days the expanded EBVSTs were harvested for analysis or use in experiments. - In instances throughout the Examples and figures:
-
- EBVSTs generated by methods employing latent pepmixes (i.e. (i) above) are referred to as “
type 2 latent antigen (T2)-EBVSTs”; - EBVSTs generated by methods employing lytic pepmixes (i.e. (ii) above) are referred to as “Lytic-EBVSTs”;
- EBVSTs generated by methods employing latent+lytic pepmixes (i.e. (iii) above) are referred to as “broad repertoire (BR)-EBVSTs”;
- EBVSTs generated by methods employing immediate-early lytic pepmixes (i.e. (iv) above) are referred to as “Immediate-early (IE)-EBVSTs”; and
- EBVSTs generated by methods employing early lytic pepmixes (i.e. (v) above) are referred to as “early (E)-EBVSTs”.
- EBVSTs generated by methods employing latent pepmixes (i.e. (i) above) are referred to as “
- EBVSTs prepared from PBMCs of EBV-positive lymphoma patients using the different pepmixes were analysed by ELISPOT to determine their ability to recognise different EBV antigens.
- Briefly, EBVSTs were plated at 1×105 cells/well in 96-well plates pre-coated with anti-IFNγ capture antibody, and stimulated with pepmixes corresponding to the indicated EBV peptides. After 18-20 hrs incubation, plates were developed for IFNγ+ spots, dried overnight at room temperature in the dark, and quantified. The frequency of T cells specific to each antigen was expressed as specific spot-forming cells (SFCs) per input cell number.
-
FIGS. 1A and 1B show that T-cells specific for lytic cycle antigens can be generated by stimulation with premixes for lytic cycle antigens alone. Combining the pepmixes for latent and lytic antigens did not compromise the specificity for any single antigen, and the total frequency of antigen-specific T-cells was greater when pepmixes were combined. - Some patient T-cells show poor specificity when latent antigen pepmixes or lytic antigen pepmixes are used alone, but when latent antigen pepmixes and lytic antigen pepmixes are used in combination, good specificity can be achieved (see donor 2). This is thought to result of the production of cytokines by activated T-cells, which provide help for each other.
-
FIG. 2 shows that the number of cells that secrete IFNγ in response to stimulation with pepmixes corresponding to EBV latent and lytic antigens is greater for EBVSTs generated using a combination of latent antigen and lytic antigen pepmixes, than for EBVSTs generated using latent antigen pepmixes alone, or lytic antigen pepmixes alone. There is a super-additive increase in the number of IFNγ-producing cells when a combination of latent antigen and lytic antigen pepmixes. - In further experiments, EBVSTs prepared from PBMCs of healthy donors using the different pepmixes were analysed by ELISPOT to determine their ability to recognise different EBV antigens, as described above.
- The results are shown in
FIG. 3 , and demonstrate that it was possible to expand T cells specific for latent cycle antigens, immediate-early lytic antigens and early lytic antigens from PBMCs of healthy donors. - EBVSTs obtained by stimulation of PBMCs using different pepmixes were analysed for their ability to kill autologous EBV-transformed B cell lines.
- 10 μl of Cr51 was added to 1×106 autologous LCLs, which were pulsed with 10 ng EBV latent+lytic pepmixes (see (iii) of Example 1) and incubated at 37° C. for 1 hr. The LCLs were then washed 3 times with CTL media and resuspended in CTL media to 50,000 cells/ml. EBVSTs were plated with corresponding autologous, pepmix-pulsed LCLs at an Effector:Target cell ratio of 20:1 (100,000 EBVSTs+5,000 LCLs), in 200 μl CTL media in wells of a V-shaped well 96-well plates. The coculture was incubated at 37° C. at 5% CO2 for 4 hrs. The supernatant was then harvested and % specific lysis of target cells was determined using a Gamma-ray counter to measure of Cr51 released by killed target cells. The results are shown in
FIG. 4 . EBV antigen-specific T-cells obtained by stimulation of PBMCs using different pepmixes were able to kill autologous EBV-transformed B-cell lines. - The potent ability of EBVSTs obtained using methods employing lytic antigen pepmixes to kill EBV-LCLs was surprising, because only a small proportion of the LCLs would be expected to be in the lytic cycle (and thus express the target antigen). The results may be explained by phagocytosis and presentation of antigens from dying cells in the lytic phase.
- The inventors investigated the comparative ability of BR-EBVSTs and T2-EBVSTs to treat EBV-positive cancer in vivo using a murine xenograft model.
- Briefly, EBV-positive tumors were established by subcutaneous implantation of 3.5×106 firefly luciferase-expressing autologous LCLs in matrigel, into the flanks of NSG mice. 8 days later, when tumors were visible, mice were administered with PBS (control group), 5×106 BR-EBVSTs, or 5×106 T2-EBVSTs by intravenous injection.
- Tumors were monitored throughout the experiment by bioluminescence imaging; luciferase activity was monitored by intraperitoneal injection of D-Luciferin (1.5 mg per mouse), and imaging of the
mice 10 min later using an IVIS imager (Xenogen). Tumor volume was also monitored by measurement using calipers. - Prior to infusion, the BR-EBVSTs and T2-EBVSTs were analysed by ELISPOT for their ability to produce IFNγ in response to stimulation with different EBV antigens or EBV-LCLs. The results are shown in
FIG. 5 , and demonstrate that populations of immune cells expanded using peptides corresponding to EBV latent and lytic antigens comprise cells reactive to both EBV latent and lytic antigens, and comprise a greater proportion of cells which produce IFNγ in response to stimulation with EBV-LCLs as compared to populations of immune cells expanded using peptides corresponding to EBV latent antigens only. -
FIGS. 6 and 7 show that BR-EBVSTs more rapidly controlled EBV-positive tumors than T2-EBVSTs. -
FIG. 7 also shows that BR-EBVST-treated mice displayed reduced metastasis than mice treated with T2-EBVSTs. - In a further experiment EBV-positive tumors were established by subcutaneous implantation of 3.5×106 firefly luciferase-expressing autologous LCLs as above, and 8 days later mice were administered with PBS (control group), 1×106 BR(2)-EBVSTs, 1×106 Lytic(2)-EBVSTs, or 1×106 T2-EBVSTs by intravenous injection.
- The Lytic(2)-EVBSTs and BR(2)-EBVSTs used in this experiment were generated as described in Example 1, with the exception that the following combinations of pepmixes were used in stimulations to expand the EBVSTs:
-
- (vi) BZLF1 pepmix+BRLF1 pepmix+BMRF1 pepmix+BMLF1 pepmix+BXLF1 pepmix+BALF1 pepmix+BLLF2 pepmix+BALF2 pepmix+BNLF2A pepmix—“Lytic (2) pepmixes”
- (vii) EBNA1 pepmix+LMP1 pepmix+LMP2 pepmix+BZLF1 pepmix+BRLF1 pepmix+BMRF1 pepmix+BMLF1 pepmix+BXLF1 pepmix+BALF1 pepmix+BLLF2 pepmix+BALF2 pepmix+BNLF2A pepmix—“Lytic (2)+latent pepmixes”
- Pepmixes for BMLF1, BXLF1, BALF1, BLLF2, BALF2 and BNLF2A were prepared by combining individual constituent peptides obtained from Genemed. The pepmixes for EBNA1, LMP1, LMP2, BZLF1, BRLF1 and BMRF1 were obtained from JPT technologies as shown in Example 1.
- The EBVSTs generated by methods employing lytic pepmixes (i.e. (vi) above) are referred to as “Lytic(2)-EBVSTs”, and the EBVSTs generated by methods employing lytic (2)+latent pepmixes (i.e. (vii) above) are referred to as “BR(2)-EBVSTs”.
- Tumors were monitored throughout the experiment by bioluminescence imaging as described above, and tumor volume was also monitored by measurement using calipers.
- Blood plasma samples were also collected from the mice at
days - The results are shown in
FIGS. 8 and 9 . - EBVSTs expanded by stimulations using peptides of EBV latent+lytic antigens strongly inhibited tumor growth (
FIGS. 8A to 8D ). EBVSTs expanded by stimulations using only EBV lytic antigens were also able to inhibit tumor growth, and did so to a similar or greater extent to EBVSTs expanded by stimulations using only EBV latent antigens. - Mice treated with EBVSTs expanded by stimulations using peptides of EBV latent+lytic antigens also had increased levels of proinflammatory cytokines in their serum relative to mice treated with EBVSTs expanded by stimulations using only EBV latent antigens, whilst mice treated with EBVSTs expanded by stimulations using peptides of EBV lytic antigens only displayed similar or increased levels of proinflammatory cytokines in their serum relative to mice treated with EBVSTs expanded by stimulations using only EBV latent antigens (
FIGS. 9A and 9B ). - By contrast, Mice treated with EBVSTs expanded by stimulations using peptides of EBV latent+lytic antigens had reduced levels of IL-10 in their serum relative to mice treated with EBVSTs expanded by stimulations using only EBV latent antigens, whilst mice treated with EBVSTs expanded by stimulations using peptides of EBV lytic antigens only displayed similar or reduced levels of IL-10 in their serum relative to mice treated with EBVSTs expanded by stimulations using only EBV latent antigens (
FIG. 9C ). - So BR-EBVSTs were found to kill greater numbers of tumor cells and produce a greater amount of proinflammatory cytokines. Without wishing to be bound by any particular theory, this may result in a change in the tumor microenvironment leading to increased epitope spreading in vivo, and additional tumor cell killing by non-viral tumor antigen-specific T-cells.
- To summarise, the inventors have shown that:
-
- Populations of T cells containing T cells specific for lytic and latent EBV antigens can be obtained by stimulating PBMCs from both healthy donors and lymphoma patients with pepmixes corresponding to lytic and latent EBV antigens (see e.g.
FIGS. 1 and 3 ); - Stimulating PBMCs with pepmixes corresponding to lytic and latent EBV antigens yields more EBV antigen-reactive T cells than stimulations using pepmixes corresponding to lytic EBV antigens only, or latent EBV antigens only (see e.g.
FIG. 2 ); - Populations of T cells obtained by stimulating PBMCs with pepmixes corresponding to lytic+latent EBV antigens, or immediate-early lytic antigens, or early lytic antigens are capable of killing EBV-LCLs, with similar ability as cells populations of T cells obtained by stimulating PBMCs with pepmixes corresponding latent EBV antigens (see e.g.
FIG. 4 ); - Populations of T cells obtained by stimulating PBMCs with pepmixes corresponding to lytic+latent EBV antigens comprise a greater proportion of cells reactive for EBV-infected cells as compared to populations of T cells obtained by stimulating PBMCs with pepmixes corresponding latent EBV antigens only (see e.g.
FIG. 5 ); - Populations of T cells obtained by stimulating PBMCs with pepmixes corresponding to lytic+latent EBV antigens display improved control of tumor growth and reduced metastasis for EBV-positive cancer as compared to populations of T cells obtained by stimulating PBMCs with pepmixes corresponding latent EBV antigens (see e.g.
FIGS. 6 and 7 ). - Populations of T cells obtained by stimulating PBMCs with pepmixes corresponding lytic EBV antigens display similar or improved control of tumor growth for EBV-positive cancer as compared to populations of T cells obtained by stimulating PBMCs with pepmixes corresponding latent EBV antigens (see e.g.
FIG. 8 ). - Subjects having EBV-positive cancer which are treated with T cells obtained by stimulating PBMCs with pepmixes corresponding to lytic+latent EBV antigens have elevated levels of proinflammatory cytokines (GM-CSF, IFNγ) and reduced levels of anti-inflammatory cytokines (IL-10) in the peripheral blood as compared to subjects treated with T cells obtained by stimulating PBMCs with pepmixes corresponding latent EBV antigens (see e.g.
FIG. 9 ). - Subjects having EBV-positive cancer which are treated with T cells obtained by stimulating PBMCs with pepmixes corresponding to lytic EBV antigens have similar or elevated levels of proinflammatory cytokines (GM-CSF, IFNγ) and similar or reduced levels of anti-inflammatory cytokines (IL-10) in the peripheral blood as compared to subjects treated with T cells obtained by stimulating PBMCs with pepmixes corresponding latent EBV antigens (see e.g.
FIG. 9 ).
- Populations of T cells containing T cells specific for lytic and latent EBV antigens can be obtained by stimulating PBMCs from both healthy donors and lymphoma patients with pepmixes corresponding to lytic and latent EBV antigens (see e.g.
- The inventors next investigated the effect of depleting PBMC populations of CD45RA-positive cells on the expanded population of EBV-specific T cells.
- Outgrowth of NK cells from PBMC populations can be problematic in methods for expanding EBVSTs from NK cell populations due to IL-15-mediated stimulation of NK cell proliferation. CD45RA is a naïve T-cell marker that is also expressed on natural T-regulatory cells and NK cells, so it was reasoned that depletion of CD45RA+ cells would remove the NK cells from the starting PBMC population. Depletion of CD45RA+ cells also removes T regulatory cells that can inhibit the outgrowth of antigen-specific T-cells, especially in cancer patients, and also removes naïve cells that can grow as bystander cells and dilute the antigen-specific T-cells.
- PBMCs were depleted of CD45RA-expressing cells using Miltenyi® columns and CD45RA-conjugated beads, and the PBMCs depleted of CD45RA-positive cells were subsequently used to expand EBV-specific T cells by stimulation with latent pepmixes essentially as described in Example 1.
- PBMCs depleted of CD45RA-positive cells were also used as the starting population for producing ATCs used in restimulations, which were produced essentially as described in Example 1.
- The following experimental conditions were compared:
-
- (i) EBVSTs expanded from whole PBMCs (i.e. PBMCs not depleted of CD45RA-positive cells)+restimulations using ATCs produced from whole PBMCs—referred to in
FIG. 10 as “WW” (i.e. whole+whole) - (ii) EBVSTs expanded from whole PBMCs+restimulations using ATCs produced from PBMCs depleted of CD45RA-positive cells—referred to in
FIG. 10 as “WD” (i.e. whole+depleted) - (iii) EBVSTs expanded from PBMCs depleted of CD45RA-positive cells+restimulations using ATCs produced from whole PBMCs—referred to in
FIG. 10 as “DW” (i.e. depleted+whole) - (iv) EBVSTs expanded from PBMCs depleted of CD45RA-positive cells+restimulations using ATCs produced from PBMCs depleted of CD45RA-positive cells—referred to in
FIG. 10 as “DD” (i.e. depleted+depleted)
- (i) EBVSTs expanded from whole PBMCs (i.e. PBMCs not depleted of CD45RA-positive cells)+restimulations using ATCs produced from whole PBMCs—referred to in
- EBVSTs prepared according to (i) to (iv) above from PBMCs obtained from four different healthy donors (
D # 1 to D #4) were analysed by ELISPOT to determine their ability to recognise different EBV antigens. ELISPOT analysis was performed essentially as described in Example 2. - The results are shown in
FIG. 10 . For each donor, using PBMCs depleted of CD45RA-positive cells as the starting population for expanding EBVSTs yielded an increased proportion of cells in the expanded population that secrete IFNγ in response to stimulation with EBV pepmixes, as compared to methods using whole PBMC populations. Similarly, using PBMCs depleted of CD45RA-positive cells as the starting population for generating ATCs used in restimulations resulted in a greater proportion of cells in the expanded population that secrete IFNγ in response to stimulation with EBV pepmixes. - The inventors analysed expression of the costimulatory molecule CD80 and HLA-DR (MHC class II) on the ATCs generated from whole PBMCs, or from PBMCs depleted of CD45RA-positive cells, by flow cytometry.
- The results are shown in
FIG. 11 . The ATCs generated from PBMCs depleted of CD45RA-positive cells had higher expression of CD80 and HLA-DR, and thus improved antigen-presenting and costimulatory properties as compared to ATCs generated from whole PBMCs.
Claims (26)
1. A method for generating or expanding a population of immune cells comprising immune cells specific for an Epstein Barr Virus (EBV) lytic antigen, comprising stimulating immune cells specific for an EBV lytic antigen by contacting peripheral blood mononuclear cells (PBMCs) with: (i) one or more peptides corresponding to all or part of one or more EBV lytic antigens; or (ii) antigen presenting cells (APCs) presenting one or more peptides corresponding to all or part of one or more EBV lytic antigens.
2. The method according to claim 1 , wherein the method further comprises re-stimulating the immune cells specific for an EBV lytic antigen by contacting them with APCs presenting one or more peptides corresponding to all or part of one or more EBV lytic antigens.
3. A method for generating or expanding a population of immune cells comprising immune cells specific for an Epstein Barr Virus (EBV) lytic antigen and immune cells specific for an EBV latent antigen, comprising stimulating immune cells specific for an EBV lytic antigen and immune cells specific for an EBV latent antigen by contacting peripheral blood mononuclear cells (PBMCs) with: (i) one or more peptides corresponding to all or part of one or more EBV lytic antigens, and one or more peptides corresponding to all or part of one or more EBV latent antigens; or (ii) antigen presenting cells (APCs) presenting one or more peptides corresponding to all or part of one or more EBV lytic antigens, and one or more peptides corresponding to all or part of one or more EBV latent antigens.
4. The method according to claim 3 , wherein the method further comprises re-stimulating the immune cells specific for an EBV lytic antigen and the immune cells specific for an EBV latent antigen by contacting them with APCs presenting one or more peptides corresponding to all or part of one or more EBV lytic antigens, and one or more peptides corresponding to all or part of an EBV latent antigen.
5. The method according to any one of claims 1 to 4 , wherein the one or more EBV lytic antigens are selected from BZLF1, BRLF1, BMLF1, BMRF1, BXLF1, BALF1, BALF2, BGLF5, BHRF1, BNLF2A, BNLF2B, BHLF1, BLLF2, BKRF4, BMRF2, BALF4, BILF1, BILF2, BNFR1, BVRF2, BALF3, BALF5 and BDLF3.
6. The method according to any one of claims 1 to 5 , wherein the one or more EBV lytic antigens are selected from BZLF1, BRLF1, BMLF1, BMRF1, BALF2, BNLF2A, BNLF2B, BMRF2 and BDLF3.
7. The method according to any one of claims 3 to 6 , wherein the one or more EBV latent antigens are selected from EBNA1, EBNA-LP, EBNA2, EBNA3A, EBNA3B, EBNA3C, BARF1, LMP1, LMP2A and LMP2B.
8. The method according to any one of claims 3 to 7 , wherein the one or more EBV latent antigens are selected from EBNA1, LMP1, LMP2A and LMP2B.
9. The method according to any one of claims 1 to 8 , wherein the PBMCs are PBMCs depleted of CD45RA-positive cells.
10. An isolated population of immune cells obtained or obtainable by a method according to any one of claims 1 to 9 .
11. An isolated population of immune cells comprising immune cells specific for an Epstein Barr Virus (EBV) lytic antigen.
12. An isolated population of immune cells comprising immune cells specific for an Epstein Barr Virus (EBV) lytic antigen and immune cells specific for an EBV latent antigen.
13. A pharmaceutical composition comprising an isolated population of immune cells according to any one of claims 10 to 12 .
14. An isolated population of immune cells according to any one of claims 10 to 12 , or a pharmaceutical composition according to claim 13 , for use in a method of treatment or prevention of a disease or disorder.
15. Use of isolated population of immune cells according to any one of claims 10 to 12 , or a pharmaceutical composition according to claim 13 , in the manufacture of a medicament for use in a method of treatment or prevention of a disease or disorder.
16. A method for treating or preventing a disease or disorder associated, comprising administering an isolated population of immune cells according to any one of claims 10 to 12 , or a pharmaceutical composition according to claim 13 , to a subject.
17. The isolated population of immune cells or pharmaceutical composition for use according to claim 14 , the use according to claim 15 , or the method according to claim 16 , wherein the disease or disorder is a disease or disorder associated with EBV infection.
18. The isolated population of immune cells or pharmaceutical composition for use according to claim 14 , the use according to claim 15 , or the method according to claim 16 , wherein the disease or disorder is a cancer.
19. The isolated population of immune cells or pharmaceutical composition for use, the use, or the method according to claim 17 , wherein the disease or disorder associated with EBV infection is an EBV-associated cancer.
20. The isolated population of immune cells or pharmaceutical composition for use, the use, or the method according to claim 18 , wherein the cancer is an EBV-associated cancer.
21. The isolated population of immune cells or pharmaceutical composition for use, the use, or the method according to claim 19 or claim 20 , wherein the EBV-associated cancer is selected from EBV-positive lymphoma, EBV-positive nasopharyngeal carcinoma, and EBV-positive gastric carcinoma.
22. A method for killing a cell infected with EBV, comprising contacting a cell infected with EBV with an isolated population of immune cells according to any one of claims 10 to 12 , or a pharmaceutical composition according to claim 13 .
23. Use of an isolated population of immune cells according to any one of claims 10 to 12 , or a pharmaceutical composition according to claim 13 to kill a cell infected with EBV.
24. A method for killing a cancer cell, comprising contacting a cancer cell with an isolated population of immune cells according to any one of claims 10 to 12 , or a pharmaceutical composition according to claim 13 .
25. Use of an isolated population of immune cells according to any one of claims 10 to 12 , or a pharmaceutical composition according to claim 13 to kill a cancer cell.
26. The method or use according to claim 24 or claim 25 , wherein the cancer cell is infected with EBV.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/753,875 US20220401478A1 (en) | 2019-04-18 | 2020-04-09 | Ebv-specific immune cells |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/388,776 US10772914B1 (en) | 2019-04-18 | 2019-04-18 | EBV-specific immune cells |
US17/753,875 US20220401478A1 (en) | 2019-04-18 | 2020-04-09 | Ebv-specific immune cells |
PCT/US2020/027456 WO2020214479A1 (en) | 2019-04-18 | 2020-04-09 | Ebv-specific immune cells |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/388,776 Continuation US10772914B1 (en) | 2019-04-18 | 2019-04-18 | EBV-specific immune cells |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220401478A1 true US20220401478A1 (en) | 2022-12-22 |
Family
ID=72425595
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/388,776 Active US10772914B1 (en) | 2019-04-18 | 2019-04-18 | EBV-specific immune cells |
US17/753,875 Pending US20220401478A1 (en) | 2019-04-18 | 2020-04-09 | Ebv-specific immune cells |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/388,776 Active US10772914B1 (en) | 2019-04-18 | 2019-04-18 | EBV-specific immune cells |
Country Status (10)
Country | Link |
---|---|
US (2) | US10772914B1 (en) |
EP (1) | EP3955958A4 (en) |
JP (1) | JP2022529687A (en) |
KR (1) | KR20210153685A (en) |
CN (1) | CN113939312A (en) |
AU (1) | AU2020257876A1 (en) |
CA (1) | CA3137070A1 (en) |
SG (1) | SG11202111515TA (en) |
TW (1) | TW202104245A (en) |
WO (1) | WO2020214479A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021221927A1 (en) | 2020-04-27 | 2021-11-04 | Parsons Corporation | Narrowband iq signal obfuscation |
CA3218235A1 (en) * | 2021-04-27 | 2022-11-03 | Baylor College Of Medicine | Virus-specific immune cells expressing chimeric antigen receptors |
WO2023060179A1 (en) * | 2021-10-08 | 2023-04-13 | Baylor College Of Medicine | Generation of t cell lines with specificity against one or more neoantigens |
WO2023198744A1 (en) | 2022-04-13 | 2023-10-19 | Tessa Therapeutics Ltd. | Therapeutic t cell product |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5641628A (en) | 1989-11-13 | 1997-06-24 | Children's Medical Center Corporation | Non-invasive method for isolation and detection of fetal DNA |
US6821778B1 (en) | 1993-12-01 | 2004-11-23 | The Board Of Trustees Of Leland Stanford Junior University | Methods for using dendritic cells to activate gamma/delta-T cell receptor-positive T cells |
US6300090B1 (en) | 1994-07-29 | 2001-10-09 | The Rockefeller University | Methods of use of viral vectors to deliver antigen to dendritic cells |
EP0747481B1 (en) * | 1995-06-06 | 2001-12-19 | Organon Teknika B.V. | Epstein-Barr virus peptides and antibodies against these peptides |
EP2058389B1 (en) | 1997-10-27 | 2016-05-18 | Rockefeller University | Defined dendritic cell maturation medium comprising TNF-alpha, IL-1beta, IL-6 |
DE60042606D1 (en) | 1999-11-24 | 2009-09-03 | Ernest G Hope | ANTI-ANGIOGENIC CELLULAR AGENT FOR CANCER TREATMENT |
US20040022761A1 (en) | 2001-05-11 | 2004-02-05 | Banchereau Jacques F | Compositions and methods for producing antigen-presenting cells |
HU228242B1 (en) | 2001-09-28 | 2013-02-28 | Heinrich-Guenter Schumacher | Mowing blade comprising a blade bar composed of bar sections |
IL158140A0 (en) | 2003-09-25 | 2004-03-28 | Hadasit Med Res Service | Multiepitope polypeptides for cancer immunotherapy |
AU2004280623B2 (en) | 2003-10-08 | 2010-12-02 | Wilson Wolf Manufacturing, LLC | Cell culture methods and devices utilizing gas permeable materials |
US7785875B2 (en) | 2004-07-03 | 2010-08-31 | Mogam Biotechnology Research Institute | Polynucleotide encoding HCV epitopes which can bind to various HLA supertypes, immunogenic composition comprising same and method of inducing an HCV-specific immune response using same |
US20060045883A1 (en) | 2004-08-26 | 2006-03-02 | Jeffrey Molldrem | Anti-cancer vaccines |
JP4731867B2 (en) | 2004-10-01 | 2011-07-27 | 国立大学法人三重大学 | Method for inducing CD8 positive cytotoxic T lymphocytes |
JP4824389B2 (en) | 2005-10-28 | 2011-11-30 | 株式会社医学生物学研究所 | Cytotoxic T cell epitope peptide that specifically attacks Epstein-Barr virus infected cells and uses thereof |
EP1948232A4 (en) * | 2005-11-18 | 2010-09-22 | Univ Ohio State Res Found | Viral gene products and methods for vaccination to prevent viral associated diseases |
WO2007121276A2 (en) | 2006-04-12 | 2007-10-25 | Biocept, Inc. | Enrichment of circulating fetal dna |
JP5366820B2 (en) | 2006-12-07 | 2013-12-11 | ウィルソン ウォルフ マニュファクチャリング コーポレイション | Apparatus and method effective for cell culture |
US20100254958A1 (en) | 2007-10-24 | 2010-10-07 | Anne Letsch | Antigen-Specific T-Cell Preparations from Bone Marrow |
MX2012002365A (en) | 2009-08-24 | 2012-07-17 | Baylor College Medicine | Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses. |
US20130115617A1 (en) * | 2009-12-08 | 2013-05-09 | John R. Wilson | Methods of cell culture for adoptive cell therapy |
GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
HRP20221303T1 (en) | 2012-02-09 | 2022-12-23 | Baylor College Of Medicine | Pepmixes to generate multiviral ctls with broad specificity |
WO2016073595A1 (en) | 2014-11-05 | 2016-05-12 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | T cells and dendritic cells for polyomavirus therapy |
KR102501827B1 (en) * | 2016-09-16 | 2023-02-22 | 베이롤 칼리지 오브 메드신 | Platform for activation and expansion of virus-specific T-cells |
-
2019
- 2019-04-18 US US16/388,776 patent/US10772914B1/en active Active
-
2020
- 2020-04-09 EP EP20790717.1A patent/EP3955958A4/en active Pending
- 2020-04-09 KR KR1020217037468A patent/KR20210153685A/en unknown
- 2020-04-09 WO PCT/US2020/027456 patent/WO2020214479A1/en unknown
- 2020-04-09 US US17/753,875 patent/US20220401478A1/en active Pending
- 2020-04-09 SG SG11202111515TA patent/SG11202111515TA/en unknown
- 2020-04-09 AU AU2020257876A patent/AU2020257876A1/en active Pending
- 2020-04-09 JP JP2021562004A patent/JP2022529687A/en active Pending
- 2020-04-09 CN CN202080040271.3A patent/CN113939312A/en active Pending
- 2020-04-09 CA CA3137070A patent/CA3137070A1/en active Pending
- 2020-04-17 TW TW109113107A patent/TW202104245A/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2022529687A (en) | 2022-06-23 |
AU2020257876A1 (en) | 2021-12-02 |
US10772914B1 (en) | 2020-09-15 |
CA3137070A1 (en) | 2020-10-22 |
KR20210153685A (en) | 2021-12-17 |
EP3955958A4 (en) | 2023-01-25 |
WO2020214479A1 (en) | 2020-10-22 |
CN113939312A (en) | 2022-01-14 |
EP3955958A1 (en) | 2022-02-23 |
SG11202111515TA (en) | 2021-11-29 |
TW202104245A (en) | 2021-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220401478A1 (en) | Ebv-specific immune cells | |
Tanaka et al. | Vaccination targeting native receptors to enhance the function and proliferation of chimeric antigen receptor (CAR)-modified T cells | |
US10500265B2 (en) | Generation of HPV-specific T-cells | |
KR102501827B1 (en) | Platform for activation and expansion of virus-specific T-cells | |
Martorelli et al. | Role of CD4+ cytotoxic T lymphocytes in the control of viral diseases and cancer | |
US20090324630A1 (en) | Fusion multiviral chimeric antigen | |
WO2013088114A1 (en) | Process of expanding t cells | |
CN115996734A (en) | Treatment and prevention of cancer using virus-specific immune cells expressing chimeric antigen receptor | |
KR101867942B1 (en) | Method for enrichment and expansion of virus antigen-specific T cells | |
WO2023102328A2 (en) | Treatment of cd30-positive cancer | |
CN117529551A (en) | Virus-specific immune cells expressing chimeric antigen receptor | |
Withers | Third-party virus-specific T-cells can provide long-term viral control without toxicity in allogeneic haemopoietic stem cell transplant patients with recurrent or refractory viral infection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BAYLOR COLLEGE OF MEDICINE, TEXAS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ROONEY, CLIONA M.;SHARMA, SANDHYA;REEL/FRAME:059288/0022 Effective date: 20190423 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |